CA2686065A1 - Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement - Google Patents
Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement Download PDFInfo
- Publication number
- CA2686065A1 CA2686065A1 CA002686065A CA2686065A CA2686065A1 CA 2686065 A1 CA2686065 A1 CA 2686065A1 CA 002686065 A CA002686065 A CA 002686065A CA 2686065 A CA2686065 A CA 2686065A CA 2686065 A1 CA2686065 A1 CA 2686065A1
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- sensor
- fluorescence
- glucose
- fluorophore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/1459—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
- A61B5/1473—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
- A61B5/14735—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter comprising an immobilised reagent
Abstract
Embodiments of the present invention relates to analyte sensors 13. In particular, the preferred embodiments of the present invention relate to non-consuming intravascular glucose sensors 13 based on fluorescence chemistry.
Description
EQUILIBRIUM NON-CONSUMING FLUORESCENCE SENSOR FOR REAL TIME
IN TRAVASCULAR GLU COSE MEASUREMENT
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit to U.S. Provisional No.
60/917,307 filed May 10, 2007, the entirety of whicb is hereby incorporated by reference herein.
BACKGROUND OF THE INVENTION
Field of the Invention [0002] Embodiments of the present invention relates to analyte sensors. In particular, the preferred embodiments of the present invention relate to non-consuming intravascular glucose sensors based on fluorescence cbcrnistry.
Description of the Rel atedArt [0003] There has been an on-going effort over many years to use fluorescence techniques to rneasure polyhydroxyl compound (e.g., glucose) concentration in bodily fluids.
But despite the effort. no practical system has been developed and commercialized for in vivo monitoring. Several attempts have been made to detect glucose by fluorescence using dyes associated with boronic acid groups. Boronate moicties bind glucose reversibly. When boronic acid functionalized fluorescent dyes bind glucose, the properties of the dye are affected, such that a signal related to the concentration of glucose may be generated and detected. These changes have been used in the past to measure glucose concentration.
IN TRAVASCULAR GLU COSE MEASUREMENT
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit to U.S. Provisional No.
60/917,307 filed May 10, 2007, the entirety of whicb is hereby incorporated by reference herein.
BACKGROUND OF THE INVENTION
Field of the Invention [0002] Embodiments of the present invention relates to analyte sensors. In particular, the preferred embodiments of the present invention relate to non-consuming intravascular glucose sensors based on fluorescence cbcrnistry.
Description of the Rel atedArt [0003] There has been an on-going effort over many years to use fluorescence techniques to rneasure polyhydroxyl compound (e.g., glucose) concentration in bodily fluids.
But despite the effort. no practical system has been developed and commercialized for in vivo monitoring. Several attempts have been made to detect glucose by fluorescence using dyes associated with boronic acid groups. Boronate moicties bind glucose reversibly. When boronic acid functionalized fluorescent dyes bind glucose, the properties of the dye are affected, such that a signal related to the concentration of glucose may be generated and detected. These changes have been used in the past to measure glucose concentration.
[0004] Russell (ll_S. Pat. Nos. 5,137,833 and 5,512,246) used a boronic acid functionalized dye that bound glucose and generated a signal related to the glucose concentration. James et al. (U.S. Pat. No. 5,503,770) employed a similar principle, but combined a fluorescent dye, an amine quenching functionaliÃy, and boronic acid in a single complex. The fluorescence emission from the complex varied with the amount of glucose binding. Van Antwerp et al. (U.S. Pat. Nos. 6,002,954 and 6,011,984) combined features of the previously cited references and also disclosed a device purported to be irnplantable. A. E.
Colvin, Jr. (U.S. Pat. No. 6.304,766) also disclosed optical-based sensing devices for in situ sensing in humans that utilize boronate-functionalized dyes.
100051 Certain measurable parameters using blood or bodily fluid, such as pH
and concentrations of 02, CO,. Na+. W. and polyhydroxyl compounds. like glucose, have been determined in vivo. The ability to do these measurements in vivo is important because it is necessary to make frecluent determinations of such analytes wlien monitoring a patient.
Typically, one sensor for each analyte has been placed in a patient's blood vessel(s). If it is desired to measure several analytes, a plurality of sensors is often required, which can cause attendant discomfort to the patient and complexity of the electronic monitoring equipment.
[0006] In an effort to solve the design problenls posed by the limitation in physical dimension for in vivo inonitoring, others have incorporated different dyes into one device to get simultaneous readings of two parameters. For example, Alder et al. (U.S. Pat.
No. 5,922,612) disclosed a method for optical determination of pH and ionic strength of an aqueous sample using two different dyes on one sensor. Gray et al. (U.S. Pat.
No. 5,176,882) taught the use of a fiber optic device incorporating a hydrophilic polymer with immobilized pH sensitive dye and potassium or calcium sensitive fluorescent dyes to measure the analyte concentration in conjunction with pH. In U.S. Pat. No. 4,785,814, Kane also disclosed the use of two dyes embedded in a composite membrane for the simultaneous measurements of pH and oxygen content in blood. However, incorporation of multiple dyes into a single sensor complicates the manufacture of such sensors.
100071 Besides the foregoing problems associated with separate indwelling sensors for each analyte being monitored, particularly in the intensive care setting, and multiple dye sensors, another problem associated with many dye-based analyte sensors is pH
sensitivity. A slight change in pH may modify or attenuate fluorescence emissions, and cause inaccurate readings. This problem is particularly acute for monitoring blood glucose levels in diabetic patients, whose blood pH may fluctuate rapidly. Since accurate blood glucose level measurements are essential for treating these patients, there is a significant need for a glucose sensor that facilitates real-time correction of the pH effect without requiring separate indwelling pH and analyte sensors, or sensors having multiple dyes.
100081 Ratiometric pH deteraxaination using fluorescent dye(s) is known. Given a fluorophore that has an acid and base form, the ratio of the emission intensity of the two forms can be used as a m.easure of the pH that is insensitive to fluorophore concentration .
See e.g., U.S. Patent Publication No. 2005/0090014 which describes an HPTS-derived pH
sensitive dye (incorporated herein in its entirety by reference); Niu C.G. et al. 2005 Anal.
Biaanal. Chein. 383(2):349-357, which describes a pH-sensitive dye meso-5,10,15,20-tetra-(4-allyloxyphenyl)porphyrin (TAPP) as an indicator, and a pH-insensitive benzothioxanthene derivative as a reference, for fluorescence ra.tiometric measurement; Turner N.G. et al. 1998 J. Investig. Derrnatol. Symp. Proc. Aug 3(2):110-3, which discloses dual-emission ratiometric imaging using the fluorophore, carboxy seminaphthorhodafluor-1, which displays a pH-dependent shift in its emission spectrum; and Badugu R. et a]. 2005 Talanta 66:569-574, which describes the use of 6-aminoquinolinium boronic acid dyes that show spectral shifts and intensity changes with pH in a wavelength-ratiometric manner.
100091 However, despite the inventor's recognition of a substantial urimet need for a sensor adapted to provide continuous intravascular monitoring of pH and glucose, wherein the glucose measurement may be corrected for pH effects, no one has disclosed or even suggested using a sensor comprising a single fluorophore that exhibits properties suitable to make a ratiometric pH measurement that is independent of the fluorophore concentration, where the same fluorophore is functionalized to bind glucose and generate a signal the intensity of which is related to the glucose concentration_ SUMMARY OF THE INVENTION
100101 An intravascular sensor is disclosed in accordance with preferred embodiments of the present invention for determining the analyte concentration in blood.
The sensor comprises an analyte binding molecule, wherein the analyte binding molecule is associated with a fluorophore; an analyte analog, wherein the analyte analog is associated with an acceptor, wherein the fluorophore is capable of einitting radiation at a wavelength that is absorbed at least in part by the acceptor, wherein the fluorophore is capable of transferring energy to the acceptor via fluorescence resonance energy transfer when the fluorophore is in close proximity to the acceptor; a light source; and a detector.
[0011] In some embodiments, the sensor further comprises a hydrogel, wherein the analyte binding molecule and the analyte analog are substantially immobilized in the hydrogel, wherein the hydrogel is permeable to the analyte.
100I21 In some embodiments, the light source is a laser.
[0013] In some embodiments, the laser is capable of delivering a frequency modulated excitation signal.
[00141 In some embodiments, the laser is capable of delivery a pulse of light.
100151 In some embodiments, the sensor further comprises an optical fiber.
[0016] In some embodiments, the analyte is glucose.
[0017] A method is disclosed in accordance with preferred embodiments of the present invention for determining the glucose concentration in blood. The method comprises providing the sensor as described above; inserting the sensor into a blood vessel; irradiating the fluorophore with an excitation signal; detecting a fluorescence emission from the fluorophore; and determining the concentration of glucose.
[0018] In some embodiments, the excitation signal is a pulse of light.
100191 In some embodiments, the method further comprises measuring the decay of the fluorescence emission over time and calculating a fluorescence lifetime.
[00201 In some embodiments, the excitation signal is frequency modulated.
100211 In some embodirnents, the method further comprises measuring the phase shift between the emission and the excitation signal.
100221 In some embodiments, the method further comprises calculating a fluorescence lifetime.
100231 In some embodiments, the method further comprises measuring a modulation ratio and calculating a fluorescence lifetime.
[00241 In one preferred embodiment, an intravascular sensor is disclosed for determining an analyte concentration in blood. The sensor comprises an optical fiber comprising a sensor chemistry portion disposed along a distal region of the optical fiber, wherein the sensor chemistry portion is sized and physiologically compatible with residing in a blood vessel, wherein the sensor chemistry portion is selected from equilibrium fluoresceDce chemistry or lifetime chemistry.
BRIEF DESCRIPTION OF THE DRAWINGS
100251 FIG. I is a flow chart showing the sensing mechanism of one embodiment of the present inventian.
100261 FIG_ 2 shows a glucose and pH sensor and optical systein comprising two excitation light sources and two detectors in accordance with one prefen-ed ernbodirnent of the present invention.
100271 FIG. 3 shows the absorption spectra ofHPTS at different pHs.
100281 FIG. 4 shows independence of ratiometric pH sensing using HPTS/MABP4 using the Ir~QSejll~,soj ratio from glucose concentration_ The data are plotted as a ratio of the fluorescence emission for corresponding to excitation at 454 iirn (base) and 422 nm (isobestic point) vs. pH in various glucose concentrations.
100291 FIG. 5 shows glucose response curves for HPTS/MABP4 excited at 422 rnm (isobestic point) at different pHs.
100301 FIG. 6 shows the absorption spectra of SNARF-I at different pHs in solution.
[0031] FIG. 7 shows glucose response curves for SNARF-1/3,3'-oBBV in solution at different pHs excited at 514 nm/emission at 587 nm.
100321 FIG. 8 shows glucose response curves for SNARF-1/3,3'-oBBV in solution at different pHs excited at 514 nm/emission at 625 nin.
100331 FIG. 9 shows ratiomet.ric sensing of pH at different glucose concentrations with SNARF- l/3,3'-oBBV in solution using the I(6as,)1I(,,d) ratio.
10034] FIG. 10 shows glucose response curves for HPTS-triLysMA/3,3'-oBBV/DMAA at different pHs.
100351 FIG. II shows ratiometric sensing of pH at different glucose concentrations using HPTS-triLysMAl3,3-oBBV/DMAA, using the l(haSP/i(,,d) ratio.
100361 FIG. 12 shows ratiometric sensing of pH at different glucose concentrations using HPTS-triCysMA/3,3'-oBBV/DMMA wherein the indicator system is immobilized on the end of an optical fiber, using the I(bQSe)/I(ac,d) ratio.
100371 FIG. 13 shows a graph of the decay of fluorescence intensity over time after a fluorophore is subjected to a pulse of excitation light.
100381 FIG. 14 shows a graph of the emission signal resulting from a frequency modulated excitation signal.
100391 FIGS. 15A-C show the interaction between a glucose binding molecule linked to a fluorophore, a glucose analog linked to an acceptor and a glucose molecule.
Colvin, Jr. (U.S. Pat. No. 6.304,766) also disclosed optical-based sensing devices for in situ sensing in humans that utilize boronate-functionalized dyes.
100051 Certain measurable parameters using blood or bodily fluid, such as pH
and concentrations of 02, CO,. Na+. W. and polyhydroxyl compounds. like glucose, have been determined in vivo. The ability to do these measurements in vivo is important because it is necessary to make frecluent determinations of such analytes wlien monitoring a patient.
Typically, one sensor for each analyte has been placed in a patient's blood vessel(s). If it is desired to measure several analytes, a plurality of sensors is often required, which can cause attendant discomfort to the patient and complexity of the electronic monitoring equipment.
[0006] In an effort to solve the design problenls posed by the limitation in physical dimension for in vivo inonitoring, others have incorporated different dyes into one device to get simultaneous readings of two parameters. For example, Alder et al. (U.S. Pat.
No. 5,922,612) disclosed a method for optical determination of pH and ionic strength of an aqueous sample using two different dyes on one sensor. Gray et al. (U.S. Pat.
No. 5,176,882) taught the use of a fiber optic device incorporating a hydrophilic polymer with immobilized pH sensitive dye and potassium or calcium sensitive fluorescent dyes to measure the analyte concentration in conjunction with pH. In U.S. Pat. No. 4,785,814, Kane also disclosed the use of two dyes embedded in a composite membrane for the simultaneous measurements of pH and oxygen content in blood. However, incorporation of multiple dyes into a single sensor complicates the manufacture of such sensors.
100071 Besides the foregoing problems associated with separate indwelling sensors for each analyte being monitored, particularly in the intensive care setting, and multiple dye sensors, another problem associated with many dye-based analyte sensors is pH
sensitivity. A slight change in pH may modify or attenuate fluorescence emissions, and cause inaccurate readings. This problem is particularly acute for monitoring blood glucose levels in diabetic patients, whose blood pH may fluctuate rapidly. Since accurate blood glucose level measurements are essential for treating these patients, there is a significant need for a glucose sensor that facilitates real-time correction of the pH effect without requiring separate indwelling pH and analyte sensors, or sensors having multiple dyes.
100081 Ratiometric pH deteraxaination using fluorescent dye(s) is known. Given a fluorophore that has an acid and base form, the ratio of the emission intensity of the two forms can be used as a m.easure of the pH that is insensitive to fluorophore concentration .
See e.g., U.S. Patent Publication No. 2005/0090014 which describes an HPTS-derived pH
sensitive dye (incorporated herein in its entirety by reference); Niu C.G. et al. 2005 Anal.
Biaanal. Chein. 383(2):349-357, which describes a pH-sensitive dye meso-5,10,15,20-tetra-(4-allyloxyphenyl)porphyrin (TAPP) as an indicator, and a pH-insensitive benzothioxanthene derivative as a reference, for fluorescence ra.tiometric measurement; Turner N.G. et al. 1998 J. Investig. Derrnatol. Symp. Proc. Aug 3(2):110-3, which discloses dual-emission ratiometric imaging using the fluorophore, carboxy seminaphthorhodafluor-1, which displays a pH-dependent shift in its emission spectrum; and Badugu R. et a]. 2005 Talanta 66:569-574, which describes the use of 6-aminoquinolinium boronic acid dyes that show spectral shifts and intensity changes with pH in a wavelength-ratiometric manner.
100091 However, despite the inventor's recognition of a substantial urimet need for a sensor adapted to provide continuous intravascular monitoring of pH and glucose, wherein the glucose measurement may be corrected for pH effects, no one has disclosed or even suggested using a sensor comprising a single fluorophore that exhibits properties suitable to make a ratiometric pH measurement that is independent of the fluorophore concentration, where the same fluorophore is functionalized to bind glucose and generate a signal the intensity of which is related to the glucose concentration_ SUMMARY OF THE INVENTION
100101 An intravascular sensor is disclosed in accordance with preferred embodiments of the present invention for determining the analyte concentration in blood.
The sensor comprises an analyte binding molecule, wherein the analyte binding molecule is associated with a fluorophore; an analyte analog, wherein the analyte analog is associated with an acceptor, wherein the fluorophore is capable of einitting radiation at a wavelength that is absorbed at least in part by the acceptor, wherein the fluorophore is capable of transferring energy to the acceptor via fluorescence resonance energy transfer when the fluorophore is in close proximity to the acceptor; a light source; and a detector.
[0011] In some embodiments, the sensor further comprises a hydrogel, wherein the analyte binding molecule and the analyte analog are substantially immobilized in the hydrogel, wherein the hydrogel is permeable to the analyte.
100I21 In some embodiments, the light source is a laser.
[0013] In some embodiments, the laser is capable of delivering a frequency modulated excitation signal.
[00141 In some embodiments, the laser is capable of delivery a pulse of light.
100151 In some embodiments, the sensor further comprises an optical fiber.
[0016] In some embodiments, the analyte is glucose.
[0017] A method is disclosed in accordance with preferred embodiments of the present invention for determining the glucose concentration in blood. The method comprises providing the sensor as described above; inserting the sensor into a blood vessel; irradiating the fluorophore with an excitation signal; detecting a fluorescence emission from the fluorophore; and determining the concentration of glucose.
[0018] In some embodiments, the excitation signal is a pulse of light.
100191 In some embodiments, the method further comprises measuring the decay of the fluorescence emission over time and calculating a fluorescence lifetime.
[00201 In some embodiments, the excitation signal is frequency modulated.
100211 In some embodirnents, the method further comprises measuring the phase shift between the emission and the excitation signal.
100221 In some embodiments, the method further comprises calculating a fluorescence lifetime.
100231 In some embodiments, the method further comprises measuring a modulation ratio and calculating a fluorescence lifetime.
[00241 In one preferred embodiment, an intravascular sensor is disclosed for determining an analyte concentration in blood. The sensor comprises an optical fiber comprising a sensor chemistry portion disposed along a distal region of the optical fiber, wherein the sensor chemistry portion is sized and physiologically compatible with residing in a blood vessel, wherein the sensor chemistry portion is selected from equilibrium fluoresceDce chemistry or lifetime chemistry.
BRIEF DESCRIPTION OF THE DRAWINGS
100251 FIG. I is a flow chart showing the sensing mechanism of one embodiment of the present inventian.
100261 FIG_ 2 shows a glucose and pH sensor and optical systein comprising two excitation light sources and two detectors in accordance with one prefen-ed ernbodirnent of the present invention.
100271 FIG. 3 shows the absorption spectra ofHPTS at different pHs.
100281 FIG. 4 shows independence of ratiometric pH sensing using HPTS/MABP4 using the Ir~QSejll~,soj ratio from glucose concentration_ The data are plotted as a ratio of the fluorescence emission for corresponding to excitation at 454 iirn (base) and 422 nm (isobestic point) vs. pH in various glucose concentrations.
100291 FIG. 5 shows glucose response curves for HPTS/MABP4 excited at 422 rnm (isobestic point) at different pHs.
100301 FIG. 6 shows the absorption spectra of SNARF-I at different pHs in solution.
[0031] FIG. 7 shows glucose response curves for SNARF-1/3,3'-oBBV in solution at different pHs excited at 514 nm/emission at 587 nm.
100321 FIG. 8 shows glucose response curves for SNARF-1/3,3'-oBBV in solution at different pHs excited at 514 nm/emission at 625 nin.
100331 FIG. 9 shows ratiomet.ric sensing of pH at different glucose concentrations with SNARF- l/3,3'-oBBV in solution using the I(6as,)1I(,,d) ratio.
10034] FIG. 10 shows glucose response curves for HPTS-triLysMA/3,3'-oBBV/DMAA at different pHs.
100351 FIG. II shows ratiometric sensing of pH at different glucose concentrations using HPTS-triLysMAl3,3-oBBV/DMAA, using the l(haSP/i(,,d) ratio.
100361 FIG. 12 shows ratiometric sensing of pH at different glucose concentrations using HPTS-triCysMA/3,3'-oBBV/DMMA wherein the indicator system is immobilized on the end of an optical fiber, using the I(bQSe)/I(ac,d) ratio.
100371 FIG. 13 shows a graph of the decay of fluorescence intensity over time after a fluorophore is subjected to a pulse of excitation light.
100381 FIG. 14 shows a graph of the emission signal resulting from a frequency modulated excitation signal.
100391 FIGS. 15A-C show the interaction between a glucose binding molecule linked to a fluorophore, a glucose analog linked to an acceptor and a glucose molecule.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
100401 In a preferred embodiment, the present invention is directed to an optical sensor capable of ineasuring two analytes with a single indicalor system. More particularly, the preferred sensor employs a single fluorophore (e_g., a fluorescent dye) to: (l) determine the concentration of a first analyte, e.g., H-' (pH), by a ratiometric method, wherein such determination is independent of the concentration of the fluorophore; and (2) determine the concentration of a second analyte, e.g., a polyhydroxyl compounds (e.g., preferably glucose) by measuring the apparent fluorophore concentration (e.g., emission intensity of the fluorophore upon excitation), wherein the apparent fluorophore concentration is dependent on the concentration of the second a.nalyte. Further, where measurement of the second analyte concentration is dependent on the first analyte concentration (e.g., in optical systems in which glucose measurement varies with pH-a common problem in this field), then in accordance with a preferred embodiment of the present invention, the measured second analyte concentration may be corrected for the contribution of the first analyte coiicentration.
The sensor is preferably stable in aqueous media (e.g., physiological media, blood, interstitial fluid, etc.), and more preferably, the sensor is configured to be inserted into a blood vessel where it can remain indwelling for a period of time. Thus, in accordance with a preferred embodiment of the present invention, an optical sensor configured for intravascular placement is disclosed, which sensor is capable of measuring two analytes (preferably pH and glucose) with a single indicator system and correcting the glucose measurement for any contributions of pH.
100411 Although preferred embodiments of the sensor are directed intei= alia to ratiometric pH sensing, other first analyte concentrations rnay be detenruned in accordance with the broader scope of the present invention, as long as the indicator system comprises a fluorophore that exists in at least two forms the concentration of which are associated with the concentration of the frst analyte and the emission ratio of which is independent of the fluorophore concentration. Likewise, although glucose is used as a second analyte example herein, it is understood that the concentration of other polybydroxyl-containing organic compounds (carbohydrates, 1,2-diols, 1,3-diols and the like) in a solution may be determined using embodiments of this invention, as long as the indicator system comprises a fluorophore that is operably coupled to a binding moiety that binds the second analyte, wherein the signal intensity of the fluorophore varies with the concentration of second analyte.
In some embodiments, the concentration of second analytes may including non-carbohydrates.
Indicator System 10042] The indicator systems used in accordance with preferred embodiments of the present invention cornprise a fluorophore operably coupled to an analyte binding moiety, wherein analyte binding causes an apparent optical change in the fluorophore concentration (e.g., emission intensity). It is further desired that the fluorophore has different acid and base forms that exhibit a detectable difference in spectral properties such that ratiometric pH
sensing may be enabled. For example, a glucose binding moiety such as 3,3'-oBBV
(described in detail below) that is operably coupled to a fluorescent dye such as HPTS-triLysMA (described in detail below) will quench the emission intensity of the fluorescent dye, wherein the extent of quenching is reduced upon glucose binding resulting in an increase in emission intensity related to glucose concentration. In preferred embodiments, the indicator systems comprise a dye having at least two anionic groups and a quencher having at least two boronic acids. In further preferred embodiments, the indicator systems also comprise a nieans for immobilizing the sensing moieties (e.g., dye-quencher) such that they remain physically close enough to one another to react (quenching). Where in vivo sensing is desired, such immobilizing means are preferably insoluble in an aqueous environment (e.g., intravascular), permeable to the target analytes, and iinpermeable to the sensing moieties.
Typically, the immobilizing means comprises a water-insoluble organic polymer matrix. For example, the HPTS-triLysMA dye and 3,3'-oBBV quencher may be effectively immobilized within a DMAA (N,N-dimethylacrylamide) hydrogel matrix (described in detail below), which allows pH and glucose sensing in vivo.
[00431 Some exemplary and preferred fluorophores, analyte binding moieties and immobilizing means are set forth in greater detail below.
Fluorophores [0044] "Fluorophore" refers to a substance that when illuminated by light at a particular wavelength emits light at a longer wavelength; i.e_ it fluoresces.
Fluorophores include but are not limited to organic dyes, organometallic compounds, metal chelates, fluorescent conjugated polymers, quantum dots or nanoparticles and combinations of the above. Fluorophores may be discrete moieties or substituents attached to a polymer.
100451 Fluorophores that may be used in preferred embodiments are capable of being excited by light of wavelength at or greater than about 400 nm, with a Stokes shifl large enough that the excitation and emission waveleilgths are separable by at least 10 nm. In some embodiments, the separation between the excitation and emission wavelengths may be equal to or greater than about 30 nm. These fluorophores are preferably susceptible to quenehing by electron acceptor molecules, such as viologens, and are resistant to photo-bleaching. They are also preferably stable against photo-oxidation, hydrolysis and biodegradation_ 1004fi] In some embodiments, the #luorophore may be a discrete compound.
100471 In some embodiments, the fluorophore may be a pendant group or a chain unit in a water-soluble or water-dispersible polymer having molecular weight of about 10,000 daltons or greater, forrning a dye-polymer unit. In one embodiment, such dye-polymer unit may also be non-covalently associated with a water-insoluble polymer matrix M' and is physically immobilized within the polymer matrix M', wherein M' is permeable to or in contact with analyte solution. In another embodiment, the dye on the dye-polymer unit may be negatively charged, and the dye-polymer unit may be immobilized as a complex with a cationic water-soluble polyiner, wherein said complex is permeable to or in contact with the analyte solution. In one embodiment, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid. The polymeric dyes may be water-soluble, water-swellable or dispersible in water. In soine embodiments, the polymeric dyes may also be cross-linked.
In preferred embodiments, the dye has a negative charge.
100481 In other embodiments, the dye molecule may be covalently bonded to the water-insoluble polymer matrix M', wherein said M' is permeable to or in contact with the analyte solution_ The dye molecule bonded to M' may form a structure M'-L'-Dye. L' is a hydrolytically stable covalent linker that covalently connects the sensing moiety to the polymer or matrix. Examples of L' include lower alkylene (e.g., Cl-C$
alkylene), optionally terninated with or interrupted by one or more divalent connecting groups selected from sulfonamide (--SO2NI1--), amide --(C=O)N--, ester --(C=O)--0--, ether.--O--, sulfide --S--, sulfone (--SO2--), phenylene --CbH4--, urethane --NH(C=O)--O--, urea --NH(C=O)NH--, thiourea --NH(C=S)--NH--, amide --(C=O)NH--, amine --NR-- (where R is defined as alkyl having I to 6 carbon atoms) and the like, or a combination thereof In one embodiment, the dye is bonded to a polymer matrix through the sulfonamide functional groups.
[0049] In some embodiments, useful dyes include pyranine der~r vatives (e.g.
hydroxypyrene trisulfonamide derivatives and the like), which have the following formula:
u R'-S OH
~ \ 4 II
II
O o wherein R~, R2, R3 are each -NHR4. R4 is -CH2CH2(-OCH,CH2-),X}; wherein X' is -OH, -OCH3COOH, -CONH2, -SO3H, -NH7, or OMe; and n is between about 70 and 10,000.
In one emboditnent, the dyes may be bonded to a polymer through the sulfonamide functional groups. In other embodiments, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid.
100501 In some embodiments, the fluorescent dye may be 8-hydroxypyrene-1,3,6-trisulfonate (HPTS). The counterions can be H{ or a3iy other cation. HPTS
exhibits two excitation wavelengths at around 450 nm and around 405 nrn, which correspond to the absorption wavelengths of the acid and its conjugate base_ The shift in excitation wavelength is due to the pH-dependent ionization of the hydroxyl group on HPTS. As the pH
increases, HPTS shows an increase in absorbance at about 450 nm, and a decrease in absorbance below about 420 nm. The pH-dependent shift in the absorption maximum enables dual-excitation ratiometric detection in the physiological range. This dye has a molecular weight of less than 500 daltons, so it will not stay within the polymer matrix, but it can be used with an anion exclusion membrane.
100401 In a preferred embodiment, the present invention is directed to an optical sensor capable of ineasuring two analytes with a single indicalor system. More particularly, the preferred sensor employs a single fluorophore (e_g., a fluorescent dye) to: (l) determine the concentration of a first analyte, e.g., H-' (pH), by a ratiometric method, wherein such determination is independent of the concentration of the fluorophore; and (2) determine the concentration of a second analyte, e.g., a polyhydroxyl compounds (e.g., preferably glucose) by measuring the apparent fluorophore concentration (e.g., emission intensity of the fluorophore upon excitation), wherein the apparent fluorophore concentration is dependent on the concentration of the second a.nalyte. Further, where measurement of the second analyte concentration is dependent on the first analyte concentration (e.g., in optical systems in which glucose measurement varies with pH-a common problem in this field), then in accordance with a preferred embodiment of the present invention, the measured second analyte concentration may be corrected for the contribution of the first analyte coiicentration.
The sensor is preferably stable in aqueous media (e.g., physiological media, blood, interstitial fluid, etc.), and more preferably, the sensor is configured to be inserted into a blood vessel where it can remain indwelling for a period of time. Thus, in accordance with a preferred embodiment of the present invention, an optical sensor configured for intravascular placement is disclosed, which sensor is capable of measuring two analytes (preferably pH and glucose) with a single indicator system and correcting the glucose measurement for any contributions of pH.
100411 Although preferred embodiments of the sensor are directed intei= alia to ratiometric pH sensing, other first analyte concentrations rnay be detenruned in accordance with the broader scope of the present invention, as long as the indicator system comprises a fluorophore that exists in at least two forms the concentration of which are associated with the concentration of the frst analyte and the emission ratio of which is independent of the fluorophore concentration. Likewise, although glucose is used as a second analyte example herein, it is understood that the concentration of other polybydroxyl-containing organic compounds (carbohydrates, 1,2-diols, 1,3-diols and the like) in a solution may be determined using embodiments of this invention, as long as the indicator system comprises a fluorophore that is operably coupled to a binding moiety that binds the second analyte, wherein the signal intensity of the fluorophore varies with the concentration of second analyte.
In some embodiments, the concentration of second analytes may including non-carbohydrates.
Indicator System 10042] The indicator systems used in accordance with preferred embodiments of the present invention cornprise a fluorophore operably coupled to an analyte binding moiety, wherein analyte binding causes an apparent optical change in the fluorophore concentration (e.g., emission intensity). It is further desired that the fluorophore has different acid and base forms that exhibit a detectable difference in spectral properties such that ratiometric pH
sensing may be enabled. For example, a glucose binding moiety such as 3,3'-oBBV
(described in detail below) that is operably coupled to a fluorescent dye such as HPTS-triLysMA (described in detail below) will quench the emission intensity of the fluorescent dye, wherein the extent of quenching is reduced upon glucose binding resulting in an increase in emission intensity related to glucose concentration. In preferred embodiments, the indicator systems comprise a dye having at least two anionic groups and a quencher having at least two boronic acids. In further preferred embodiments, the indicator systems also comprise a nieans for immobilizing the sensing moieties (e.g., dye-quencher) such that they remain physically close enough to one another to react (quenching). Where in vivo sensing is desired, such immobilizing means are preferably insoluble in an aqueous environment (e.g., intravascular), permeable to the target analytes, and iinpermeable to the sensing moieties.
Typically, the immobilizing means comprises a water-insoluble organic polymer matrix. For example, the HPTS-triLysMA dye and 3,3'-oBBV quencher may be effectively immobilized within a DMAA (N,N-dimethylacrylamide) hydrogel matrix (described in detail below), which allows pH and glucose sensing in vivo.
[00431 Some exemplary and preferred fluorophores, analyte binding moieties and immobilizing means are set forth in greater detail below.
Fluorophores [0044] "Fluorophore" refers to a substance that when illuminated by light at a particular wavelength emits light at a longer wavelength; i.e_ it fluoresces.
Fluorophores include but are not limited to organic dyes, organometallic compounds, metal chelates, fluorescent conjugated polymers, quantum dots or nanoparticles and combinations of the above. Fluorophores may be discrete moieties or substituents attached to a polymer.
100451 Fluorophores that may be used in preferred embodiments are capable of being excited by light of wavelength at or greater than about 400 nm, with a Stokes shifl large enough that the excitation and emission waveleilgths are separable by at least 10 nm. In some embodiments, the separation between the excitation and emission wavelengths may be equal to or greater than about 30 nm. These fluorophores are preferably susceptible to quenehing by electron acceptor molecules, such as viologens, and are resistant to photo-bleaching. They are also preferably stable against photo-oxidation, hydrolysis and biodegradation_ 1004fi] In some embodiments, the #luorophore may be a discrete compound.
100471 In some embodiments, the fluorophore may be a pendant group or a chain unit in a water-soluble or water-dispersible polymer having molecular weight of about 10,000 daltons or greater, forrning a dye-polymer unit. In one embodiment, such dye-polymer unit may also be non-covalently associated with a water-insoluble polymer matrix M' and is physically immobilized within the polymer matrix M', wherein M' is permeable to or in contact with analyte solution. In another embodiment, the dye on the dye-polymer unit may be negatively charged, and the dye-polymer unit may be immobilized as a complex with a cationic water-soluble polyiner, wherein said complex is permeable to or in contact with the analyte solution. In one embodiment, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid. The polymeric dyes may be water-soluble, water-swellable or dispersible in water. In soine embodiments, the polymeric dyes may also be cross-linked.
In preferred embodiments, the dye has a negative charge.
100481 In other embodiments, the dye molecule may be covalently bonded to the water-insoluble polymer matrix M', wherein said M' is permeable to or in contact with the analyte solution_ The dye molecule bonded to M' may form a structure M'-L'-Dye. L' is a hydrolytically stable covalent linker that covalently connects the sensing moiety to the polymer or matrix. Examples of L' include lower alkylene (e.g., Cl-C$
alkylene), optionally terninated with or interrupted by one or more divalent connecting groups selected from sulfonamide (--SO2NI1--), amide --(C=O)N--, ester --(C=O)--0--, ether.--O--, sulfide --S--, sulfone (--SO2--), phenylene --CbH4--, urethane --NH(C=O)--O--, urea --NH(C=O)NH--, thiourea --NH(C=S)--NH--, amide --(C=O)NH--, amine --NR-- (where R is defined as alkyl having I to 6 carbon atoms) and the like, or a combination thereof In one embodiment, the dye is bonded to a polymer matrix through the sulfonamide functional groups.
[0049] In some embodiments, useful dyes include pyranine der~r vatives (e.g.
hydroxypyrene trisulfonamide derivatives and the like), which have the following formula:
u R'-S OH
~ \ 4 II
II
O o wherein R~, R2, R3 are each -NHR4. R4 is -CH2CH2(-OCH,CH2-),X}; wherein X' is -OH, -OCH3COOH, -CONH2, -SO3H, -NH7, or OMe; and n is between about 70 and 10,000.
In one emboditnent, the dyes may be bonded to a polymer through the sulfonamide functional groups. In other embodiments, the dye may be one of the polymeric derivatives of hydroxypyrene trisulfonic acid.
100501 In some embodiments, the fluorescent dye may be 8-hydroxypyrene-1,3,6-trisulfonate (HPTS). The counterions can be H{ or a3iy other cation. HPTS
exhibits two excitation wavelengths at around 450 nm and around 405 nrn, which correspond to the absorption wavelengths of the acid and its conjugate base_ The shift in excitation wavelength is due to the pH-dependent ionization of the hydroxyl group on HPTS. As the pH
increases, HPTS shows an increase in absorbance at about 450 nm, and a decrease in absorbance below about 420 nm. The pH-dependent shift in the absorption maximum enables dual-excitation ratiometric detection in the physiological range. This dye has a molecular weight of less than 500 daltons, so it will not stay within the polymer matrix, but it can be used with an anion exclusion membrane.
Na' pss ~ QH
Na'C35 / 503 ha' (the Na{ salt of HPTS-"pyranine") 100511 In another embodiment, the fluorescent dye may be polymers of 8-acetoxy-pyrene-1,3,6-N, N',N"-tris-(methacryIpropylamidosulfonarr)ide) (acetoxy-HPTS-MA):
H II
N-s ay ~O I /
o lo ~ _~
~-~ NH
O O~\~--!!//\
[0052] It is noted that dyes such as acetoxy-HPTS-MA (above) having no anionic groups, may not give very strong glucose response when operably coupled to a viologen quencher, particularly a viologen quencher having only a single boronic acid moiety.
[0053] In another embodiment, the fluorescent dye may be 8-hydroxy-pyrene-1,3,6-N, N',N"-tris-(carboxypropylsulfonamide) (HPTS-C02):
H li O~/ IO
HO/ E I /
OE ! O
HN-5 $ NH
Ip O \_ _ HO OH
[0054] In another embodiment, the fluorescent dye may be 8-hydroxy-pyrene-1,3,6-N, N',N"-tris-(methoxypolyethoxyethyl (-125) sulfonamide) (HPTS-PEG):
Na'C35 / 503 ha' (the Na{ salt of HPTS-"pyranine") 100511 In another embodiment, the fluorescent dye may be polymers of 8-acetoxy-pyrene-1,3,6-N, N',N"-tris-(methacryIpropylamidosulfonarr)ide) (acetoxy-HPTS-MA):
H II
N-s ay ~O I /
o lo ~ _~
~-~ NH
O O~\~--!!//\
[0052] It is noted that dyes such as acetoxy-HPTS-MA (above) having no anionic groups, may not give very strong glucose response when operably coupled to a viologen quencher, particularly a viologen quencher having only a single boronic acid moiety.
[0053] In another embodiment, the fluorescent dye may be 8-hydroxy-pyrene-1,3,6-N, N',N"-tris-(carboxypropylsulfonamide) (HPTS-C02):
H li O~/ IO
HO/ E I /
OE ! O
HN-5 $ NH
Ip O \_ _ HO OH
[0054] In another embodiment, the fluorescent dye may be 8-hydroxy-pyrene-1,3,6-N, N',N"-tris-(methoxypolyethoxyethyl (-125) sulfonamide) (HPTS-PEG):
H II
~N-S Y OH
O 10 r~
~O n I I
o~ ~ H hl HN--S S-NH
~~ lo l0 7 o oMe ONie 100551 It is noted that dyes such as HPTS-PEG (above) having no anionic groups, may not provide a very strong glucose response when operably coupled to a viologen quencher, particularly a viologen quencher having only a single boronic acid moiety.
100561 Representative dyes as discrete compounds are the tris adducts formed by reacting 8-acetoxypyrene-1,3,6-trisulfonylchloride (HPTS-Cl) with an amino acid, sucb as amino butyric acid. Hydroxypyrene trisulfonamide dyes bonded to a polymer and bearing one or more anionic groups are most preferred, such as copolymers of 8-hydroxypyrene-I -N-(methaerylamidopropylsulfonamido)-N',N"-3,6-bis(carboxypropylsulfonamide) HPTS-MA with HEMA, PEGMA, and the like.
100571 In another embodiment, the fluorescent dye may be HPTS-TriCys-MA:
6Nhli~S
H H~ 0 t~-S Dti ~
Bu4N03~ SC)3NBt,4 t'1-5 ~-N IN
~ H 0 11 i~ H
100581 This dye may be used with a quencher comprising boronic acid, such as 3,3'-oBBV.
100591 Of course, in some embodiments, substitutions otlier than Cys-MA on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. Either L or D
stereoisomers of cysteine may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to I-NPTS-CysMA sliown above, otber counterions besides NBu4+ may be used, including positively charged metals, e.g., Na{. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc.
functional groups.
10060] Another suitable dye is HPTS-LysMA, which is pictured below as follows:
PJH
rda0g j ~
rdaE?~C Ct?'Na a fH HPT-S-Ly.61A
HT+I--~
10061] Other examples include soluble copolymers of 8-acetoxypyrene-1,3,6-N, N', N"-tris(methacrylamidopropylsulfonamide) with HEMA, PEGMA, or other hydrophilic comonomers. The phenolic substituent in the dye is protected during polymerization by a blocking group that can be removed by hydrolysis after completion of polymerization. Such suitable blocking groups, as for example, acetoxy, trifluoroacetoxy, and the like, are well known in the art-10062] Fluorescent dyes, including HPTS and its derivatives are known and many have been used in analyte detection. See e.g., U.S. Pat. Nos. 6,653,I41, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; and co-pending U.S. Patent Application Nos.
11/296,898 and 60/833,081; each of which is incorporated herein in its entirety by reference thereto.
[0063] The SNARF and SNAFL dyes from Molecular Probes may also be useful fluorophores in accordance with aspects of the present invention. The structures of SNARF-I and SNAFL-l are shown below.
~N-S Y OH
O 10 r~
~O n I I
o~ ~ H hl HN--S S-NH
~~ lo l0 7 o oMe ONie 100551 It is noted that dyes such as HPTS-PEG (above) having no anionic groups, may not provide a very strong glucose response when operably coupled to a viologen quencher, particularly a viologen quencher having only a single boronic acid moiety.
100561 Representative dyes as discrete compounds are the tris adducts formed by reacting 8-acetoxypyrene-1,3,6-trisulfonylchloride (HPTS-Cl) with an amino acid, sucb as amino butyric acid. Hydroxypyrene trisulfonamide dyes bonded to a polymer and bearing one or more anionic groups are most preferred, such as copolymers of 8-hydroxypyrene-I -N-(methaerylamidopropylsulfonamido)-N',N"-3,6-bis(carboxypropylsulfonamide) HPTS-MA with HEMA, PEGMA, and the like.
100571 In another embodiment, the fluorescent dye may be HPTS-TriCys-MA:
6Nhli~S
H H~ 0 t~-S Dti ~
Bu4N03~ SC)3NBt,4 t'1-5 ~-N IN
~ H 0 11 i~ H
100581 This dye may be used with a quencher comprising boronic acid, such as 3,3'-oBBV.
100591 Of course, in some embodiments, substitutions otlier than Cys-MA on the HPTS core are consistent with aspects of the present invention, as long as the substitutions are negatively charged and have a polymerizable group. Either L or D
stereoisomers of cysteine may be used. In some embodiments, only one or two of the sulfonic acids may be substituted. Likewise, in variations to I-NPTS-CysMA sliown above, otber counterions besides NBu4+ may be used, including positively charged metals, e.g., Na{. In other variations, the sulfonic acid groups may be replaced with e.g., phosphoric, carboxylic, etc.
functional groups.
10060] Another suitable dye is HPTS-LysMA, which is pictured below as follows:
PJH
rda0g j ~
rdaE?~C Ct?'Na a fH HPT-S-Ly.61A
HT+I--~
10061] Other examples include soluble copolymers of 8-acetoxypyrene-1,3,6-N, N', N"-tris(methacrylamidopropylsulfonamide) with HEMA, PEGMA, or other hydrophilic comonomers. The phenolic substituent in the dye is protected during polymerization by a blocking group that can be removed by hydrolysis after completion of polymerization. Such suitable blocking groups, as for example, acetoxy, trifluoroacetoxy, and the like, are well known in the art-10062] Fluorescent dyes, including HPTS and its derivatives are known and many have been used in analyte detection. See e.g., U.S. Pat. Nos. 6,653,I41, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; and co-pending U.S. Patent Application Nos.
11/296,898 and 60/833,081; each of which is incorporated herein in its entirety by reference thereto.
[0063] The SNARF and SNAFL dyes from Molecular Probes may also be useful fluorophores in accordance with aspects of the present invention. The structures of SNARF-I and SNAFL-l are shown below.
O O
~
N O, ~ HO O
OH OH
i I O O
HO~ HO'~
O O
[0064] Additionally, a set of isomeric water-soluble f3uorescent probes based on both the 6-aminoyuinolinium and boronic acid moieties which show spectral shifts and intensity changes with pH, in a wavelength-ratiometric and colorimetric rnariner may be useful in accordance with some embodiments of the present invention (See e.g., Badugu, R.
et al. 2005 Talanta 65 (3):762-768; and Badugu, R. et al. 2005 Bioorg. Med.
Chem. 13 (1):113-119); incorporated herein in its entirety by reference.
[0065] Another example of a fluorescence dye that may be pH and saccharide sensitive is tetrakis(4-sulfophenyl)porphine (TSPP)-shown below. TSPP may not work optimally in blood, where the porphyrin ring may react with certain metal ions, like ferric, and become non-fluorescent.
NH
O3~;_ N
HN
30j (TSPP) 100661 Additional examples of pH sensitive fluorescent indicators that may be useful for simultaneous determination of pH and glucose in the sensor of the present invention are described in US 2005/0233465 and US 2005/0090014; each of which is incorporated herein by reference in its entirety.
Analyte Binding Moieties-Quenchers 10067] In accordance with broad aspects of the present invention, the analyte binding moiety provides the at least dual functionality of being able to bind analyte and being able to modulate the apparent concentration of the fluorophore (e.g., detected as a change in emission signal intensity) in a manner related to the amount of analyte binding. In preferred embodiments, the analyte binding moiety is associated with a quencher.
"Quencher' refers to a compound that reduces the emission of a fluorophore when in its presence.
Quencher (Q) is selected from a discrete compound, a reactive intermediate which is convertible to a second discrete compound or to a polymerizable compound or Q is a pendant group or chain unit in a polymer prepared from said reactive intermediate or polyi-nerizable compound, which polyrner is water-soluble or dispersible or is an insoluble polymer, said polymer is optionally crosslinked.
[0068] In one example, the moiety that provides glucose recognition in the embodiments is an aromatic boronic acid. The boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen).
"Viologen" refers generally to compounds having the basic stnicture of a nitrogen containing conjugated N-substituted heterocyclic ai-omatic bis-onium salt, such as 2,2'-, 3,3'- or 4,4'-N,N' bis-(benzyl) bipyridium dihalide (i.e., dichloride, bromide chloride), etc.
Viologen also includes the substituted phenanthroline compounds. The boronic acid substituted quencher preferably has a pKa of between about 4 and 9, and reacts reversibly with glucose in aqueous media at a pH from about 6.8 to 7_8 to form boronate esters. The extent of reaction is related to glucose concentration in the medium. pormation of a boronate ester diminisbes quenehing of the fluorphore by the viologen resulting in an increase in fluorescence dependent on glucose concentration. A useful bis-oniurn salt is compatible with the analyte solution and capable of producing a detectable change in the fluorescent emission of the dye in the presence of the analyte to be detected.
100691 Bis-onium salts in the embodiments of this invention are prepared from conjugated heterocyclic aromatic di-nitrogen compounds. The conjugated heterocyclic aromatic di-nitrogen compounds are selected from dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes. phenanthrolines, and diazafluorenes, wherein the nitrogen atoms are in a different aromatic ring and are able to form an onium salt. It is understood that all isomers of said conjugated heterocyclic aromatic di-nitrogen compounds in which both nitrogens can be substituted are useful in this invention. In one embodiment, the quencher may be one of the bis-oniurn salts derived from 3,3'-dipyridyl, 4,4'-dipyridyl and 4,7-phenanthroline.
100701 In some embodiments, the viologen-boronic acid adduct may be a discrete compound having a molecular weight of about 400 daltons or greater. In other embodiments, it may also be a pendant group or a chain unit of a water-soluble or water-dispersible polymer with a molecular weight greater than about 10,000 daltons. In one embodiment, the quencher-polymer unit may be non-covalently associated with a polymer matrix and is physically immobilized therein. In yet anotber embodiment, the quencher-polymer unit may be immobilized as a complex witli a negatively charge water-soluble polymer.
100711 In other embodiments, the viologen-boronic acid moiety may be a pendant group or a chain unit in a crosslinked, hydrophilic polymer or hydrogel sufficiently penneable to the analyte (e.g., glucose) to allow equilibrium to be established.
100721 In other embodiments, the quencher may be covalently bonded to a second water-insoluble polymer matrix M2, which can be represented by the structure MZ-LZ-Q. L 2 is a linker selected from the group consisting of a lower alkylene (e.g., Cl-Cg alkylene), sulfonamide, amide, quaternary ammonium, pyridinium, ester, ether, sulfide, sulfone, phenylene, urea, thiourea, urethane, amine, and a combination thereof. The quencher may be linked to M2 at one or two sites in some embodiments.
100731 For the polymeric quencher precursors, multiple options are available for attaching the boronic acid moiety and a reactive group which may be a polymerizable group or a coupling group to two different nitrogens in the beteroaromatic centrally located group.
These are:
a) a reactive group on a first aromatic moiety is attached to one nitrogen and a second aromatic group containing at least one -B(OH)2 group is attached to the second nitrogen;
~
N O, ~ HO O
OH OH
i I O O
HO~ HO'~
O O
[0064] Additionally, a set of isomeric water-soluble f3uorescent probes based on both the 6-aminoyuinolinium and boronic acid moieties which show spectral shifts and intensity changes with pH, in a wavelength-ratiometric and colorimetric rnariner may be useful in accordance with some embodiments of the present invention (See e.g., Badugu, R.
et al. 2005 Talanta 65 (3):762-768; and Badugu, R. et al. 2005 Bioorg. Med.
Chem. 13 (1):113-119); incorporated herein in its entirety by reference.
[0065] Another example of a fluorescence dye that may be pH and saccharide sensitive is tetrakis(4-sulfophenyl)porphine (TSPP)-shown below. TSPP may not work optimally in blood, where the porphyrin ring may react with certain metal ions, like ferric, and become non-fluorescent.
NH
O3~;_ N
HN
30j (TSPP) 100661 Additional examples of pH sensitive fluorescent indicators that may be useful for simultaneous determination of pH and glucose in the sensor of the present invention are described in US 2005/0233465 and US 2005/0090014; each of which is incorporated herein by reference in its entirety.
Analyte Binding Moieties-Quenchers 10067] In accordance with broad aspects of the present invention, the analyte binding moiety provides the at least dual functionality of being able to bind analyte and being able to modulate the apparent concentration of the fluorophore (e.g., detected as a change in emission signal intensity) in a manner related to the amount of analyte binding. In preferred embodiments, the analyte binding moiety is associated with a quencher.
"Quencher' refers to a compound that reduces the emission of a fluorophore when in its presence.
Quencher (Q) is selected from a discrete compound, a reactive intermediate which is convertible to a second discrete compound or to a polymerizable compound or Q is a pendant group or chain unit in a polymer prepared from said reactive intermediate or polyi-nerizable compound, which polyrner is water-soluble or dispersible or is an insoluble polymer, said polymer is optionally crosslinked.
[0068] In one example, the moiety that provides glucose recognition in the embodiments is an aromatic boronic acid. The boronic acid is covalently bonded to a conjugated nitrogen-containing heterocyclic aromatic bis-onium structure (e.g., a viologen).
"Viologen" refers generally to compounds having the basic stnicture of a nitrogen containing conjugated N-substituted heterocyclic ai-omatic bis-onium salt, such as 2,2'-, 3,3'- or 4,4'-N,N' bis-(benzyl) bipyridium dihalide (i.e., dichloride, bromide chloride), etc.
Viologen also includes the substituted phenanthroline compounds. The boronic acid substituted quencher preferably has a pKa of between about 4 and 9, and reacts reversibly with glucose in aqueous media at a pH from about 6.8 to 7_8 to form boronate esters. The extent of reaction is related to glucose concentration in the medium. pormation of a boronate ester diminisbes quenehing of the fluorphore by the viologen resulting in an increase in fluorescence dependent on glucose concentration. A useful bis-oniurn salt is compatible with the analyte solution and capable of producing a detectable change in the fluorescent emission of the dye in the presence of the analyte to be detected.
100691 Bis-onium salts in the embodiments of this invention are prepared from conjugated heterocyclic aromatic di-nitrogen compounds. The conjugated heterocyclic aromatic di-nitrogen compounds are selected from dipyridyls, dipyridyl ethylenes, dipyridyl phenylenes. phenanthrolines, and diazafluorenes, wherein the nitrogen atoms are in a different aromatic ring and are able to form an onium salt. It is understood that all isomers of said conjugated heterocyclic aromatic di-nitrogen compounds in which both nitrogens can be substituted are useful in this invention. In one embodiment, the quencher may be one of the bis-oniurn salts derived from 3,3'-dipyridyl, 4,4'-dipyridyl and 4,7-phenanthroline.
100701 In some embodiments, the viologen-boronic acid adduct may be a discrete compound having a molecular weight of about 400 daltons or greater. In other embodiments, it may also be a pendant group or a chain unit of a water-soluble or water-dispersible polymer with a molecular weight greater than about 10,000 daltons. In one embodiment, the quencher-polymer unit may be non-covalently associated with a polymer matrix and is physically immobilized therein. In yet anotber embodiment, the quencher-polymer unit may be immobilized as a complex witli a negatively charge water-soluble polymer.
100711 In other embodiments, the viologen-boronic acid moiety may be a pendant group or a chain unit in a crosslinked, hydrophilic polymer or hydrogel sufficiently penneable to the analyte (e.g., glucose) to allow equilibrium to be established.
100721 In other embodiments, the quencher may be covalently bonded to a second water-insoluble polymer matrix M2, which can be represented by the structure MZ-LZ-Q. L 2 is a linker selected from the group consisting of a lower alkylene (e.g., Cl-Cg alkylene), sulfonamide, amide, quaternary ammonium, pyridinium, ester, ether, sulfide, sulfone, phenylene, urea, thiourea, urethane, amine, and a combination thereof. The quencher may be linked to M2 at one or two sites in some embodiments.
100731 For the polymeric quencher precursors, multiple options are available for attaching the boronic acid moiety and a reactive group which may be a polymerizable group or a coupling group to two different nitrogens in the beteroaromatic centrally located group.
These are:
a) a reactive group on a first aromatic moiety is attached to one nitrogen and a second aromatic group containing at least one -B(OH)2 group is attached to the second nitrogen;
b) one or more boronic acid groups are attached to a first aromatic moiety which is attached to one nitrogen and one boronic acid and a reactive group are attached to a second aromatic group which second aromatic group is attached to the second nitrogen:
c) one boronic acid goup and a reactive group are attached to a first aromatic moiety which first aromatic group is attached to one nitrogen, and a boronic acid group and a reactive group are attached to a second aromatic moiety which is attached to the second nitrogen; and d) one boronic acid is attached to each nitrogen and a reactive group is attached to the heteroaromatic ring.
100741 Preferred embodiments comprise two boronic acid moieties and one polymerizable group or coupling group wherein the aroinatic group is a benzyl substituent bonded to the nitrogen and the boronic acid groups are attached to the benzyl ring and may be in the ortho- meta or para- positions.
[0075] In some einbodirnents, the boronic acid substituted viologen as a discrete compo-und useful for in vitro sensing may be represented by one of the following fornnulas:
/ \ 0 ZXO
o N- NOo Y'-(CH2)n n(H2C)-Y2 / ~ - ~
Y'-(CFiz)n`-oN ~ ~N-(H2C)-YZ
O+/ \ -Y~-(CHZ}õ-N \ /
NO
_ 2X~ n(tipC)-Y2 100761 where n 1-3, X is halogen, and Y' and YZ are independently selected from phenyl boronic acid (o- m- or p-isomers) and naphthyl boronic acid_ In other embodiments, the cluench.er may comprise a boronic acid group as a substituent on the heterocyclic ring of a viologen.
100771 A specific example used with TSPP is m-BBV:
c) one boronic acid goup and a reactive group are attached to a first aromatic moiety which first aromatic group is attached to one nitrogen, and a boronic acid group and a reactive group are attached to a second aromatic moiety which is attached to the second nitrogen; and d) one boronic acid is attached to each nitrogen and a reactive group is attached to the heteroaromatic ring.
100741 Preferred embodiments comprise two boronic acid moieties and one polymerizable group or coupling group wherein the aroinatic group is a benzyl substituent bonded to the nitrogen and the boronic acid groups are attached to the benzyl ring and may be in the ortho- meta or para- positions.
[0075] In some einbodirnents, the boronic acid substituted viologen as a discrete compo-und useful for in vitro sensing may be represented by one of the following fornnulas:
/ \ 0 ZXO
o N- NOo Y'-(CH2)n n(H2C)-Y2 / ~ - ~
Y'-(CFiz)n`-oN ~ ~N-(H2C)-YZ
O+/ \ -Y~-(CHZ}õ-N \ /
NO
_ 2X~ n(tipC)-Y2 100761 where n 1-3, X is halogen, and Y' and YZ are independently selected from phenyl boronic acid (o- m- or p-isomers) and naphthyl boronic acid_ In other embodiments, the cluench.er may comprise a boronic acid group as a substituent on the heterocyclic ring of a viologen.
100771 A specific example used with TSPP is m-BBV:
N\ / \ /N' B(OH)~ ( HO)2B
m-BBV
100781 The quencher precursors suitable for making sensors may be selected from the folIowiiig:
4x0 ~N ~ ~ B(OH)z ~ \
~ i ~ \ I ~~
B(OH)2 -D
(k0 )2B(O}i)2 OOJ$I1II) O~
NH
O
NH
+
~ / \ \
/ \N D N\
4X pi \ o ND
( )zB B(OH)2 (HO)2B 2X 6(DH)2 NH NH
\ / \ N _ ~
2 0 ~y B(OH)2 (HO)Zs (HQ)zB B(OH)2 o~
NH
F F
O
B(OH)2 2X (HC)}28 NH
O O
a/ T
(HO)z8 N \ ~ /
pN
p (HO)2B
NH
2Br NH
N._ N
(H0)2B b C B(OH)2 3,3'-oBBV
100791 The quencher precursor 3,3-oBBV may be used with HPTS-LysMA or HPTS-CysMA to make hydrogels in accordance with prefeiTed aspects of the invention.
100801 Preferred quenchers are prepared from precursors comprising viologens derived from 3,3'-dipyridyl substituted on the nitrogens with benzylboronic acid groups and at other positions on the dipyridyl rings with a polymerizable group or a coupling group.
Representative viologens include:
m-BBV
100781 The quencher precursors suitable for making sensors may be selected from the folIowiiig:
4x0 ~N ~ ~ B(OH)z ~ \
~ i ~ \ I ~~
B(OH)2 -D
(k0 )2B(O}i)2 OOJ$I1II) O~
NH
O
NH
+
~ / \ \
/ \N D N\
4X pi \ o ND
( )zB B(OH)2 (HO)2B 2X 6(DH)2 NH NH
\ / \ N _ ~
2 0 ~y B(OH)2 (HO)Zs (HQ)zB B(OH)2 o~
NH
F F
O
B(OH)2 2X (HC)}28 NH
O O
a/ T
(HO)z8 N \ ~ /
pN
p (HO)2B
NH
2Br NH
N._ N
(H0)2B b C B(OH)2 3,3'-oBBV
100791 The quencher precursor 3,3-oBBV may be used with HPTS-LysMA or HPTS-CysMA to make hydrogels in accordance with prefeiTed aspects of the invention.
100801 Preferred quenchers are prepared from precursors comprising viologens derived from 3,3'-dipyridyl substituted on the nitrogens with benzylboronic acid groups and at other positions on the dipyridyl rings with a polymerizable group or a coupling group.
Representative viologens include:
L-Z
CC
N N} -R,/ X Rõ R' R"
10081] where L is Ll or L2 and is a linking group 10082] Z is a reactive group; and [0083] R' is --B(OH)2 in the ortho- ineta- or para- positions on the benzyl ring and R" is H- ; or optionally R'' is a coupling group as is deflned herein or a substituent specifically used to modify the acidity of the boronic acid such as fluoro- or rnethoxy-100841 L is a divalent moiety that covalently connects the sensing moiety to a reactive group that is used to bind the viologen to a polymer or matrix.
Examples of L
include those which are each independently selected from a direct bond or, a lower alkylene having I to $ carbon atoms, optionallv terminated with or interrupted by one or more divalent connecting groups selected from sulfonamide (-SOZNH-), amide -(C-O)N-, ester -(C=O)-O-, ether -0-, sulfide -S-, sulfone (-SO2-), phenylene -C6H4-, urethane -NH(C=O)-0-, urea -NH(C=O)NH-, thiourea -NH(C=S)-NH-, amide -(C-O)NH-, amine -NR- (where R is defined as alkyl having I to 6 carbon atoins) and the like.
100851 Z is either a polymerizable ethylenically unsaturated group selected from but not limited to methacrylarnido-, acrylamido-, inethacryloyl-, acryloyl-, or styryl- or optionally Z is a reactive functional group, capable of forming a covalent bond with a polymer or matrix. Such groups include but are not limited to -Br, -OH, -SH, -CO2H, and -NHz.
[0086] Boronic acid substituted polyviologens are another class of preferred quenchers. The term polyviologen ineludes: a discrete compound comprised of two or more viologens covalently bonded together by a linking group, a polymer comprised of viologen repeat units in the chain, a polymer with viologen groups pendant to the chain, a dendrimer comprised of viologen units, preferably including viologen terminal groups, an oligomer comprisecl of viologen units, preferably including viologen endgroups, and combinations thereof. Polymers in which mono-viologen groups form a minor component are not included.
CC
N N} -R,/ X Rõ R' R"
10081] where L is Ll or L2 and is a linking group 10082] Z is a reactive group; and [0083] R' is --B(OH)2 in the ortho- ineta- or para- positions on the benzyl ring and R" is H- ; or optionally R'' is a coupling group as is deflned herein or a substituent specifically used to modify the acidity of the boronic acid such as fluoro- or rnethoxy-100841 L is a divalent moiety that covalently connects the sensing moiety to a reactive group that is used to bind the viologen to a polymer or matrix.
Examples of L
include those which are each independently selected from a direct bond or, a lower alkylene having I to $ carbon atoms, optionallv terminated with or interrupted by one or more divalent connecting groups selected from sulfonamide (-SOZNH-), amide -(C-O)N-, ester -(C=O)-O-, ether -0-, sulfide -S-, sulfone (-SO2-), phenylene -C6H4-, urethane -NH(C=O)-0-, urea -NH(C=O)NH-, thiourea -NH(C=S)-NH-, amide -(C-O)NH-, amine -NR- (where R is defined as alkyl having I to 6 carbon atoins) and the like.
100851 Z is either a polymerizable ethylenically unsaturated group selected from but not limited to methacrylarnido-, acrylamido-, inethacryloyl-, acryloyl-, or styryl- or optionally Z is a reactive functional group, capable of forming a covalent bond with a polymer or matrix. Such groups include but are not limited to -Br, -OH, -SH, -CO2H, and -NHz.
[0086] Boronic acid substituted polyviologens are another class of preferred quenchers. The term polyviologen ineludes: a discrete compound comprised of two or more viologens covalently bonded together by a linking group, a polymer comprised of viologen repeat units in the chain, a polymer with viologen groups pendant to the chain, a dendrimer comprised of viologen units, preferably including viologen terminal groups, an oligomer comprisecl of viologen units, preferably including viologen endgroups, and combinations thereof. Polymers in which mono-viologen groups form a minor component are not included.
The preferred quenchers are water soluble or dispersible polymers, or crosslinked, hydrophilic polymers or hydrogels sufficiently permeable to glucose to function as part of a sensor. Alternatively the polyviologen boronic acid may be directly bonded to an inert substrate.
[0087] A polyviologen guencher as a polymer comprised of viologen repeat units has the formula:
2Br O / ~ O
N N
B[(OH)2 n 100881 In another embodiment, the polvviologen boronic acid adducts are formed by covalently linking two or more viol ogen/boroni c acid intermediates. The bridging group is typically a small divalent radical bonded to one nitrogen in each viologen, or to a carbon in the aromatic ring of each viologen, or one bond may be to a ring carbon i_n one viologen and to a nitrogen in the other. Two or rnore boronic acid groups are attached to the polyviologen. Optionally, the polyviologen boronie acid adduct is substituted with a polymerizable group or coupling group attached directly to the viologen or to the bridging group. Preferably the polyviologen moiety includes only one such group.
Preferably, the bridging group is selected to enhance cooperative binding of the boronic acids to glucose.
10089] The coupling moiety is a linking group as defined previously with the proviso that the linking group is optionally further substituted with a boronic acid, a polymerizable group, an additional coupling group, or is a segment in a polymer chain in which the viologen is a ehain unit, a pendant group, or any combination thereof Immobilizing Means [0090] In some embodiments, for use in vilro not involving a moving stream, the sensing components are used as individual (discrete) components. The dye and quencher are inixed together in liquid solution, analyte is added, the change in fluorescence intensity is measured, and the components are discarded. Polyineric matrices that can be used to trap the sensing components to prevent leaching need not be present. Optionally, the sensing components are imrnobilized which allows their use to measure analytes in a moving stream.
100911 For in vivo applications, the sensor is used in a moving stream of physiological fluid which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor asseinbly. Thus, for use in vivo, the sensing components are preferably part of an organic polyiner sensing assembly. Soluble dyes and quenchers can be confned by a semi-permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using as sensing moieties soluble molecules that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selective semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific 3-nolecular weight cutoff between the two so that the sensiiig moieties are quantitatively retained.
10092J Preferably the sensing moieties are immobilized in an insoluble polymer matrix, whicli is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest.
100931 The function of the polymer matrix is to bold together and immobilize the fluorophore and quencher moieties while at the same time allowing contact with the analyte, and binding of the analyte to the boronic acid. To achieve this effeet, the matrix must be insoluble in the medium, and in close association with it by establishing a high surface area interface between matrix and analyte solution. For example, an ultra-thin film or microporous support matrix is used. Alternatively, the matrix is swellable in the analyte solution, e.g. a hydrogel matrix is used for aqueous systems. ]n some instances, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. In all cases, the matrix inust not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases.
Techniques for preparing ultra-thin films. microporous polymers, microporous sol-gels, and hvdrogels are established in the art. All useful matrices are defined as being analyte perineable.
100941 Hydrogel polymers are used in some embodiments. The term, hydrogel, as used herein refers to a polymer that swells substantially, but does not dissolve in water. Such hydrogels may be linear, branched, or network polymers, or polyelectrolyte complexes, with the proviso that they contain no soluble or leachable fractions. Typically, hydrogel networks are prepared by a crosslinking step, which is performed on water-soluble polymers so that they swell but do not dissolve in aqueous media_ Alternatively, the hydrogel polyiners are prepared by copolymerizing a mixture of hydrophilic and crosslinking monomers to obtain a water swellable network polymer. Such polymers are formed either by addition or condensation polymerization, or by combination process. In these cases, the sensing moieties are incorporated into the polymer by copolymerization using monomeric derivatives in combination with network-forrning monomers. Alternatively, reactive moieties are coupled to an already prepared matrix using a post polyrnerization reaction. Said sensing moieties are units in the polymer chain or pendant groups attached to the chain.
[0095J The hydrogels useful in this invention are also monolithic polymers, such as a single network to whlch both dye and quencher are covalently bonded, or multi-component hydrogels. Multi-component hydrogels include interpenetrating networks, polyelectrolyte complexes, and various other blends of two or more polymers to obtain a water swellable composite, which includes dispersions of a second polyrner in a hydrogel rnatrix and alternating microlayer assemblies.
100961 Monolithic hydrogels are typically formed by free radical copolymerization of a mixture of hydrophilic monomers, including but not limited to HEMA, PEGMA, methacrylic acid, hydroxyethyl acrylate, N-vinyl pyrrolidone, acrylamide, N,N'-dimethyl acrylamide, and the like; ionic monomers include methacryloylaminopropyl trimethylammonium chloride, diallyl dimethyl ammonium. chloride, vinyl benzyl trimethyl ainmonium chloride, sodium sulfopropyl methacrylate, and the like;
crosslinkers include ethylene dimethacrylate, PEGDMA, trimethylolpropane triacrylate, and the like.
The ratios of monomers are chosen to optimize network properties including permeability, swelling index, and gel strength using principles well established in the art. In one embodiment, the dye moiety is derived from an ethylenically unsaturated derivative of a dye molecule, sueh as 8-acetoxvpyrene-1,3,6-N, N', N"-tris(methacrylamidopropylsu3fonamide) the quencher moiety is derived from an ethylenically unsaturated viologen such as 4-N-(benzyl-3-boronic acid)-4'-N'-(benzyl-4ethenyl)-dipyridinium dihalide (m-SBBV) and the matrix is made from HEMA and PEGDMA. The concentration of dye is chosen to optimize emission intensity.
The ratio of quencher to dye is adjusted to provide sufficient quenching to produce the desired measurable signal.
100971 In some embodiments, a monolithic hydrogel is formed by a condensation polymerization. For example, acetoxy pyrene trisulfonyl chlorade is reacted with an excess of PEG diamine to obtain a tris-(amino PEG) adduct dissolved in the unreacted diamine. A
solution of excess trimesoyl chloride and an acid acceptor is reacted with 4-N-(benzyl-3-boronic acid)-4'-N'-(2 hydroxyethyl) bipyridinium dihalide to obtain an acid chloride functional ester of the viologen. The two reactive mixtures are brought into contact with each other and allowed to react to form the hydrogel, e.g. by casting a thin film of one mixture and dipping it into the other.
10098] In other embodiments, multi-component hydrogels wherein the dye is incorporated in one component and the quencher in another are preferred for making the sensor of this invention. Further, these systems are optionally molecularly imprinted to enhance interaction between components and to provide selectivity for glucose over other polyhydroxy analytes. Preferably, the multicomponent system is an interpenetrating polymer network (IPN) or a semi-interpenetrating polymer network (semi-IPN).
100991 The IPN polymers are typically made by seguential polymerization.
First, a network comprising the quencher is formed. The network is then swollen with a mixture of monomers including the dye monomer and a second polymerization is carried out to obtain the IPN hydrogel.
101001 The semi-IPN hydrogel is formed by dissolving a soluble polymer containing dye moieties in a mixture of monomers including a quencher monomer and polyrnerizing the mixture. In some embodiments, the sensing moieties are immobilized by an insoluble polymer matrix which is freely permeable to polyhydroxyl compounds.
Additional details on hydrogel systems have been disclosed in US Patent Publications Nos.
[0087] A polyviologen guencher as a polymer comprised of viologen repeat units has the formula:
2Br O / ~ O
N N
B[(OH)2 n 100881 In another embodiment, the polvviologen boronic acid adducts are formed by covalently linking two or more viol ogen/boroni c acid intermediates. The bridging group is typically a small divalent radical bonded to one nitrogen in each viologen, or to a carbon in the aromatic ring of each viologen, or one bond may be to a ring carbon i_n one viologen and to a nitrogen in the other. Two or rnore boronic acid groups are attached to the polyviologen. Optionally, the polyviologen boronie acid adduct is substituted with a polymerizable group or coupling group attached directly to the viologen or to the bridging group. Preferably the polyviologen moiety includes only one such group.
Preferably, the bridging group is selected to enhance cooperative binding of the boronic acids to glucose.
10089] The coupling moiety is a linking group as defined previously with the proviso that the linking group is optionally further substituted with a boronic acid, a polymerizable group, an additional coupling group, or is a segment in a polymer chain in which the viologen is a ehain unit, a pendant group, or any combination thereof Immobilizing Means [0090] In some embodiments, for use in vilro not involving a moving stream, the sensing components are used as individual (discrete) components. The dye and quencher are inixed together in liquid solution, analyte is added, the change in fluorescence intensity is measured, and the components are discarded. Polyineric matrices that can be used to trap the sensing components to prevent leaching need not be present. Optionally, the sensing components are imrnobilized which allows their use to measure analytes in a moving stream.
100911 For in vivo applications, the sensor is used in a moving stream of physiological fluid which contains one or more polyhydroxyl organic compounds or is implanted in tissue such as muscle which contains said compounds. Therefore, it is preferred that none of the sensing moieties escape from the sensor asseinbly. Thus, for use in vivo, the sensing components are preferably part of an organic polyiner sensing assembly. Soluble dyes and quenchers can be confned by a semi-permeable membrane that allows passage of the analyte but blocks passage of the sensing moieties. This can be realized by using as sensing moieties soluble molecules that are substantially larger than the analyte molecules (molecular weight of at least twice that of the analyte or greater than 1000 preferably greater than 5000); and employing a selective semipermeable membrane such as a dialysis or an ultrafiltration membrane with a specific 3-nolecular weight cutoff between the two so that the sensiiig moieties are quantitatively retained.
10092J Preferably the sensing moieties are immobilized in an insoluble polymer matrix, whicli is freely permeable to glucose. The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials. Alternatively, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest.
100931 The function of the polymer matrix is to bold together and immobilize the fluorophore and quencher moieties while at the same time allowing contact with the analyte, and binding of the analyte to the boronic acid. To achieve this effeet, the matrix must be insoluble in the medium, and in close association with it by establishing a high surface area interface between matrix and analyte solution. For example, an ultra-thin film or microporous support matrix is used. Alternatively, the matrix is swellable in the analyte solution, e.g. a hydrogel matrix is used for aqueous systems. ]n some instances, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane. In all cases, the matrix inust not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases.
Techniques for preparing ultra-thin films. microporous polymers, microporous sol-gels, and hvdrogels are established in the art. All useful matrices are defined as being analyte perineable.
100941 Hydrogel polymers are used in some embodiments. The term, hydrogel, as used herein refers to a polymer that swells substantially, but does not dissolve in water. Such hydrogels may be linear, branched, or network polymers, or polyelectrolyte complexes, with the proviso that they contain no soluble or leachable fractions. Typically, hydrogel networks are prepared by a crosslinking step, which is performed on water-soluble polymers so that they swell but do not dissolve in aqueous media_ Alternatively, the hydrogel polyiners are prepared by copolymerizing a mixture of hydrophilic and crosslinking monomers to obtain a water swellable network polymer. Such polymers are formed either by addition or condensation polymerization, or by combination process. In these cases, the sensing moieties are incorporated into the polymer by copolymerization using monomeric derivatives in combination with network-forrning monomers. Alternatively, reactive moieties are coupled to an already prepared matrix using a post polyrnerization reaction. Said sensing moieties are units in the polymer chain or pendant groups attached to the chain.
[0095J The hydrogels useful in this invention are also monolithic polymers, such as a single network to whlch both dye and quencher are covalently bonded, or multi-component hydrogels. Multi-component hydrogels include interpenetrating networks, polyelectrolyte complexes, and various other blends of two or more polymers to obtain a water swellable composite, which includes dispersions of a second polyrner in a hydrogel rnatrix and alternating microlayer assemblies.
100961 Monolithic hydrogels are typically formed by free radical copolymerization of a mixture of hydrophilic monomers, including but not limited to HEMA, PEGMA, methacrylic acid, hydroxyethyl acrylate, N-vinyl pyrrolidone, acrylamide, N,N'-dimethyl acrylamide, and the like; ionic monomers include methacryloylaminopropyl trimethylammonium chloride, diallyl dimethyl ammonium. chloride, vinyl benzyl trimethyl ainmonium chloride, sodium sulfopropyl methacrylate, and the like;
crosslinkers include ethylene dimethacrylate, PEGDMA, trimethylolpropane triacrylate, and the like.
The ratios of monomers are chosen to optimize network properties including permeability, swelling index, and gel strength using principles well established in the art. In one embodiment, the dye moiety is derived from an ethylenically unsaturated derivative of a dye molecule, sueh as 8-acetoxvpyrene-1,3,6-N, N', N"-tris(methacrylamidopropylsu3fonamide) the quencher moiety is derived from an ethylenically unsaturated viologen such as 4-N-(benzyl-3-boronic acid)-4'-N'-(benzyl-4ethenyl)-dipyridinium dihalide (m-SBBV) and the matrix is made from HEMA and PEGDMA. The concentration of dye is chosen to optimize emission intensity.
The ratio of quencher to dye is adjusted to provide sufficient quenching to produce the desired measurable signal.
100971 In some embodiments, a monolithic hydrogel is formed by a condensation polymerization. For example, acetoxy pyrene trisulfonyl chlorade is reacted with an excess of PEG diamine to obtain a tris-(amino PEG) adduct dissolved in the unreacted diamine. A
solution of excess trimesoyl chloride and an acid acceptor is reacted with 4-N-(benzyl-3-boronic acid)-4'-N'-(2 hydroxyethyl) bipyridinium dihalide to obtain an acid chloride functional ester of the viologen. The two reactive mixtures are brought into contact with each other and allowed to react to form the hydrogel, e.g. by casting a thin film of one mixture and dipping it into the other.
10098] In other embodiments, multi-component hydrogels wherein the dye is incorporated in one component and the quencher in another are preferred for making the sensor of this invention. Further, these systems are optionally molecularly imprinted to enhance interaction between components and to provide selectivity for glucose over other polyhydroxy analytes. Preferably, the multicomponent system is an interpenetrating polymer network (IPN) or a semi-interpenetrating polymer network (semi-IPN).
100991 The IPN polymers are typically made by seguential polymerization.
First, a network comprising the quencher is formed. The network is then swollen with a mixture of monomers including the dye monomer and a second polymerization is carried out to obtain the IPN hydrogel.
101001 The semi-IPN hydrogel is formed by dissolving a soluble polymer containing dye moieties in a mixture of monomers including a quencher monomer and polyrnerizing the mixture. In some embodiments, the sensing moieties are immobilized by an insoluble polymer matrix which is freely permeable to polyhydroxyl compounds.
Additional details on hydrogel systems have been disclosed in US Patent Publications Nos.
US2004/0028612, and 2006/0083688 which are hereby incorporated by reference in their entireties.
101011 The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials.
AltemativeIy, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest. The function of the polymer matrix is to hold together and immobilize the fluorescent dye and quencher moieties while at the same time allowing contact with the analytes (e.g., polyhydroxyl compounds, H+ and OH-), and binding of the polyhydroxyl compounds to the boronic acid. Therefore, the matrix is insoluble in the medium and in close association with it by establishing a high surface area interface between matrix and analyte solution. The matrix also does not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. In one embodiment, an ultra-thin film or microporous support i-natrix may be used. In another einbodiinent, the matrix that is swellable in the analyte solution (e.g. a hydrogel matrix) can be used for aqueous systems. In some embodiments, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane.
Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels have been established in the prior art.
[01021 In one preferred embodiment, the boronic acid substituted viologen may be covalently bonded to a fluorescent dye. The adduct may be a polymerizable compound or a unit in a polymer. One such adduct for example may be prepared by first forming an unsymmetrical viologen from 4,4'-dipyridyl by attaching a benzyl-3-boronic acid group to one nitrogen and an aminoethyl group to the other nitrogen atom. The viologen is condensed sequentially first with 8-acetoxy-pyrene-1,3,6-trisulfonyl chloride in a l:l mole ratio followed by reaction with excess PEG diamine to obtain a prepolymer mixture.
An acid acceptor is included in both steps to scavange the byproduct acid. The prepolymer rnixture is crosslinked by reaction with a polyisocyanate to obtain a hydrogel. The product is treated with base to remove the acetoxy blocking group. lncomplete reaction products and unreacted starting materials are leached out of the hydrogel by exhaustive extraction with deionized water before further use. The product is responsive to glucose when used as the sensing component as described herein.
101031 Alternatively, such adducts are ethylenically unsaturated 3-nonomer derivatives. For example, dirnethyl bis-bromomethyl benzene boronate is reacted with excess 4,4'-dipyridyl to form a half viologen adduct. After removing the excess dipyridyl, the adduct is further reacted with an excess of bromoethylamine hydrochloride to form the bis-viologen adduct. This adduct is coupled to a pyranine dye by reaction with the 8-acetoxypyrene-tris sulfonyl chloride in a 1:1 mole ratio in the presence of an acid acceptor followed by reaction with excess aminopropylmethacrylamide. Finally, any residual amino groups may be reacted with methacrylol chloride. After purification, the dye/viologen monomer may be copolyznerized with HEMA and PEGDMA to obtain a hydrogel.
Ratiometric pHSensing 101041 Ratiometric pH sensing is known. See e.g., US Pat. Publication Nos.
2006/0105174; 2005/0090014; incorporated berein in their entirety by reference. Given an indicator system comprising a fluorophore (e.g., a fluorescent indicator dye) that exists in two forms (an acid form and a base form) the ratio of the emission intensity at the two wavelengths can be used to measure pH independent of the fluorophore concentration. The fluorescent indicator dyes suitable for ratiometric pH sensing may be: (1) dyes that exhibit dual excitation wavelengths (corresponding to acid and conjugate base forms) and single emission wavelengths (e.g., HPTS dyes); (2) single excitation wavelengths and dual emission wavelengths (acid and base forms); or (3) dual excitation - dual emission dyes. Some dyes, such as the SNARF or SNAFL dyes may have both dual-emission and dual-excitation properties. However a dual-dual dye, e.g., SNARF can be used as a single-dual or a dual-single.
101051 Dual emission fiber-optic sensors based on seminapthofluorescein and carboxynaphthofluorescein have been described that rapidly and reliably correlate intensity ratios to pH. See e.g., respectively, Xu, Z., A. Rollins, et al. (1998) "A
novel fiber-optic pH
sensor incorporating carboxy SNAFL-2 and fluorescent wavelength-ratiometric detection"
Journal of Biomedical Materials Research 39: 9-15, and Song, A., S. Parus, et al. (1997) "High-performance fiber-optic pH microsensors for practical physiological measurements using a dual-emission sensitive dye" Analytical Chemistry 69: 863-867. The extensive photobleaching observed for these dyes may be accounted for by the ratiometric approach, but it would still limit the useful lifetime of the sensor.
101061 The fluorescent dye 8-hydroxy-1,3,6-pyrene trisulphonic acid trisodium salt (HPTS) consists of a pyrene core with three sulfonic acid groups and a hydroxyl group that imparts pH sensitivity around a pKa of approximately 7.3 (Wolfbeis, O.
S., E.
Fuerlinger, et al. (1983). "Fluorimetric analysis. I_ Study on fluorescent indicators for measuring near neutral ('physiological') pH values." Fresneius' Z. Anal. Chem.
314(2): 119-124); Wolfbeis et al, also have several patents on immobilized HPTS. Yafuso and Hui describe another immobilized fluorescent dye pH sensor in US Pat. No_ 4,886,338;
incorporated herein in its entirety by reference thereto. HPTS exhibits two excitation wavelengths, one at 405 nm and one at 457 nm, that correspond to the acid and its conjugate base (Agayn, V_ 1. and Dr. R. Walt (1993). "Fiber-optic sensor for continuous monitoring of fennentation pH." Biotechiiology 72(6):6-9). The subsequent pH-dependent shift in excitation maximum about the pKa of 7.3 enables dual -excitation/ single emission ratiometric detection in the physiological range. This, together with a low toxicity (Lutty, G. A_ (1978).
"The acute intravenous toxicity of stains, dyes, and other fluorescent substances." Toxical Pharmacol. 44: 225-229) and insensitivity to oxygen concentration (Zbujun, Z_ and W. R.
Seitz (1984). "A fluorescence sensor for quantifying pH in the range from 6.5 to 8.5."
Analytical Chimica Acta 160: 47-55), makes HPTS a suitable probe for physiological and bioprocess pH measurements.
10107] The presence of the three strongly anionic sulphonic acid groups allows for HPTS to be immobilized by ionic binding to cationic supports. To date, covalent attachment of HPTS has been via sulfonamide coupling (U.S. Pat. No.
4,798,738). While effective in immobilizing the dye and preserving pH sensitivity, polymer substrates are limited to those that contain primary amines. In addition, amine groups which remain on the substrate after coupling will affect the local pH inside the polymer matrix.
The dye has been covalently attached to controlled pore glass (4ffenbacher, H., O. S. Wolfbeis, et al_ (1986).
"Fluorescence optical sensors for continuous determination of near-neutral pH
values."
Sensor Actuator 9: 73-84) and aminoethyl cellulose (Schulman, S. G., S. Chen, et al. (1995).
101011 The polymer matrix is comprised of organic, inorganic or combinations of polymers thereof. The matrix may be composed of biocompatible materials.
AltemativeIy, the matrix is coated with a second biocompatible polymer that is permeable to the analytes of interest. The function of the polymer matrix is to hold together and immobilize the fluorescent dye and quencher moieties while at the same time allowing contact with the analytes (e.g., polyhydroxyl compounds, H+ and OH-), and binding of the polyhydroxyl compounds to the boronic acid. Therefore, the matrix is insoluble in the medium and in close association with it by establishing a high surface area interface between matrix and analyte solution. The matrix also does not interfere with transport of the analyte to the binding sites so that equilibrium can be established between the two phases. In one embodiment, an ultra-thin film or microporous support i-natrix may be used. In another einbodiinent, the matrix that is swellable in the analyte solution (e.g. a hydrogel matrix) can be used for aqueous systems. In some embodiments, the sensing polymers are bonded to a surface such as the surface of a light conduit, or impregnated in a microporous membrane.
Techniques for preparing ultra-thin films, microporous polymers, microporous sol-gels, and hydrogels have been established in the prior art.
[01021 In one preferred embodiment, the boronic acid substituted viologen may be covalently bonded to a fluorescent dye. The adduct may be a polymerizable compound or a unit in a polymer. One such adduct for example may be prepared by first forming an unsymmetrical viologen from 4,4'-dipyridyl by attaching a benzyl-3-boronic acid group to one nitrogen and an aminoethyl group to the other nitrogen atom. The viologen is condensed sequentially first with 8-acetoxy-pyrene-1,3,6-trisulfonyl chloride in a l:l mole ratio followed by reaction with excess PEG diamine to obtain a prepolymer mixture.
An acid acceptor is included in both steps to scavange the byproduct acid. The prepolymer rnixture is crosslinked by reaction with a polyisocyanate to obtain a hydrogel. The product is treated with base to remove the acetoxy blocking group. lncomplete reaction products and unreacted starting materials are leached out of the hydrogel by exhaustive extraction with deionized water before further use. The product is responsive to glucose when used as the sensing component as described herein.
101031 Alternatively, such adducts are ethylenically unsaturated 3-nonomer derivatives. For example, dirnethyl bis-bromomethyl benzene boronate is reacted with excess 4,4'-dipyridyl to form a half viologen adduct. After removing the excess dipyridyl, the adduct is further reacted with an excess of bromoethylamine hydrochloride to form the bis-viologen adduct. This adduct is coupled to a pyranine dye by reaction with the 8-acetoxypyrene-tris sulfonyl chloride in a 1:1 mole ratio in the presence of an acid acceptor followed by reaction with excess aminopropylmethacrylamide. Finally, any residual amino groups may be reacted with methacrylol chloride. After purification, the dye/viologen monomer may be copolyznerized with HEMA and PEGDMA to obtain a hydrogel.
Ratiometric pHSensing 101041 Ratiometric pH sensing is known. See e.g., US Pat. Publication Nos.
2006/0105174; 2005/0090014; incorporated berein in their entirety by reference. Given an indicator system comprising a fluorophore (e.g., a fluorescent indicator dye) that exists in two forms (an acid form and a base form) the ratio of the emission intensity at the two wavelengths can be used to measure pH independent of the fluorophore concentration. The fluorescent indicator dyes suitable for ratiometric pH sensing may be: (1) dyes that exhibit dual excitation wavelengths (corresponding to acid and conjugate base forms) and single emission wavelengths (e.g., HPTS dyes); (2) single excitation wavelengths and dual emission wavelengths (acid and base forms); or (3) dual excitation - dual emission dyes. Some dyes, such as the SNARF or SNAFL dyes may have both dual-emission and dual-excitation properties. However a dual-dual dye, e.g., SNARF can be used as a single-dual or a dual-single.
101051 Dual emission fiber-optic sensors based on seminapthofluorescein and carboxynaphthofluorescein have been described that rapidly and reliably correlate intensity ratios to pH. See e.g., respectively, Xu, Z., A. Rollins, et al. (1998) "A
novel fiber-optic pH
sensor incorporating carboxy SNAFL-2 and fluorescent wavelength-ratiometric detection"
Journal of Biomedical Materials Research 39: 9-15, and Song, A., S. Parus, et al. (1997) "High-performance fiber-optic pH microsensors for practical physiological measurements using a dual-emission sensitive dye" Analytical Chemistry 69: 863-867. The extensive photobleaching observed for these dyes may be accounted for by the ratiometric approach, but it would still limit the useful lifetime of the sensor.
101061 The fluorescent dye 8-hydroxy-1,3,6-pyrene trisulphonic acid trisodium salt (HPTS) consists of a pyrene core with three sulfonic acid groups and a hydroxyl group that imparts pH sensitivity around a pKa of approximately 7.3 (Wolfbeis, O.
S., E.
Fuerlinger, et al. (1983). "Fluorimetric analysis. I_ Study on fluorescent indicators for measuring near neutral ('physiological') pH values." Fresneius' Z. Anal. Chem.
314(2): 119-124); Wolfbeis et al, also have several patents on immobilized HPTS. Yafuso and Hui describe another immobilized fluorescent dye pH sensor in US Pat. No_ 4,886,338;
incorporated herein in its entirety by reference thereto. HPTS exhibits two excitation wavelengths, one at 405 nm and one at 457 nm, that correspond to the acid and its conjugate base (Agayn, V_ 1. and Dr. R. Walt (1993). "Fiber-optic sensor for continuous monitoring of fennentation pH." Biotechiiology 72(6):6-9). The subsequent pH-dependent shift in excitation maximum about the pKa of 7.3 enables dual -excitation/ single emission ratiometric detection in the physiological range. This, together with a low toxicity (Lutty, G. A_ (1978).
"The acute intravenous toxicity of stains, dyes, and other fluorescent substances." Toxical Pharmacol. 44: 225-229) and insensitivity to oxygen concentration (Zbujun, Z_ and W. R.
Seitz (1984). "A fluorescence sensor for quantifying pH in the range from 6.5 to 8.5."
Analytical Chimica Acta 160: 47-55), makes HPTS a suitable probe for physiological and bioprocess pH measurements.
10107] The presence of the three strongly anionic sulphonic acid groups allows for HPTS to be immobilized by ionic binding to cationic supports. To date, covalent attachment of HPTS has been via sulfonamide coupling (U.S. Pat. No.
4,798,738). While effective in immobilizing the dye and preserving pH sensitivity, polymer substrates are limited to those that contain primary amines. In addition, amine groups which remain on the substrate after coupling will affect the local pH inside the polymer matrix.
The dye has been covalently attached to controlled pore glass (4ffenbacher, H., O. S. Wolfbeis, et al_ (1986).
"Fluorescence optical sensors for continuous determination of near-neutral pH
values."
Sensor Actuator 9: 73-84) and aminoethyl cellulose (Schulman, S. G., S. Chen, et al. (1995).
"Dependence of the fluorescence of immobilized 1-hydroxypyrene-3,6,8-trisulfonate on solution pH: extension of the range of applicability of a pH fluorosensor."
Anal Chim Acta 304: 165-170) in the development of fluorescence-based pH sensors that operate in neutral and acidic environments, as well as an intravascular blood gas monitoring system where it was used for both pH and pCO2 detection (Gehrich, J. L., D. W. Lubbers, et al.
(1986).
"Optical fluorescence and its application to an intravascular blood gas monitoring system."
IEE TBio-med Eng BME-33: 117-132). Fiber-optic pH sensors have been described with HPTS bound to an anion exchange membrane (Zhujun, Z. and W. R. Seitz (1984)) or resin (Zhang, S., S. Tanaka, et al. (1995). "Fibre-optical sensor based on fluorescent indicator for monitoring physiological pH values." Med Biol Eng Comput 33: 152-156) and fixed to the tip of the optical fiber.
101081 For example U.S. Pat. No. 5,114,676 (incorporated by reference herein in its entirety) provides a pH sensor with a fluorescent indicator which may be covalently attached to a particle or to a microcrystalline cellulose fiber_ The sensor comprises an optically transparent substrate, a thermoplastsc layer and a hydrogel. Part of the particle with the indicator attached thereto is imbedded in a therrmoplastic layer that is coated on the substrate and mechanically adhered using heat and pressure. The majority of the particle/indicator is imbedded within a hydrogel layer that is applied over the thermoplastic layer. The pH sensor is applied to the tip of an optical waveguide.
101091 Furthermore, with the recent availability of low cost UV LEDs, the dye can be measured with relatively inexpensive instrumentation that combines UV
and blue LEDs and a photodiode module. Such a setup has been described (Kostov, Y., P.
Harms, et al. (2001). "Low-cost microbioreactor for high-throughput bioprocessing."
Biotechnol Bioeng 72: 346-352) to detect the pH of a high throughput microbioreactor system via HPTS
directly dissolved in the fermentation media.
101101 In one embodiment of the present invention, the preferred sensing device comprises at least one light source, a detector, and a sensor comprising a fluorescent reporter dye system. In one embodiment, the fluorescent reporter dye system comprises a fluorescent dye operably coupled to an analyte-binding quencher. The dye may be covalently bound to the quencher or merely associated with the quencher. The dye and quencher are preferably operably coupled, which means that in operation, the cluencher is in close enough proximity to the dye to interact with and modulate its fluorescence. In one embodiinent, the dye and quencher may be constrained together within an analyte-penneable hydrogel or other polymeric matrix. When excited by light of appropriate wavelength, the flvorescent dye emits light (e.g., fluoresces). The intensity of the light is dependent on the extent of cluenching which varies with the amount of analyte binding. In other embodiments, the fluorescent dye and the quencher may be covalently attached to hydrogel or other polymeric matrix, instead of to one another.
[0111] ln one embodiment, a separate pH indicator dye is combined with a different dye that is functionalized with an analyte-binding moiety, such that the two dye system are immobilized togetlier (e.g., in a hydrogel) in the sensor.
101121 Some fluorescent pH indicator molecules absorb light at a particular wavelength and emit light at a second, longer wavelength. Their pH indicating function typically involves protonation and deprotonation. This means that -these '#luorescent pH
indicators include a hydrogen atom (proton, H+) which forms part of the molecule (is bound to the molecule) in one pH range, but within another pH range the proton is dissociated from the molecule_ When the proton is disassociated from the molecule, the molecule takes on a negative charge, which is balanced by a positively-charged ion (e.g., Na+) in solution with the indicator. This arrangement is illustrated by Equation 1. R-H > R+H+
(0113} Where R represents a fluorescent molecule, it generally will exhibit fluorescence at a different wavelength (will be visible as a very different color) based upon whether it is in the R H form or in the R form. For most molecules represented by R, this change will occur generally quite abruptly within a very narrow pH range, allowing R to serve as a very simple and reliable pH indicator. When placed in solution, it will exhibit one very distinct color (a color associated with its R--H form), and another very distinct color associated with its R _ 101141 For example, 8-Hydroxyl-1,3,6-pyrenetrisulphonate (HPTS) has been considered one of the best potential indicators for pH determination because of its excellent photo-stability, high quantum yield, dual excitation, large Stokes' shift and long fluorescence emission. A desirable feature of this indicator is that the acidic (associated HPTS form) and basic (dissociated PTS-) forms have different excitation wavelengths at 406 and 460 nm, with an isosbestic point at 418 nm, but exhibit a similar fluorescence emission maximum at 515 nm. The dual excitation and single einission make HPTS suitable for ratiometric detection of pH. The fluorescence intensity at 406 nm for the acid form decreases but the intensity at 460 nm for the base form increases as the pH is raised accompanying the conversion of the acidic into basic forms of the dye.
101151 Due to the hydroxyl (-OH) group on dyes such as HPTS and its derivatives, these dyes are sensitive to the pH changes in the environment.
The pH-dependent ionization of the hydroxyl group causes these pyranine derivatives to have a pH-dependent absorption spectra with different absorption maxima in its acidic form and basic form. The first absorption maximum is the first excitation wavelength and the second absorption maximum is the second excitation wavelength. The arnounts of light absorbed by the fluorescent dye at the first excitation wavelength and the second excitation wavelength depend on or relate to the pH of the medium the fluorescent dye is in contact with. The amount of light emitted by the dye (e.g., the fluorescent emission) at the emission wavelength depends on the amount of light absorption when the dye is irradiated at the excitation wavelength. Since the absorption is affected by the pH of the medium, the fluorescent emission is also affected by the pH. This provides the basis for the pH
determination while being able to measure the polyhydroxyl compound concentration.
101161 In one preferred ernbodiment of the present invention, ratiometric pH
sensing is accomplished using an optical sensor comprising at least one excitation light source operably coupled to the proximal end region of an optical fiber, wherein the fiber has disposed along its distal end region within the light path of the fiber, an indicator system configured to generate a detectable emission signal in response to the excitation light.
Preferred embodiments of the sensor further comprise optical means for sending the emission signal to a detector. Such optical means are well known in the art, and may involve e.g., a mirror to return light, filters, lens, beam splitters, and optical fiber bundles and split configurations.
[0117] In preferred embodiments, the indicator system comprises a fluorophore that exhibits at least two different forms and a pH-dependent shift between these different forms, wherein this shift can be detected as a change in the emission intensity at a single wavelength or at two different wavelengths. For example, one indicator system for ratiometric pH sensing comprises an fluorescent dye (e.g., HPTS) that absorbs light at two different wavelength maxima's (7,cid and Xbase) depending on whether the dye is in its acid or base forms, and it emits light at a single longer emission wavelength. More particularly, as pH is increased, HPTS shows an increase in absorbance corresponding to the Xbase and a decrease in absorbance corresponding to the ~.acid= These changes are due to the pH-dependent ionization of the hydroxyl group. The emission spectrum for HPTS is independent of pH, with a peak emission wavelength of about 511 nm, but the intensity of the emitted light depends on the amount of light absorbed (which varies with pH and the excitation wavelength). So for example, if one excites HPTS at a given pH with light of a first wavelength (e.g., Xn;d), one can measure the emission intensity at the single emission wavelength; the intensity will depend on the form of the dye (i.e., degree of ionization -which depends on the pH). One can also excite at a second wavelength (e.g., Xba$. ) and measure the emission intensity at the same given pH. The ratio of the emission intensities relates to the pH and is independent on the amount of the dye as well as certain optical artifacts in the system. It is noted that any excitation wavelengths may be used for the ratiometric sensing, but theXnid and Xbase are preferred in accordance with one embodiment of the invention. The wavelength at which the absorption is the same for the acid and base forms of the dye is called the isobestic point-excitation at this wavelength (k;SO) may also be used in ratiometric sensing in accordance with other preferred variations to the invention.
When a ratio of emission intensities (e.g., IbaA;so or IbasWlnid) is plotted against pH, a standard or calibration curve is generated (See e.g., FIGS. 3, 5 and 9). The ratiometric method is similar regardless of whether the dye used is a dual exciter-single emitter (like NPTS), or a single exciter dual emitter, or a dual exciter-dual emitter, as long as the dye undergoes a pH sensitive shift in form that yields a detectable change in spectral property.
Optical Glucose Sensing 101181 Indicator systems comprising fluorescent dyes, including HPTS and its derivatives, have been used in analyte detection. See e.g., U.S. Pat. Nos.
6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; and co-pending U.S. Patent Application Nos.
1 I/296,898 and 601833,081 : each of which is incorporated herein in its entirety by reference thereto. In particular, details related to soine preferred fluorescent dyes, guenchers/analyte binding moieties, and inethods for optically determining polyhydroxyl compound concentrations are disclosed in U.S. Pat. Nos. 6,653,141 and 6,627,177, and U.S. Pat.
Application Nos. ] 11296,898 and 60/833,081.
Device for lntravascular Detei7nination of pH and Glucose 101 191 In one embodiment, the method and sensor monitor the pH of the media and the concentration of analyte in vitro. In another embodiment, the method and sensor monitor pH and analyte concentration in vivo. In another embodiment, the measured pH
value can also be used to more correctly determine glucose eoncentration in vitro or in vivo.
Specifically, the simultaneous measurexnent of the pH value and the glucose concentration would enable real time correction of the signal of glucose response. Although it will be appreciated that the device in accordance with sonie embodiments comprise a sensor that may be used only to determine pH or analyte (correction of which for pH may be done by conventional two sensor technologies or by testing the blood pH in vitro).
101201 One embodiment provides a device for determining pH and the concentration of a polyhydroxyl compound simultaneously, comprising a sensor comprising a fluorescent dye operably coupled to a quencher; means for delivering one or more excitation wavelengths to said sensor; and means for detecting fluorescence emission from said sensor.
[0121) Another embodiment provides a device for determining the pH and the polyhydroxyl compound concentration in a physiological fluid, comprising a water-insoluble polymer matrix, wherein said polymer matrix is permeable to polyhydroxyl compound; a fluorescent dye associated with said polymer matrix, wherein the fluorescent dye is configured to absorb light at a first excitation wavelength and a second excitation wavelength, and to emit light at an emission wavelength; a quencher comprising an aromatic boronic acid substituted viologen, adapted to reversibly bind an amount of polyhydroxyl compound dependent on the polyhydroxyl compound concentration, wherein said quencher is associated with said polymer inatrix and operably coupled to the fluorescent dye, and wherein the quencher is conf g-ured to reduce the light intensity emitted by said fluorescent dye related to the amount of bound polyhydroxyl compound; at least one excitation light source; and an emission light detector.
10122] In one aspect, the present invention comprises a class of fluorescence quenching compounds that are responsive to the presence of polyhydroxyl compounds such as glucose in aqueous media at or near physiological pH. In other words, the quenching efficiency is controlled by the concentration of these compounds in the medium. Preferred quenchers comprise a viologen substituted with at least one boronic acid group wherein the adduct is immobilized in or covalently bonded to a polymer. The quencher, dye and polymer may also be covalently bonded to each other. In another aspect, the present invention comprises a class of fluorescent dyes which are susceptible to quenching by the viologen/boronic acid adduct.
101231 The fluorescent dye and quencher are operably coupled to each other for polyhydoxyl compound sensing. The dye and quencher may be linked through a polymer backbone in some embodiments_ In other eanbodiments, the dye and quencher could be in close proximity to each other for the quenching of the fluorescent dye to occur, thereby reducing the fluorescent emission of the dye. VJhen polyhydroxyl compound (e.g., glucose) binds to the boronic acid to form boronate ester, the boronate ester interacts with the viologen and alters its quenching efficacy according to the extent of polyhydroxyl compound binding.
As a result, the intensity of fluorescent emission increases as more polybydroxyl compounds are bonded to the quenchers.
101241 In one preferred embodiment, the device comprises an optical fiber cornprising a cavity disposed therein and having irnTnobilized within the cavity an indicator system as described above (e.g., a fluorophore operably coupled to a glucose binding moiety/quencher and an immobilizing polymeric matrix). The device further comprises a light source and a detector.
Methods for Simultaneous Determination of H and Glucose 101251 One embodiment provides a method for deterrnining the pH and the polyhydroxyl compound concentration with one fluorescent dye, comprising providing a sensor comprising a fluorescent dye operably coupled to a quencher; contacting said sensor with a sample; irradiating said sensor at the frst excitation wavelength;
detecting a first fluorescence emission of said sensor at an emission wavelength; irradiating said sensor at the second excitation wavelength; measuring a second fluorescence emission of said sensor at said emission wavelength; comparing the ratio of the first and second emissions with a pH
calibration curve to determine the pH of the sample; correlating the emission quenching with a standard curve at the known pH to determine the polyhydroxyl compound concentration in said sample. Of course other algorithms are known for ratiometric pN sensing and may be used in accordance with embodiments of the present invention. A controller, such as a computer or dedicated device, may be used in some embodiments to control the operations, including application of the excitation light, monitoring of detector signals, determining ratios, correlating ratios with calibration curves, correlating glucose signals with standard curves, correcting for pH changes, running routine sensor calibration operations, prompting operator actions, integrating user data input (e.g., finger stick glucose measurements) as programmed to maintain accuracy, etc.
[0] 26] With respect to Figure 1, a sensing device 100 in accordance with one embodiment of the present invention comprises at least one light source Il (e.g., an excitation light source), a detector 15 (e.g., an emission light detector), and a sensor 13 comprising a fluorescent dye operably coupled to a quencher and an optional polymer matrix.
In some embodiments, the light source 11 may be adapted to selectively deliver two or more different wavelength for the excitations of fluorescent dyes. This type of light source may be a tunable light source. In other embodiments, one or more light sources may be used in conjunction with an optical filter 12 for attenuating the wavelengths. In other embodiments, more than one light source 11 may be used to deliver different excitation wavelengths. Such light source is also a means for delivering a first and a second excitation wavelengths to the sensor.
101271 The sensor 13 comprises a fluorescent dye that is sensitive to both the pH
and the polyhydroxyl compound (e.g_, sugar or glucose) concentration of the medium when the dye is operably coupled to a quencher. Such fluorescent dye exhibits a shift in excitation wavelength maximum with a corresponding shift in pH of the local environment of the fluorescent dye. As the pH of the local environment changes, the absorption at a first excitation wavelength may increase, while the absorption at a second excitation wavelength decreases, or vice versa. The change in absorption at a selected wavelength can affect the Ievel of fluorescence emission, therefore ultimately permitting pH detection.
The pH
detection is independent of the concentration of the polyhydroxyl compound in the environment. A suitable fluorescent dye is also susceptible to quenching by molecules such as viologens. When the fluorescent dye is operably coupled to a quencher (e.g., a viologen), the fluorescence emission is attenuated. The quencher may have an aromatic boronic acid moiety that is capable of providing glucose recognition. The boronic acid reacts reversibly with glucose in aqueous media to form boronate ester, and the extent of such reaction is related to the glucose concentration in the medium. As more glucose is available to react with the quencher, the quencher's ability to accept electron from the dye decreases_ As a result, the attenuation of fluorescence emission by the quencher is dependent on the concentration of the polyhydroxyl compound (e.g., glucose) to be detected.
[0128) A detector 15 is used to detect the fluorescent emission and in preferred embodiments, may be linked to the electronic control 20 for analysis. Optical fllters,, e.g., 14, can be placed between the sensor 13 and the detector 15 for wavelength selection. Other optical components may also be utilized, e.g., mirrors, collimating and/or focusing lenses, beam splitters, etc. Optical fibers can be used to deliver selected wavelengths to the sensor and to deliver the fluorescen:ce emission from the sensor to the detector. The light source and the detector may be controlled by electronic control 20 such as a computer.
[0129] One embodiment of this invention provides a method for measuring pH
and polyhydroxyl compound concentration with a single fluorescent dye.
Measurements can be carried out in vitro or in vivo. It may be necessary to calibrate the sensor prior to performing the first measurement. This may be done by first acquiring the absorbance spectra of the sensor at various pHs to determine the wavelengths where isobestic point and absorption maxima for acid and base forms occur and then acquiring the emission signals from at least two of these wavelengths at at least one known pH and glucose concentration.
101301 For the pH and polyhydroxyl concentration measurements, the sensor 13 is first placed in contact with a sample. The sensor 13 is then irradiated at the first excitation wavelength followed by the second excitation wavelength. The first and second excitation wavelengths are typically chosen near the wavelength of the absorption maximum for the acidic form of the fluorescent dye the wavelength of the absorption maxinium for the basic form of the fluoresceiit dye Plbase), or the wavelength of the isobestic point (Xiso), or other selected wavelength. Thc ratio of the emissions from the first and second excitation wavelengths are used to determine the sample pH. Either the first or second emission, once corrected for pH, can be used to determine the sample glucose concentration.
10I3I1 In variations to the sensing device shown in Figure I, the detector may be a standard photodiode detector. There may be two diode detectors, one for a reference and one for the emission signal. Instead of diode detectors, the optical fiber carrying sensor output (fluorescent emission and/or reflected excitation light) may provide input directly to a spectrophotometer or microspectrometer. In a preferred embodiment, the detector comprises ainicrospectrometer such as the UV/VIS Microspectrometer Module manufactured by Boehringer Ingelheim.
101321 Figure 2 shows one embodiment of an optical system that may be used in accordance with preferred aspects of the present invention. With reference to FIG. 2, certain embodiments comprise at least two light sources, 301A and 301B. The light sources generate excitation light that may be transmitted (as illustrated) through collimator lenses 302A and 302B. In certain embodiments, the resulting light from collimator lenses may be transmitted (as illustrated) to interference filters 303A and'303B. In certain embodiments, the resulting light from interference filters may be focused (as illustrated) by focusing lenses 304A and 304B into fiber optic lines 305A and 305B. In certain embodiments, fiber optic lines merge into a single fiber 306 that is continuous with the sensor 307, having the imbedded indicator system 307A. The cross-sections of the fibers may vary (as illustrated) from a bundle of fibers surrounding a central optical fiber 306A to a single fiber 307A.
101331 In certain embodiments (as illustrated), the emission light signals generated by the indicator system 307A as well as the excitation light signals are reflected by mirror 308 and transmitted back out of the sensor into the fiber optic outlet lines 309 and 309A. In the illustrated system, the outlet lines are augmented by including two interference filters 312A, 312B and two detectors 313A, 3138. In preferred ernbodiments, the interference filter 312A is configured to block the excitation light and allow the emission light to pass to detector 313A where the emission light is detected. In certain embodiments, the signal produced by the detector 313A is amplified by the amplifier 314A
and converted into a digital signal by analog-to-digital converter 315A and transmitted to computer 316. In certain embodiments, the interference filter 312B is configured to block the emission light and allow the excitation lights to pass to detector 313B where the excitation light is measured. ln certain embodiments, the signal produced by the detector 313B is amplified by the amplifier 314B and converted into a digital signal by analog-to-digital converter 315B
and transmitted to computer 316. Ratiornetric calculations may be employed to substantially eliminate or reduce non-glucose related factors affecting the intensity of the emission light;
these methods are disclosed in detail in co-pending US Provisional Application No.
60/888,477, entitled "Optical systems and methods for ratiometric measurernent of glucose using intravascular fluorophore sensors," filed herewith on the same day, and incorporated herein in its entirety by reference thereto.
EXAMPLES
101341 Example 1- Figure 3 shows an example of the cxcitation/absorption spectrum of a fluorescent dye, in this case HPTS. From the absorption spectra of the fluorescent dye acquired at diff-erent pHs, Xa~,ia, kbase and X,50 can be determined. At a lower pH (e.g., more acidic condition), the peak at around 405 nm is higher than the peak at around 460 nm, and is therefore the absorption maximum for the acidic form of the fluorescent dye.
At a higher pH (e.g., more basic condition), the peak at round 460 nm is higher than the peak at around 405 nm, therefore is the absorption maximum for the basic form of the fluorescent dye. The ?L15L, would be the wavelength where the absorption is independent of the pH, and it would be, for example, around 422 nm for HPTS.
10135] The first fluorescence emission intensity (1x, which could be lae;a, lbase or I;SO) at a emission wavelength, resulting from the irradiation at the first excitation wavelength (e.g., Xac;d, a.base or ?.,So), is then measured by the detector and the result is stored in the electronic control. Then the sensor is again irradiated at the second excitation wavelength.
The second excitation wavelength is different from the first excitation wavelength and can also be selected from ?tac,a, Xbase or Xiso. The detector will then detect/measure the second fluorescence emission intensity (Iy, which could be la,;a, Ibase or l;so) resulting from the irradiation at the second excitation wavelength (e.g., kac;a, kbase or Xiso).
The ratio of the first and the second fluorescence emissions (1,t/Iy) can then be computed. Since the lX/ly is independent from the polyhydroxyl concentration, a pH standard curve (Ix1Iy vs. pH) can be plotted without considering the effect of polyhydroxyl concentration.
101361 Example 2 HPTS/MABP4 -- Figure 4 shows independence of ratiometric pH sensing using HPTS/MABP4 using the I(bQSe)/l(,so) ratio from glucose concentration. The structure of MABP4 is:
HN NH
4Br G) /I
N NO
\ (D N-~
B(OH)2 (F-kO)2B
MABP`j~
[0137] The data are plotted as a ratio of the fluorescence emission for corresponding to excitation at 454 nm (base) and 422 nm (isobestic point) vs_ pH in various glucose concentrations. The changes in glucose concentrations have no diseernable effects on the value of Ib1S,/I7, at each specific pH. Thus the pH of the sample can be measured using a standard curve of Ix/ly vs, pH, regardless of the polyhydroxyl compound concentration in the sample. By correlating or comparing the measured 1,,/Iy to the standard curve, one may deternnine the pH of the sample being measured.
[0138] Figure 5 shows glucose response curves for HPTS/MABP4 excited at 422 nm (isobestic point) at different pHs. By plotting the ratio of IX/Iy at various glucose levels (1) to 1X/Iy at zero glucose concentration (Ia) vs. glucose concentration, a standard polyhydroxyl response curve can be used to determine the glucose concentration in a sample from measured I/10 values. However, since 1/1() value is dependent on the pH of the sample, the standard glucose response curve can be affected by the different pH. To circumvent this, several standard glucose response curves at different pHs within the pbysiological range can be plotted and available for selection by either the electronic control or the operator of the sensor device. When the lX/lv measurement of the sample is available, the electronic control or the operator would know the pH of the sample from the standard 1x1IY vs. pH
curve, and the correct standard polyhydroxyl response curve (e.g., glucose response curve) may be used for determining the accurate glucose concentration. Although the examples shown in the figures concern determination of glucose concentration, the application of the method and device of the present invention is not limited to detecting glucose concentration. Since the fluorescent system responds to polyhydroxyl compounds the same way it responds to glucose, the sensor device can be used to detect any polyhydroxyl compound concentration and the pH at the same time.
101391 Example 3(SNARF-1) - Figure 6 shows the absorption spectra of SNARF-1 at different pHs in solution. SNARF is a tradename for a class of commercial dyes from Molecular Probes, Inc. These experiments were carried out using SNARF-1.
Figures 7 and 8 show glucose response curves for SNARF-1/3,3'-oBBV in solution at different pHs determined at 514 mn excitationl5$7 nrn emission (Figure 7), or at 514 nm excitation1625 nm emission (Figure 8). Figure 9 shows ratiometric sensing of pH at different glucose concentrations with SNARF-I13,3'-oBBV in solution using the I(bQSe)/I(Q,;d) ratio determined at a single excitation wavelength of 514 nm and emission wavelengths of 587 and 625 nm.
Thus, the dual-dual dye SNARF-I may be used operably coupled to the quencher 3,3'-oBBV
(in solution) as a single exciter-dual emitter 17uorophore to determine both pH ratiometrically and glucose.
101401 Example 4(HPTS-triLysMA/3,3'-oBBVIDMAA) - Figure 10 shows the glucose response of HPTS-tril.ysMA/3,3'-oBBV/DMAA indicator system at different pHs.
Figure I I shows ratiometric sensing of pH at different glucose concentrations with the HPTS-triLysMA/3,3'-oBBVIDMAA indicator system, using the I(base)II(uc;d) ratio. It can be seen that this indicator system provides a linear pH curve over the physiologic pH range.
[0141] Example 5(HPTS-triCysMAJ3,3'-oBBV/DMMA) - Figure 12 shows ratiometric sensing of pH at different glucose concentrations with the HPTS-triCysMA/3,3'-oBBV/DMMA indicator system, using the 1(vu.sP)1I(Q,,d) ratio. It can be seen that this indicator system provides a linear pH curve over the physiologic pH range. For this example, the indicator system was immobilized in a hydrogel eznbedded at the end of an optical fiber. The acid and base emission signals were measured using a hand-held detector.
101421 Lifetime Chemistry 101431 In another preferred embodiment, glucose concentrations can be determined by exploiting the phenomena of fluorescence resonance energy transfer (FRET).
FRET is the transfer of energy from a donor fluorophore to an acceptor molecule. FRET
occurs when the donor fluorophore, which fluoresces at a wavelength absorbed at least in part by the acceptor molecule, is in close proximity to the acceptor such that the donor fluorophore can transfer energy to the acceptor through molecular interactions. The fluorescence lifetime of the fluorophore, where the fluorescence lifetime is the time the fluorophore remains in the excited state, is altered by FRET. Thus, measuring the fluorescence lifetime of the fluorophore allows one to determine whether the fluorophore is bound to the acceptor.
[0144] Lifetime can be measured by using a time-domain method where the fluorophore is excited by a brief pulse of excitation ligbt and the fluorescence intensity is measured over time. The excitation pulse can be a pulse from a laser with a duration in the picoseconds range up to a duration of about a few nanoseconds. ln other embodiments, the pulse duration can be greater than about a few nanoseconds. The fluorescenee intensity of the fluorophore as a function of time is given by the equation:
l(t) = Io * exp(-t / z) Equation l 101451 I(t) is the fluorescence intensity at time (t), lo is the initial intensity after excitation and c is the fluorescence lifetime which is defined as the time required for 1(t) to decay to lo/e. Equation I is applicable to a fluorophore with a single exponential decay of fluorescence and a lifetime that is substantially longer than the excitation pulse. Figure 13 shows a graph of the decay of the fluorescent emission 400 over time after a pulse of excitation light 402. The time it takes the initial intensity, lo, to drop to 10/e is equal to the lifetime, -1.
Anal Chim Acta 304: 165-170) in the development of fluorescence-based pH sensors that operate in neutral and acidic environments, as well as an intravascular blood gas monitoring system where it was used for both pH and pCO2 detection (Gehrich, J. L., D. W. Lubbers, et al.
(1986).
"Optical fluorescence and its application to an intravascular blood gas monitoring system."
IEE TBio-med Eng BME-33: 117-132). Fiber-optic pH sensors have been described with HPTS bound to an anion exchange membrane (Zhujun, Z. and W. R. Seitz (1984)) or resin (Zhang, S., S. Tanaka, et al. (1995). "Fibre-optical sensor based on fluorescent indicator for monitoring physiological pH values." Med Biol Eng Comput 33: 152-156) and fixed to the tip of the optical fiber.
101081 For example U.S. Pat. No. 5,114,676 (incorporated by reference herein in its entirety) provides a pH sensor with a fluorescent indicator which may be covalently attached to a particle or to a microcrystalline cellulose fiber_ The sensor comprises an optically transparent substrate, a thermoplastsc layer and a hydrogel. Part of the particle with the indicator attached thereto is imbedded in a therrmoplastic layer that is coated on the substrate and mechanically adhered using heat and pressure. The majority of the particle/indicator is imbedded within a hydrogel layer that is applied over the thermoplastic layer. The pH sensor is applied to the tip of an optical waveguide.
101091 Furthermore, with the recent availability of low cost UV LEDs, the dye can be measured with relatively inexpensive instrumentation that combines UV
and blue LEDs and a photodiode module. Such a setup has been described (Kostov, Y., P.
Harms, et al. (2001). "Low-cost microbioreactor for high-throughput bioprocessing."
Biotechnol Bioeng 72: 346-352) to detect the pH of a high throughput microbioreactor system via HPTS
directly dissolved in the fermentation media.
101101 In one embodiment of the present invention, the preferred sensing device comprises at least one light source, a detector, and a sensor comprising a fluorescent reporter dye system. In one embodiment, the fluorescent reporter dye system comprises a fluorescent dye operably coupled to an analyte-binding quencher. The dye may be covalently bound to the quencher or merely associated with the quencher. The dye and quencher are preferably operably coupled, which means that in operation, the cluencher is in close enough proximity to the dye to interact with and modulate its fluorescence. In one embodiinent, the dye and quencher may be constrained together within an analyte-penneable hydrogel or other polymeric matrix. When excited by light of appropriate wavelength, the flvorescent dye emits light (e.g., fluoresces). The intensity of the light is dependent on the extent of cluenching which varies with the amount of analyte binding. In other embodiments, the fluorescent dye and the quencher may be covalently attached to hydrogel or other polymeric matrix, instead of to one another.
[0111] ln one embodiment, a separate pH indicator dye is combined with a different dye that is functionalized with an analyte-binding moiety, such that the two dye system are immobilized togetlier (e.g., in a hydrogel) in the sensor.
101121 Some fluorescent pH indicator molecules absorb light at a particular wavelength and emit light at a second, longer wavelength. Their pH indicating function typically involves protonation and deprotonation. This means that -these '#luorescent pH
indicators include a hydrogen atom (proton, H+) which forms part of the molecule (is bound to the molecule) in one pH range, but within another pH range the proton is dissociated from the molecule_ When the proton is disassociated from the molecule, the molecule takes on a negative charge, which is balanced by a positively-charged ion (e.g., Na+) in solution with the indicator. This arrangement is illustrated by Equation 1. R-H > R+H+
(0113} Where R represents a fluorescent molecule, it generally will exhibit fluorescence at a different wavelength (will be visible as a very different color) based upon whether it is in the R H form or in the R form. For most molecules represented by R, this change will occur generally quite abruptly within a very narrow pH range, allowing R to serve as a very simple and reliable pH indicator. When placed in solution, it will exhibit one very distinct color (a color associated with its R--H form), and another very distinct color associated with its R _ 101141 For example, 8-Hydroxyl-1,3,6-pyrenetrisulphonate (HPTS) has been considered one of the best potential indicators for pH determination because of its excellent photo-stability, high quantum yield, dual excitation, large Stokes' shift and long fluorescence emission. A desirable feature of this indicator is that the acidic (associated HPTS form) and basic (dissociated PTS-) forms have different excitation wavelengths at 406 and 460 nm, with an isosbestic point at 418 nm, but exhibit a similar fluorescence emission maximum at 515 nm. The dual excitation and single einission make HPTS suitable for ratiometric detection of pH. The fluorescence intensity at 406 nm for the acid form decreases but the intensity at 460 nm for the base form increases as the pH is raised accompanying the conversion of the acidic into basic forms of the dye.
101151 Due to the hydroxyl (-OH) group on dyes such as HPTS and its derivatives, these dyes are sensitive to the pH changes in the environment.
The pH-dependent ionization of the hydroxyl group causes these pyranine derivatives to have a pH-dependent absorption spectra with different absorption maxima in its acidic form and basic form. The first absorption maximum is the first excitation wavelength and the second absorption maximum is the second excitation wavelength. The arnounts of light absorbed by the fluorescent dye at the first excitation wavelength and the second excitation wavelength depend on or relate to the pH of the medium the fluorescent dye is in contact with. The amount of light emitted by the dye (e.g., the fluorescent emission) at the emission wavelength depends on the amount of light absorption when the dye is irradiated at the excitation wavelength. Since the absorption is affected by the pH of the medium, the fluorescent emission is also affected by the pH. This provides the basis for the pH
determination while being able to measure the polyhydroxyl compound concentration.
101161 In one preferred ernbodiment of the present invention, ratiometric pH
sensing is accomplished using an optical sensor comprising at least one excitation light source operably coupled to the proximal end region of an optical fiber, wherein the fiber has disposed along its distal end region within the light path of the fiber, an indicator system configured to generate a detectable emission signal in response to the excitation light.
Preferred embodiments of the sensor further comprise optical means for sending the emission signal to a detector. Such optical means are well known in the art, and may involve e.g., a mirror to return light, filters, lens, beam splitters, and optical fiber bundles and split configurations.
[0117] In preferred embodiments, the indicator system comprises a fluorophore that exhibits at least two different forms and a pH-dependent shift between these different forms, wherein this shift can be detected as a change in the emission intensity at a single wavelength or at two different wavelengths. For example, one indicator system for ratiometric pH sensing comprises an fluorescent dye (e.g., HPTS) that absorbs light at two different wavelength maxima's (7,cid and Xbase) depending on whether the dye is in its acid or base forms, and it emits light at a single longer emission wavelength. More particularly, as pH is increased, HPTS shows an increase in absorbance corresponding to the Xbase and a decrease in absorbance corresponding to the ~.acid= These changes are due to the pH-dependent ionization of the hydroxyl group. The emission spectrum for HPTS is independent of pH, with a peak emission wavelength of about 511 nm, but the intensity of the emitted light depends on the amount of light absorbed (which varies with pH and the excitation wavelength). So for example, if one excites HPTS at a given pH with light of a first wavelength (e.g., Xn;d), one can measure the emission intensity at the single emission wavelength; the intensity will depend on the form of the dye (i.e., degree of ionization -which depends on the pH). One can also excite at a second wavelength (e.g., Xba$. ) and measure the emission intensity at the same given pH. The ratio of the emission intensities relates to the pH and is independent on the amount of the dye as well as certain optical artifacts in the system. It is noted that any excitation wavelengths may be used for the ratiometric sensing, but theXnid and Xbase are preferred in accordance with one embodiment of the invention. The wavelength at which the absorption is the same for the acid and base forms of the dye is called the isobestic point-excitation at this wavelength (k;SO) may also be used in ratiometric sensing in accordance with other preferred variations to the invention.
When a ratio of emission intensities (e.g., IbaA;so or IbasWlnid) is plotted against pH, a standard or calibration curve is generated (See e.g., FIGS. 3, 5 and 9). The ratiometric method is similar regardless of whether the dye used is a dual exciter-single emitter (like NPTS), or a single exciter dual emitter, or a dual exciter-dual emitter, as long as the dye undergoes a pH sensitive shift in form that yields a detectable change in spectral property.
Optical Glucose Sensing 101181 Indicator systems comprising fluorescent dyes, including HPTS and its derivatives, have been used in analyte detection. See e.g., U.S. Pat. Nos.
6,653,141, 6,627,177, 5,512,246, 5,137,833, 6,800,451, 6,794,195, 6,804,544, 6,002,954, 6,319,540, 6,766,183, 5,503,770, and 5,763,238; and co-pending U.S. Patent Application Nos.
1 I/296,898 and 601833,081 : each of which is incorporated herein in its entirety by reference thereto. In particular, details related to soine preferred fluorescent dyes, guenchers/analyte binding moieties, and inethods for optically determining polyhydroxyl compound concentrations are disclosed in U.S. Pat. Nos. 6,653,141 and 6,627,177, and U.S. Pat.
Application Nos. ] 11296,898 and 60/833,081.
Device for lntravascular Detei7nination of pH and Glucose 101 191 In one embodiment, the method and sensor monitor the pH of the media and the concentration of analyte in vitro. In another embodiment, the method and sensor monitor pH and analyte concentration in vivo. In another embodiment, the measured pH
value can also be used to more correctly determine glucose eoncentration in vitro or in vivo.
Specifically, the simultaneous measurexnent of the pH value and the glucose concentration would enable real time correction of the signal of glucose response. Although it will be appreciated that the device in accordance with sonie embodiments comprise a sensor that may be used only to determine pH or analyte (correction of which for pH may be done by conventional two sensor technologies or by testing the blood pH in vitro).
101201 One embodiment provides a device for determining pH and the concentration of a polyhydroxyl compound simultaneously, comprising a sensor comprising a fluorescent dye operably coupled to a quencher; means for delivering one or more excitation wavelengths to said sensor; and means for detecting fluorescence emission from said sensor.
[0121) Another embodiment provides a device for determining the pH and the polyhydroxyl compound concentration in a physiological fluid, comprising a water-insoluble polymer matrix, wherein said polymer matrix is permeable to polyhydroxyl compound; a fluorescent dye associated with said polymer matrix, wherein the fluorescent dye is configured to absorb light at a first excitation wavelength and a second excitation wavelength, and to emit light at an emission wavelength; a quencher comprising an aromatic boronic acid substituted viologen, adapted to reversibly bind an amount of polyhydroxyl compound dependent on the polyhydroxyl compound concentration, wherein said quencher is associated with said polymer inatrix and operably coupled to the fluorescent dye, and wherein the quencher is conf g-ured to reduce the light intensity emitted by said fluorescent dye related to the amount of bound polyhydroxyl compound; at least one excitation light source; and an emission light detector.
10122] In one aspect, the present invention comprises a class of fluorescence quenching compounds that are responsive to the presence of polyhydroxyl compounds such as glucose in aqueous media at or near physiological pH. In other words, the quenching efficiency is controlled by the concentration of these compounds in the medium. Preferred quenchers comprise a viologen substituted with at least one boronic acid group wherein the adduct is immobilized in or covalently bonded to a polymer. The quencher, dye and polymer may also be covalently bonded to each other. In another aspect, the present invention comprises a class of fluorescent dyes which are susceptible to quenching by the viologen/boronic acid adduct.
101231 The fluorescent dye and quencher are operably coupled to each other for polyhydoxyl compound sensing. The dye and quencher may be linked through a polymer backbone in some embodiments_ In other eanbodiments, the dye and quencher could be in close proximity to each other for the quenching of the fluorescent dye to occur, thereby reducing the fluorescent emission of the dye. VJhen polyhydroxyl compound (e.g., glucose) binds to the boronic acid to form boronate ester, the boronate ester interacts with the viologen and alters its quenching efficacy according to the extent of polyhydroxyl compound binding.
As a result, the intensity of fluorescent emission increases as more polybydroxyl compounds are bonded to the quenchers.
101241 In one preferred embodiment, the device comprises an optical fiber cornprising a cavity disposed therein and having irnTnobilized within the cavity an indicator system as described above (e.g., a fluorophore operably coupled to a glucose binding moiety/quencher and an immobilizing polymeric matrix). The device further comprises a light source and a detector.
Methods for Simultaneous Determination of H and Glucose 101251 One embodiment provides a method for deterrnining the pH and the polyhydroxyl compound concentration with one fluorescent dye, comprising providing a sensor comprising a fluorescent dye operably coupled to a quencher; contacting said sensor with a sample; irradiating said sensor at the frst excitation wavelength;
detecting a first fluorescence emission of said sensor at an emission wavelength; irradiating said sensor at the second excitation wavelength; measuring a second fluorescence emission of said sensor at said emission wavelength; comparing the ratio of the first and second emissions with a pH
calibration curve to determine the pH of the sample; correlating the emission quenching with a standard curve at the known pH to determine the polyhydroxyl compound concentration in said sample. Of course other algorithms are known for ratiometric pN sensing and may be used in accordance with embodiments of the present invention. A controller, such as a computer or dedicated device, may be used in some embodiments to control the operations, including application of the excitation light, monitoring of detector signals, determining ratios, correlating ratios with calibration curves, correlating glucose signals with standard curves, correcting for pH changes, running routine sensor calibration operations, prompting operator actions, integrating user data input (e.g., finger stick glucose measurements) as programmed to maintain accuracy, etc.
[0] 26] With respect to Figure 1, a sensing device 100 in accordance with one embodiment of the present invention comprises at least one light source Il (e.g., an excitation light source), a detector 15 (e.g., an emission light detector), and a sensor 13 comprising a fluorescent dye operably coupled to a quencher and an optional polymer matrix.
In some embodiments, the light source 11 may be adapted to selectively deliver two or more different wavelength for the excitations of fluorescent dyes. This type of light source may be a tunable light source. In other embodiments, one or more light sources may be used in conjunction with an optical filter 12 for attenuating the wavelengths. In other embodiments, more than one light source 11 may be used to deliver different excitation wavelengths. Such light source is also a means for delivering a first and a second excitation wavelengths to the sensor.
101271 The sensor 13 comprises a fluorescent dye that is sensitive to both the pH
and the polyhydroxyl compound (e.g_, sugar or glucose) concentration of the medium when the dye is operably coupled to a quencher. Such fluorescent dye exhibits a shift in excitation wavelength maximum with a corresponding shift in pH of the local environment of the fluorescent dye. As the pH of the local environment changes, the absorption at a first excitation wavelength may increase, while the absorption at a second excitation wavelength decreases, or vice versa. The change in absorption at a selected wavelength can affect the Ievel of fluorescence emission, therefore ultimately permitting pH detection.
The pH
detection is independent of the concentration of the polyhydroxyl compound in the environment. A suitable fluorescent dye is also susceptible to quenching by molecules such as viologens. When the fluorescent dye is operably coupled to a quencher (e.g., a viologen), the fluorescence emission is attenuated. The quencher may have an aromatic boronic acid moiety that is capable of providing glucose recognition. The boronic acid reacts reversibly with glucose in aqueous media to form boronate ester, and the extent of such reaction is related to the glucose concentration in the medium. As more glucose is available to react with the quencher, the quencher's ability to accept electron from the dye decreases_ As a result, the attenuation of fluorescence emission by the quencher is dependent on the concentration of the polyhydroxyl compound (e.g., glucose) to be detected.
[0128) A detector 15 is used to detect the fluorescent emission and in preferred embodiments, may be linked to the electronic control 20 for analysis. Optical fllters,, e.g., 14, can be placed between the sensor 13 and the detector 15 for wavelength selection. Other optical components may also be utilized, e.g., mirrors, collimating and/or focusing lenses, beam splitters, etc. Optical fibers can be used to deliver selected wavelengths to the sensor and to deliver the fluorescen:ce emission from the sensor to the detector. The light source and the detector may be controlled by electronic control 20 such as a computer.
[0129] One embodiment of this invention provides a method for measuring pH
and polyhydroxyl compound concentration with a single fluorescent dye.
Measurements can be carried out in vitro or in vivo. It may be necessary to calibrate the sensor prior to performing the first measurement. This may be done by first acquiring the absorbance spectra of the sensor at various pHs to determine the wavelengths where isobestic point and absorption maxima for acid and base forms occur and then acquiring the emission signals from at least two of these wavelengths at at least one known pH and glucose concentration.
101301 For the pH and polyhydroxyl concentration measurements, the sensor 13 is first placed in contact with a sample. The sensor 13 is then irradiated at the first excitation wavelength followed by the second excitation wavelength. The first and second excitation wavelengths are typically chosen near the wavelength of the absorption maximum for the acidic form of the fluorescent dye the wavelength of the absorption maxinium for the basic form of the fluoresceiit dye Plbase), or the wavelength of the isobestic point (Xiso), or other selected wavelength. Thc ratio of the emissions from the first and second excitation wavelengths are used to determine the sample pH. Either the first or second emission, once corrected for pH, can be used to determine the sample glucose concentration.
10I3I1 In variations to the sensing device shown in Figure I, the detector may be a standard photodiode detector. There may be two diode detectors, one for a reference and one for the emission signal. Instead of diode detectors, the optical fiber carrying sensor output (fluorescent emission and/or reflected excitation light) may provide input directly to a spectrophotometer or microspectrometer. In a preferred embodiment, the detector comprises ainicrospectrometer such as the UV/VIS Microspectrometer Module manufactured by Boehringer Ingelheim.
101321 Figure 2 shows one embodiment of an optical system that may be used in accordance with preferred aspects of the present invention. With reference to FIG. 2, certain embodiments comprise at least two light sources, 301A and 301B. The light sources generate excitation light that may be transmitted (as illustrated) through collimator lenses 302A and 302B. In certain embodiments, the resulting light from collimator lenses may be transmitted (as illustrated) to interference filters 303A and'303B. In certain embodiments, the resulting light from interference filters may be focused (as illustrated) by focusing lenses 304A and 304B into fiber optic lines 305A and 305B. In certain embodiments, fiber optic lines merge into a single fiber 306 that is continuous with the sensor 307, having the imbedded indicator system 307A. The cross-sections of the fibers may vary (as illustrated) from a bundle of fibers surrounding a central optical fiber 306A to a single fiber 307A.
101331 In certain embodiments (as illustrated), the emission light signals generated by the indicator system 307A as well as the excitation light signals are reflected by mirror 308 and transmitted back out of the sensor into the fiber optic outlet lines 309 and 309A. In the illustrated system, the outlet lines are augmented by including two interference filters 312A, 312B and two detectors 313A, 3138. In preferred ernbodiments, the interference filter 312A is configured to block the excitation light and allow the emission light to pass to detector 313A where the emission light is detected. In certain embodiments, the signal produced by the detector 313A is amplified by the amplifier 314A
and converted into a digital signal by analog-to-digital converter 315A and transmitted to computer 316. In certain embodiments, the interference filter 312B is configured to block the emission light and allow the excitation lights to pass to detector 313B where the excitation light is measured. ln certain embodiments, the signal produced by the detector 313B is amplified by the amplifier 314B and converted into a digital signal by analog-to-digital converter 315B
and transmitted to computer 316. Ratiornetric calculations may be employed to substantially eliminate or reduce non-glucose related factors affecting the intensity of the emission light;
these methods are disclosed in detail in co-pending US Provisional Application No.
60/888,477, entitled "Optical systems and methods for ratiometric measurernent of glucose using intravascular fluorophore sensors," filed herewith on the same day, and incorporated herein in its entirety by reference thereto.
EXAMPLES
101341 Example 1- Figure 3 shows an example of the cxcitation/absorption spectrum of a fluorescent dye, in this case HPTS. From the absorption spectra of the fluorescent dye acquired at diff-erent pHs, Xa~,ia, kbase and X,50 can be determined. At a lower pH (e.g., more acidic condition), the peak at around 405 nm is higher than the peak at around 460 nm, and is therefore the absorption maximum for the acidic form of the fluorescent dye.
At a higher pH (e.g., more basic condition), the peak at round 460 nm is higher than the peak at around 405 nm, therefore is the absorption maximum for the basic form of the fluorescent dye. The ?L15L, would be the wavelength where the absorption is independent of the pH, and it would be, for example, around 422 nm for HPTS.
10135] The first fluorescence emission intensity (1x, which could be lae;a, lbase or I;SO) at a emission wavelength, resulting from the irradiation at the first excitation wavelength (e.g., Xac;d, a.base or ?.,So), is then measured by the detector and the result is stored in the electronic control. Then the sensor is again irradiated at the second excitation wavelength.
The second excitation wavelength is different from the first excitation wavelength and can also be selected from ?tac,a, Xbase or Xiso. The detector will then detect/measure the second fluorescence emission intensity (Iy, which could be la,;a, Ibase or l;so) resulting from the irradiation at the second excitation wavelength (e.g., kac;a, kbase or Xiso).
The ratio of the first and the second fluorescence emissions (1,t/Iy) can then be computed. Since the lX/ly is independent from the polyhydroxyl concentration, a pH standard curve (Ix1Iy vs. pH) can be plotted without considering the effect of polyhydroxyl concentration.
101361 Example 2 HPTS/MABP4 -- Figure 4 shows independence of ratiometric pH sensing using HPTS/MABP4 using the I(bQSe)/l(,so) ratio from glucose concentration. The structure of MABP4 is:
HN NH
4Br G) /I
N NO
\ (D N-~
B(OH)2 (F-kO)2B
MABP`j~
[0137] The data are plotted as a ratio of the fluorescence emission for corresponding to excitation at 454 nm (base) and 422 nm (isobestic point) vs_ pH in various glucose concentrations. The changes in glucose concentrations have no diseernable effects on the value of Ib1S,/I7, at each specific pH. Thus the pH of the sample can be measured using a standard curve of Ix/ly vs, pH, regardless of the polyhydroxyl compound concentration in the sample. By correlating or comparing the measured 1,,/Iy to the standard curve, one may deternnine the pH of the sample being measured.
[0138] Figure 5 shows glucose response curves for HPTS/MABP4 excited at 422 nm (isobestic point) at different pHs. By plotting the ratio of IX/Iy at various glucose levels (1) to 1X/Iy at zero glucose concentration (Ia) vs. glucose concentration, a standard polyhydroxyl response curve can be used to determine the glucose concentration in a sample from measured I/10 values. However, since 1/1() value is dependent on the pH of the sample, the standard glucose response curve can be affected by the different pH. To circumvent this, several standard glucose response curves at different pHs within the pbysiological range can be plotted and available for selection by either the electronic control or the operator of the sensor device. When the lX/lv measurement of the sample is available, the electronic control or the operator would know the pH of the sample from the standard 1x1IY vs. pH
curve, and the correct standard polyhydroxyl response curve (e.g., glucose response curve) may be used for determining the accurate glucose concentration. Although the examples shown in the figures concern determination of glucose concentration, the application of the method and device of the present invention is not limited to detecting glucose concentration. Since the fluorescent system responds to polyhydroxyl compounds the same way it responds to glucose, the sensor device can be used to detect any polyhydroxyl compound concentration and the pH at the same time.
101391 Example 3(SNARF-1) - Figure 6 shows the absorption spectra of SNARF-1 at different pHs in solution. SNARF is a tradename for a class of commercial dyes from Molecular Probes, Inc. These experiments were carried out using SNARF-1.
Figures 7 and 8 show glucose response curves for SNARF-1/3,3'-oBBV in solution at different pHs determined at 514 mn excitationl5$7 nrn emission (Figure 7), or at 514 nm excitation1625 nm emission (Figure 8). Figure 9 shows ratiometric sensing of pH at different glucose concentrations with SNARF-I13,3'-oBBV in solution using the I(bQSe)/I(Q,;d) ratio determined at a single excitation wavelength of 514 nm and emission wavelengths of 587 and 625 nm.
Thus, the dual-dual dye SNARF-I may be used operably coupled to the quencher 3,3'-oBBV
(in solution) as a single exciter-dual emitter 17uorophore to determine both pH ratiometrically and glucose.
101401 Example 4(HPTS-triLysMA/3,3'-oBBVIDMAA) - Figure 10 shows the glucose response of HPTS-tril.ysMA/3,3'-oBBV/DMAA indicator system at different pHs.
Figure I I shows ratiometric sensing of pH at different glucose concentrations with the HPTS-triLysMA/3,3'-oBBVIDMAA indicator system, using the I(base)II(uc;d) ratio. It can be seen that this indicator system provides a linear pH curve over the physiologic pH range.
[0141] Example 5(HPTS-triCysMAJ3,3'-oBBV/DMMA) - Figure 12 shows ratiometric sensing of pH at different glucose concentrations with the HPTS-triCysMA/3,3'-oBBV/DMMA indicator system, using the 1(vu.sP)1I(Q,,d) ratio. It can be seen that this indicator system provides a linear pH curve over the physiologic pH range. For this example, the indicator system was immobilized in a hydrogel eznbedded at the end of an optical fiber. The acid and base emission signals were measured using a hand-held detector.
101421 Lifetime Chemistry 101431 In another preferred embodiment, glucose concentrations can be determined by exploiting the phenomena of fluorescence resonance energy transfer (FRET).
FRET is the transfer of energy from a donor fluorophore to an acceptor molecule. FRET
occurs when the donor fluorophore, which fluoresces at a wavelength absorbed at least in part by the acceptor molecule, is in close proximity to the acceptor such that the donor fluorophore can transfer energy to the acceptor through molecular interactions. The fluorescence lifetime of the fluorophore, where the fluorescence lifetime is the time the fluorophore remains in the excited state, is altered by FRET. Thus, measuring the fluorescence lifetime of the fluorophore allows one to determine whether the fluorophore is bound to the acceptor.
[0144] Lifetime can be measured by using a time-domain method where the fluorophore is excited by a brief pulse of excitation ligbt and the fluorescence intensity is measured over time. The excitation pulse can be a pulse from a laser with a duration in the picoseconds range up to a duration of about a few nanoseconds. ln other embodiments, the pulse duration can be greater than about a few nanoseconds. The fluorescenee intensity of the fluorophore as a function of time is given by the equation:
l(t) = Io * exp(-t / z) Equation l 101451 I(t) is the fluorescence intensity at time (t), lo is the initial intensity after excitation and c is the fluorescence lifetime which is defined as the time required for 1(t) to decay to lo/e. Equation I is applicable to a fluorophore with a single exponential decay of fluorescence and a lifetime that is substantially longer than the excitation pulse. Figure 13 shows a graph of the decay of the fluorescent emission 400 over time after a pulse of excitation light 402. The time it takes the initial intensity, lo, to drop to 10/e is equal to the lifetime, -1.
101461 An alternative method of ineasuring lifelime is by a frequency-domain method where the fluorophore is excited by a frequency modulated excitation light. The fluorescence lifetime, 'r, can be determined by measuring the phase shift of the emission from the fluorophore relative to the excitation light, or by measuring the modulation ratio, using the following equations:
r~ = (v-' *tan(O) Equation 2 Equation 3 o) = 21r zf,, = w-' *(1Y1 -z -1)1 2 Equation 4 (AC 1 DC) E 1? .
M = Equation 5 (ACI DC)L,v zO is the lifetime detennined by measuring the phase shift, 0. c~ is the angular frequency of the frequency modulated excitation ligbt and f is the linear frequency. r.' is the lifetime determined by measuring the modulation ratio, M. AC is the magnitude of the alternating portion of the signal, or the amplitude of the wave, while DC is the amplitude of the DC portion of the signal. EM refers to the emission signal, and EX refers to the excitation signal. Figure 14 is a graph showing the relationship between the emission signal 500 and the excitation signal 502 and the variables described in Equations 2-5.
101471 Preferred binding assay configurations for use in the sensor include a reversible competitive, reagent limited, binding assay, the components of which include an analyte analog and an analyte binding agent capable of reversibly binding both the analyte of interest and the analyte analog. The analyte of interest and the analyte analog compete for binding to the saine binding site on the analyte binding agent. SUCh competitive binding assay configurations are well known in the art of clinical diagnostics and are described, by way of example, in The lmmunoassay Handbook, ed. David Wild, Macmillan Press 1994.
Suitable analyte binding agents for use in the assay would include antibodies or antibody fragments which retain an analyte binding site (e.g. Fab fragments), lectins (e.g.
concanavalin A), hormone receptors, drug receptors, aptarners and molecularly-imprinted polymers. Preferably the analyte analog should be a substance of higher molecular weight than the analyte such that it cannot freely diffuse out of the sensor. For example, an assay for glucose might employ a high molecular weight glucose polymer such as dextran as the analyte analog.
[0148] Suitable optical signals which can be used as an assay readout in accordance with the invention include any optical signal which can be generated by a proximity assay, such as those generated by fluorescence resonance energy transfer, fluorescence polarisation, fluorescence quenching, phosphorescence technique, luminescence enhancement, lmninescence quenching, diffraction or plasmon resonance.
[01491 In some preferred embodiments of the sensor of the invention incorporates a competitive, reagent limited binding assay which generates an optical readout using the technique of fluorescence resonance energy transfer. In this assay format the analyte analog is labelled with a first chromophore and the analyte binding agent is labelled with a second chromophore_ One of the first and second chromophores acts as a donor chromophore and the other acts as an acceptor chromophore. It is an important feature of the assay that the fluorescence einission spectrum of the donor chromophore overlaps with the absorption spectrum of the acceptor chromophore, such that when the donor and acceptor chromophores are brought into close proximity by the binding agent a proportion of the energy which normally would produce fluorescence emitted by the donor chromophore (following irradiation with incident radiation of a wavelength absorbed by the donor chromophore) will be non radiatively transferred to the adjacent acceptor chromophore, a process known in the art as FRET, with the result that a proportion of the fluorescent signal emitted by the donor chromophore is quenched and, in some instances, that the acceptor chromophore emits fluorescence. Fluorescence resonance energy transfer will generally only occur when the donor and acceptor chromophores are brought into close proximity by the binding of analyte analog to analyte binding agent. Thus, in the presence of analyte, which competes with the analyte analog for binding to the analyte binding agent, the amount of quenching is reduced (resulting in a measurable increase in the intensity of the fluorescent signal emitted by the donor chromophore or a fall in the intensity of the signal emitted by the acceptor chromophore) as labelled analyte analog is displaced from binding to the analyte binding agent. The intensity or lifetime of the fluorescent signal emitted from the donor chromophore thus correlates with the concentration of analyte in the fluid bathing the sensor.
r~ = (v-' *tan(O) Equation 2 Equation 3 o) = 21r zf,, = w-' *(1Y1 -z -1)1 2 Equation 4 (AC 1 DC) E 1? .
M = Equation 5 (ACI DC)L,v zO is the lifetime detennined by measuring the phase shift, 0. c~ is the angular frequency of the frequency modulated excitation ligbt and f is the linear frequency. r.' is the lifetime determined by measuring the modulation ratio, M. AC is the magnitude of the alternating portion of the signal, or the amplitude of the wave, while DC is the amplitude of the DC portion of the signal. EM refers to the emission signal, and EX refers to the excitation signal. Figure 14 is a graph showing the relationship between the emission signal 500 and the excitation signal 502 and the variables described in Equations 2-5.
101471 Preferred binding assay configurations for use in the sensor include a reversible competitive, reagent limited, binding assay, the components of which include an analyte analog and an analyte binding agent capable of reversibly binding both the analyte of interest and the analyte analog. The analyte of interest and the analyte analog compete for binding to the saine binding site on the analyte binding agent. SUCh competitive binding assay configurations are well known in the art of clinical diagnostics and are described, by way of example, in The lmmunoassay Handbook, ed. David Wild, Macmillan Press 1994.
Suitable analyte binding agents for use in the assay would include antibodies or antibody fragments which retain an analyte binding site (e.g. Fab fragments), lectins (e.g.
concanavalin A), hormone receptors, drug receptors, aptarners and molecularly-imprinted polymers. Preferably the analyte analog should be a substance of higher molecular weight than the analyte such that it cannot freely diffuse out of the sensor. For example, an assay for glucose might employ a high molecular weight glucose polymer such as dextran as the analyte analog.
[0148] Suitable optical signals which can be used as an assay readout in accordance with the invention include any optical signal which can be generated by a proximity assay, such as those generated by fluorescence resonance energy transfer, fluorescence polarisation, fluorescence quenching, phosphorescence technique, luminescence enhancement, lmninescence quenching, diffraction or plasmon resonance.
[01491 In some preferred embodiments of the sensor of the invention incorporates a competitive, reagent limited binding assay which generates an optical readout using the technique of fluorescence resonance energy transfer. In this assay format the analyte analog is labelled with a first chromophore and the analyte binding agent is labelled with a second chromophore_ One of the first and second chromophores acts as a donor chromophore and the other acts as an acceptor chromophore. It is an important feature of the assay that the fluorescence einission spectrum of the donor chromophore overlaps with the absorption spectrum of the acceptor chromophore, such that when the donor and acceptor chromophores are brought into close proximity by the binding agent a proportion of the energy which normally would produce fluorescence emitted by the donor chromophore (following irradiation with incident radiation of a wavelength absorbed by the donor chromophore) will be non radiatively transferred to the adjacent acceptor chromophore, a process known in the art as FRET, with the result that a proportion of the fluorescent signal emitted by the donor chromophore is quenched and, in some instances, that the acceptor chromophore emits fluorescence. Fluorescence resonance energy transfer will generally only occur when the donor and acceptor chromophores are brought into close proximity by the binding of analyte analog to analyte binding agent. Thus, in the presence of analyte, which competes with the analyte analog for binding to the analyte binding agent, the amount of quenching is reduced (resulting in a measurable increase in the intensity of the fluorescent signal emitted by the donor chromophore or a fall in the intensity of the signal emitted by the acceptor chromophore) as labelled analyte analog is displaced from binding to the analyte binding agent. The intensity or lifetime of the fluorescent signal emitted from the donor chromophore thus correlates with the concentration of analyte in the fluid bathing the sensor.
]0150] An additional advantageous feature of the fluorescence resonance energy transfer assay format arises from the fact that any fluorescent signal emitted by the acceptor chromophore following excitation with a beam of incident radiation at a wavelength within the absorption spectrum of the acceptor chromophore is unaffected by the fluorescence resonance energy transfer process. lt is therefore possible to use the intensity of the fluorescent signal emitted by the acceptor chromophore as an internal reference signal, for example in continuous calibration of the sensor or to monitor the extent to which the sensor has degraded and thus indicate the need to replace the sensor. As the sensor degrades, the amount of acceptor chromophore present in the sensor will decrease and hence the intensity of fluorescent signal detected upon excitation of the acceptor chrornophore will also decrease.
The fall of this signal below an acceptable baseline level would indicate the need to implant or inject a fresh sensor. Competitive binding assays using the fluorescence resonance energy transfer technique which are capable of being adapted for use in the sensor of the invention are known in the art. U.S. Pat. No. 3,996,345 describes immunoassays employing antibodies and fluorescence resonance energy transfer between a fluorescer-quencher chromophoric pair. Meadows and Schultz (Anal. Chim. Acta (1993 280: pp2l -30) describe a homogeneous assay method for the measurement of glucose based on fluorescence resonance energy transfer between a labelled glucose analog (FITC labelled dextran) and a labelled glucose binding agent (rhodamine labelled concanavalin A). ln all of these configurations the acceptor and donor chrornophores/quenchers can be linked to either the binding agent or the analyte analog.
10I511 Fluorescence lifetime or fluorescence intensity measurements may be made. As described in Lakowitz et al, Analytica Chimica Acta, 271, (1993), 155-164, fluorescence lifetime may be measured by phase modulation techniques.
10152] In some preferred embodiments as shown in Figures 15A, 15B and I5C, a competitive binding system to measure glucose using FRET comprises a glucose binding molecule 600 linked to a donor fluorophore 602 and a glucose analog 604 linked to an acceptor molecule 606. The glucose binding molecule 600 is capable of binding with both glucose 608 and the glucose analog 604. As shown in Figure 15A, when the glucose analog 604 is bound to the glucose binding molecule 600, the fluorescent emission 500 from the fluorophore 602 is reduced in magnitude and shifted in phase and lifetime by because the fluorophore 502 is in close proximity to the acceptor 606. In other embodiments, the fluorophore 602 is linked to the glucose analog 604 and the acceptor 606 is linked to the glucose binding molecule 600.
101531 As shown in Figure 15B, glucose 608 competes with the glucose analog 604 for the binding site on the glucose binding molecule 600. As shown in Figure 15C, the glucose molecule 608 can displace the glucose analog 604 from the glucose binding molecule 600 so that the acceptor 606 does not alter the emission lifetime 500 of the fluorophore 602 via FRET 610.
101541 In a system where there are a certain concentration of glucose binding molecules, glucose analogs and glucose molecules, an eguilibrium will exist between the number of bound glucose molecules to the number of bound glucose analogs. A
change in the nuinber of glucose molecules in the system, changes the equilibrium between bound glucose molecules to bound glucose analogs. This in turn changes the mean lifetime of the fluorophore emission.
10155] In some preferred embodiments, the system is excited by a frequency modUlated excitation light less than approximately 1 MHz, between approximately I to 200 MHZ, or greater than approximately 200 MHz. In some embodiments, the frequency is approximately 0.05, 0.1, 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 MHz. By measuring the degree of the phase shift of the system, an average FRET induced phase shift for the system can be determined which corresponds to an average lifetime value for the system as defined by Equations 2 and 3 described above. Both the phase shift and the lifetime values can be correlated to the glucose concentration. The magnitude of the phase shift is independent of the amplitude of the emission.
101561 In other preferred embodiments, the system is excited by a pulse and the decay of the fluorescence is measured over time. The lifetime can be determined using Equation I described above, and glucose concentration can be correlated to the lifetime value.
(0157] In preferred embodiments, the glucose binding molecule with a donor fluorophore and the glucose analog with an acceptor can be substantially immobilized in the hydrogel described above such that diffiision of the glucose binding molecule and the glucose analog out of the hydrogel is substantially reduced. In addition, the sensor is configured to provide excitation light at a wavelength absorbed by the donor fluorophore as described above. In some embodiments, the excitation light is provided as a short pulse from a laser or a light emitting diode (LED). In other embodiments, the excitation light is frequency modulated. In some embodiments, the frequency modulated excitation light is provided by a laser. In some embodiments the frequency modulated excitation light is provided by a LED.
The sensor also has a detector that detects the amplitude of the emission over time and/or the phase shift of the emission and/or the amplitudes of the AC and DC portions of the emission and excitation light. The detector can be a photodetector or multiple photodetectors. The excitation and emission light can be transmitted tbroughout the sensor via optical fibers.
101581 In some embodiments, the sensor can be introduced into a patient's blood vessel, such as a vein, artery or capillary, for measuring the intravascular concentration of an analyte in the patient"s blood. ln some embodiments, the chemistry used to measure the concentration of the analyte is based on a correlation of fluorescence intensity of a fluorophore to analyte concentration, as described above in more detail. ln some embodiments, the chemistry used to measure the concentration of the analyte is based on a correlation of fluorescence lifetime of a fluorophore to analyte concentration, as described above in more detail. ln some embodiments, the sensor is used to measure the concentration of glucose.
10159] While a number of preferred embodiments of the invention and variations thereof have been described in detail, other modifications and methods of using and medical applications for the same will be apparent to those of skill in the art.
Accordingly, it should be understood that various applications, modifications, and substitutions may be made of equivalents without departing from the spirit of the invention or the scope of the claims.
The fall of this signal below an acceptable baseline level would indicate the need to implant or inject a fresh sensor. Competitive binding assays using the fluorescence resonance energy transfer technique which are capable of being adapted for use in the sensor of the invention are known in the art. U.S. Pat. No. 3,996,345 describes immunoassays employing antibodies and fluorescence resonance energy transfer between a fluorescer-quencher chromophoric pair. Meadows and Schultz (Anal. Chim. Acta (1993 280: pp2l -30) describe a homogeneous assay method for the measurement of glucose based on fluorescence resonance energy transfer between a labelled glucose analog (FITC labelled dextran) and a labelled glucose binding agent (rhodamine labelled concanavalin A). ln all of these configurations the acceptor and donor chrornophores/quenchers can be linked to either the binding agent or the analyte analog.
10I511 Fluorescence lifetime or fluorescence intensity measurements may be made. As described in Lakowitz et al, Analytica Chimica Acta, 271, (1993), 155-164, fluorescence lifetime may be measured by phase modulation techniques.
10152] In some preferred embodiments as shown in Figures 15A, 15B and I5C, a competitive binding system to measure glucose using FRET comprises a glucose binding molecule 600 linked to a donor fluorophore 602 and a glucose analog 604 linked to an acceptor molecule 606. The glucose binding molecule 600 is capable of binding with both glucose 608 and the glucose analog 604. As shown in Figure 15A, when the glucose analog 604 is bound to the glucose binding molecule 600, the fluorescent emission 500 from the fluorophore 602 is reduced in magnitude and shifted in phase and lifetime by because the fluorophore 502 is in close proximity to the acceptor 606. In other embodiments, the fluorophore 602 is linked to the glucose analog 604 and the acceptor 606 is linked to the glucose binding molecule 600.
101531 As shown in Figure 15B, glucose 608 competes with the glucose analog 604 for the binding site on the glucose binding molecule 600. As shown in Figure 15C, the glucose molecule 608 can displace the glucose analog 604 from the glucose binding molecule 600 so that the acceptor 606 does not alter the emission lifetime 500 of the fluorophore 602 via FRET 610.
101541 In a system where there are a certain concentration of glucose binding molecules, glucose analogs and glucose molecules, an eguilibrium will exist between the number of bound glucose molecules to the number of bound glucose analogs. A
change in the nuinber of glucose molecules in the system, changes the equilibrium between bound glucose molecules to bound glucose analogs. This in turn changes the mean lifetime of the fluorophore emission.
10155] In some preferred embodiments, the system is excited by a frequency modUlated excitation light less than approximately 1 MHz, between approximately I to 200 MHZ, or greater than approximately 200 MHz. In some embodiments, the frequency is approximately 0.05, 0.1, 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 MHz. By measuring the degree of the phase shift of the system, an average FRET induced phase shift for the system can be determined which corresponds to an average lifetime value for the system as defined by Equations 2 and 3 described above. Both the phase shift and the lifetime values can be correlated to the glucose concentration. The magnitude of the phase shift is independent of the amplitude of the emission.
101561 In other preferred embodiments, the system is excited by a pulse and the decay of the fluorescence is measured over time. The lifetime can be determined using Equation I described above, and glucose concentration can be correlated to the lifetime value.
(0157] In preferred embodiments, the glucose binding molecule with a donor fluorophore and the glucose analog with an acceptor can be substantially immobilized in the hydrogel described above such that diffiision of the glucose binding molecule and the glucose analog out of the hydrogel is substantially reduced. In addition, the sensor is configured to provide excitation light at a wavelength absorbed by the donor fluorophore as described above. In some embodiments, the excitation light is provided as a short pulse from a laser or a light emitting diode (LED). In other embodiments, the excitation light is frequency modulated. In some embodiments, the frequency modulated excitation light is provided by a laser. In some embodiments the frequency modulated excitation light is provided by a LED.
The sensor also has a detector that detects the amplitude of the emission over time and/or the phase shift of the emission and/or the amplitudes of the AC and DC portions of the emission and excitation light. The detector can be a photodetector or multiple photodetectors. The excitation and emission light can be transmitted tbroughout the sensor via optical fibers.
101581 In some embodiments, the sensor can be introduced into a patient's blood vessel, such as a vein, artery or capillary, for measuring the intravascular concentration of an analyte in the patient"s blood. ln some embodiments, the chemistry used to measure the concentration of the analyte is based on a correlation of fluorescence intensity of a fluorophore to analyte concentration, as described above in more detail. ln some embodiments, the chemistry used to measure the concentration of the analyte is based on a correlation of fluorescence lifetime of a fluorophore to analyte concentration, as described above in more detail. ln some embodiments, the sensor is used to measure the concentration of glucose.
10159] While a number of preferred embodiments of the invention and variations thereof have been described in detail, other modifications and methods of using and medical applications for the same will be apparent to those of skill in the art.
Accordingly, it should be understood that various applications, modifications, and substitutions may be made of equivalents without departing from the spirit of the invention or the scope of the claims.
Claims (20)
1. An intravascular sensor for determining an analyte concentration in blood comprising:
an optical fiber comprising a sensor chemistry portion capable of insertion into a blood vessel, the sensor chemistry portion comprising:
an analyte binding molecule capable of binding an analyte; and a fluorophore associated with the analyte binding molecule, the fluorophore having a first fluorescence when the analyte binding molecule is not bound to the analyte and a second fluorescence when the analyte binding molecule is bound to the analyte;
a light source; and a detector.
an optical fiber comprising a sensor chemistry portion capable of insertion into a blood vessel, the sensor chemistry portion comprising:
an analyte binding molecule capable of binding an analyte; and a fluorophore associated with the analyte binding molecule, the fluorophore having a first fluorescence when the analyte binding molecule is not bound to the analyte and a second fluorescence when the analyte binding molecule is bound to the analyte;
a light source; and a detector.
2. The sensor of Claim 1, wherein the first fluorescence is a first fluorescence intensity and the second fluorescence is a second fluorescence intensity.
3. The sensor of Claim 1, wherein the first fluorescence is a first fluorescence lifetime and the second fluorescence is a second fluorescence lifetime.
4. The sensor of Claim 1, wherein the analyte is glucose.
5. The sensor of Claim 1, further comprising an optical fiber.
6. The sensor of Claim 1, wherein the light source is a laser.
7. The sensor of Claim 1, wherein the light source is a light emitting diode.
8. The sensor of Claim 1, wherein the sensor chemistry portion further comprises a hydrogel that substantially immobilizes the analyte binding molecule and the fluorophore and is permeable to the analyte.
9. The sensor of Claim 1, wherein the sensor chemistry portion further comprises a membrane wlierein the analyte binding molecule and the fluorophore are substantially retained within a volume at least partially enclosed by the membrane.
10. An intravascular sensor for determining an analyte concentration in blood comprising:
a sensor chemistry portion capable of insertion into a blood vessel, the sensor chemistry portion comprising:
an analyte binding molecule capable of binding an analyte; and a fluorophore associated with the analyte binding molecule, the fluorophore having a first fluorescence intensity when the analyte binding molecule is not bound to the analyte and a second fluorescence intensity when the analyte binding molecule is bound to the analyte;
a light source; and a detector.
a sensor chemistry portion capable of insertion into a blood vessel, the sensor chemistry portion comprising:
an analyte binding molecule capable of binding an analyte; and a fluorophore associated with the analyte binding molecule, the fluorophore having a first fluorescence intensity when the analyte binding molecule is not bound to the analyte and a second fluorescence intensity when the analyte binding molecule is bound to the analyte;
a light source; and a detector.
11. An intravascular sensor for determining an analyte concentration in blood comprising:
a sensor chemistry portion capable of insertion into a blood vessel, the sensor chemistry portion comprising:
an analyte binding molecule capable of binding an analyte; and a fluorophore associated with the analyte binding molecule, the fluorophore having a first fluorescence lifetime when the analyte binding molecule is not bound to the analyte and a second fluorescence lifetime when the analyte binding molecule is bound to the analyte;
a light source; and a detector.
a sensor chemistry portion capable of insertion into a blood vessel, the sensor chemistry portion comprising:
an analyte binding molecule capable of binding an analyte; and a fluorophore associated with the analyte binding molecule, the fluorophore having a first fluorescence lifetime when the analyte binding molecule is not bound to the analyte and a second fluorescence lifetime when the analyte binding molecule is bound to the analyte;
a light source; and a detector.
12. A method for determining the glucose concentration in blood comprising:
providing the sensor of any of Claims 1-11;
inserting the sensor into a blood vessel;
irradiating the fluorophore with an excitation signal;
detecting a fluorescence emission from the fluorophore; and determining the concentration of glucose.
providing the sensor of any of Claims 1-11;
inserting the sensor into a blood vessel;
irradiating the fluorophore with an excitation signal;
detecting a fluorescence emission from the fluorophore; and determining the concentration of glucose.
13. The method of Claim 12, wherein the excitation signal is a pulse of light.
14. The method of Claim 13, further comprising measuring the decay of the fluorescence emission over time; and calculating a fluorescence lifetime.
15. The method of Claim 12, wherein the excitation signal is frequency modulated.
16. The method of Claim 15, further comprising measuring the phase shift between the fluorescence emission and the excitation signal.
17. The method of Claim 16, further comprising calculating a fluorescence lifetime.
18. The method of Claim 15, further comprising measuring a modulation ratio;
and calculating a fluorescence lifetime.
and calculating a fluorescence lifetime.
19. The method of Claim 12, further comprising measuring the fluorescence intensity of the fluorescence emission.
20. An intravascular sensor for determining an analyte concentration in blood, comprising an optical fiber comprising a sensor chemistry portion disposed along a distal region of the optical fiber, wherein the sensor chemistry portion is sized and physiologically compatible with residing in a blood vessel, wherein the sensor chemistry portion is selected from equilibrium fluorescence chemistry or lifetime chemistry.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91730707P | 2007-05-10 | 2007-05-10 | |
US60/917,307 | 2007-05-10 | ||
PCT/US2008/063330 WO2008141241A1 (en) | 2007-05-10 | 2008-05-09 | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2686065A1 true CA2686065A1 (en) | 2008-11-20 |
Family
ID=39689412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002686065A Abandoned CA2686065A1 (en) | 2007-05-10 | 2008-05-09 | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
Country Status (5)
Country | Link |
---|---|
US (2) | US8738107B2 (en) |
EP (1) | EP2162057A1 (en) |
JP (1) | JP5517919B2 (en) |
CA (1) | CA2686065A1 (en) |
WO (1) | WO2008141241A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200163595A1 (en) * | 2017-02-12 | 2020-05-28 | Hoon Kim | Portable apparatus for noninvasively measuring blood glucose level and operating method thereof |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US7192450B2 (en) | 2003-05-21 | 2007-03-20 | Dexcom, Inc. | Porous membranes for use with implantable devices |
US7657297B2 (en) * | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US8527026B2 (en) | 1997-03-04 | 2013-09-03 | Dexcom, Inc. | Device and method for determining analyte levels |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) * | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US7828728B2 (en) * | 2003-07-25 | 2010-11-09 | Dexcom, Inc. | Analyte sensor |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US8260393B2 (en) * | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US9282925B2 (en) * | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
US8423113B2 (en) * | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | Oxygen enhancing membrane systems for implantable devices |
US20100168542A1 (en) * | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US7494465B2 (en) * | 2004-07-13 | 2009-02-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
US7519408B2 (en) * | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US6931327B2 (en) * | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US8886273B2 (en) * | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US8369919B2 (en) * | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7774145B2 (en) * | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
WO2005057168A2 (en) | 2003-12-05 | 2005-06-23 | Dexcom, Inc. | Calibration techniques for a continuous analyte sensor |
US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
WO2005057175A2 (en) * | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US7637868B2 (en) * | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8277713B2 (en) * | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20050245799A1 (en) * | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US20060020192A1 (en) | 2004-07-13 | 2006-01-26 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) * | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20060270922A1 (en) | 2004-07-13 | 2006-11-30 | Brauker James H | Analyte sensor |
US7783333B2 (en) * | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8565848B2 (en) * | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8133178B2 (en) * | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
US8744546B2 (en) | 2005-05-05 | 2014-06-03 | Dexcom, Inc. | Cellulosic-based resistance domain for an analyte sensor |
US8060174B2 (en) | 2005-04-15 | 2011-11-15 | Dexcom, Inc. | Analyte sensing biointerface |
US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
EP1991110B1 (en) * | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US7831287B2 (en) | 2006-10-04 | 2010-11-09 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
EP2989975B1 (en) | 2007-02-06 | 2018-06-13 | Medtronic MiniMed, Inc. | Optical systems and methods for rationmetric measurement of blood glucose concentration |
US7751863B2 (en) | 2007-02-06 | 2010-07-06 | Glumetrics, Inc. | Optical determination of ph and glucose |
US8088097B2 (en) | 2007-11-21 | 2012-01-03 | Glumetrics, Inc. | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
US7824918B2 (en) * | 2007-08-06 | 2010-11-02 | Glumetrics, Inc. | HPTS-Mono and BIS Cys-Ma polymerizable fluorescent dyes for use in analyte sensors |
US20090018426A1 (en) * | 2007-05-10 | 2009-01-15 | Glumetrics, Inc. | Device and methods for calibrating analyte sensors |
WO2008141241A1 (en) | 2007-05-10 | 2008-11-20 | Glumetrics, Inc. | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
US20080306444A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US8202731B2 (en) * | 2007-08-06 | 2012-06-19 | Glumetrics, Inc. | HPTS-mono and bis Cys-MA polymerizable fluorescent dyes for use in analyte sensors |
EP2227132B1 (en) | 2007-10-09 | 2023-03-08 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
US20090242399A1 (en) * | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
EP3387993A3 (en) * | 2008-03-28 | 2018-11-14 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8682408B2 (en) * | 2008-03-28 | 2014-03-25 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US8583204B2 (en) | 2008-03-28 | 2013-11-12 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
US11730407B2 (en) | 2008-03-28 | 2023-08-22 | Dexcom, Inc. | Polymer membranes for continuous analyte sensors |
WO2009129186A2 (en) | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
US9042967B2 (en) | 2008-05-20 | 2015-05-26 | University Health Network | Device and method for wound imaging and monitoring |
ES2907152T3 (en) * | 2008-06-06 | 2022-04-22 | Intuity Medical Inc | Blood glucose meter and method of operation |
US8560039B2 (en) | 2008-09-19 | 2013-10-15 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
WO2010111660A1 (en) | 2009-03-27 | 2010-09-30 | Dexcom, Inc. | Methods and systems for promoting glucose management |
US8746031B2 (en) | 2009-05-18 | 2014-06-10 | Lightship Medical Limited | Glucose sensor calibration |
US9517023B2 (en) | 2009-06-01 | 2016-12-13 | Profusa, Inc. | Method and system for directing a localized biological response to an implant |
EP2483679A4 (en) * | 2009-09-30 | 2013-04-24 | Glumetrics Inc | Sensors with thromboresistant coating |
US8467843B2 (en) | 2009-11-04 | 2013-06-18 | Glumetrics, Inc. | Optical sensor configuration for ratiometric correction of blood glucose measurement |
DK2534470T3 (en) | 2010-02-08 | 2016-12-05 | Medtronic Minimed Inc | Antioxidant protection of a chemical sensor |
WO2011101626A1 (en) | 2010-02-16 | 2011-08-25 | Glysure Ltd | Barrier layer for glusose sensor |
CN102933144B (en) * | 2010-02-19 | 2015-08-12 | 格莱苏有限公司 | intravascular glucose sensor |
JP2013519483A (en) * | 2010-02-19 | 2013-05-30 | ライトシップ メディカル リミテッド | Subcutaneous glucose sensor |
EP2545373B1 (en) * | 2010-03-11 | 2022-08-24 | Medtronic Minimed, Inc. | Measuring analyte concentration incorporating temperature and ph correction |
US10010272B2 (en) | 2010-05-27 | 2018-07-03 | Profusa, Inc. | Tissue-integrating electronic apparatus |
US20120006100A1 (en) | 2010-07-06 | 2012-01-12 | Medtronic Minimed, Inc. | Method and/or system for determining blood glucose reference sample times |
US20120053427A1 (en) * | 2010-08-31 | 2012-03-01 | Glumetrics, Inc. | Optical sensor configuration and methods for monitoring glucose activity in interstitial fluid |
CN103260501B (en) * | 2010-10-06 | 2015-09-02 | 普罗弗萨股份有限公司 | Tissue integration sensor |
US8919180B2 (en) | 2010-10-28 | 2014-12-30 | Medtronic Minimed, Inc. | Determination and application of glucose sensor reliability indicator and/or metric |
US9033878B2 (en) | 2010-10-28 | 2015-05-19 | Medtronic Minimed, Inc. | Glucose sensor signal reliability analysis |
AU2011344244B2 (en) * | 2010-12-17 | 2016-03-17 | Eyesense Ag | Use of hydrogels for biosensors having elevated sensitivity |
WO2012080218A1 (en) * | 2010-12-17 | 2012-06-21 | Eyesense Ag | Competitive biosensor having elevated sensitivity |
KR101959067B1 (en) * | 2011-03-15 | 2019-03-15 | 센세오닉스, 인코포레이티드 | Integrated catalytic protection of oxidation sensitive materials |
DK3575796T3 (en) | 2011-04-15 | 2021-01-18 | Dexcom Inc | ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION |
GB201113435D0 (en) | 2011-08-03 | 2011-09-21 | Glysure Ltd | Sensor calibration |
WO2013003815A2 (en) | 2011-06-29 | 2013-01-03 | The Oregon State Board Of Higher Education On Behalf Of Portland State University | Near-infrared fluorescent dyes with large stokes shifts |
CN103748091A (en) * | 2011-06-29 | 2014-04-23 | 由俄勒冈州高等教育委员会代表的波特兰州立大学 | Analyte detection using near-infrared fluorophores |
US20130060106A1 (en) * | 2011-09-06 | 2013-03-07 | Medtronic Minimed, Inc. | Optical sensing systems and methods |
WO2013049068A1 (en) | 2011-09-27 | 2013-04-04 | Glumetrics, Inc. | Method for functionalizing a porous membrane covering of an optical sensor to facilitate coupling of an antithrom-bogenic agent |
US20130217983A1 (en) * | 2011-12-29 | 2013-08-22 | Wellsense, Inc. | Analyte sensor |
US9649056B2 (en) | 2011-12-29 | 2017-05-16 | Optica, Inc. | Analyte sensor with extended range of detection |
IN2014DN07535A (en) | 2012-03-15 | 2015-04-24 | Lightship Medical Ltd | |
US9017622B2 (en) | 2012-04-10 | 2015-04-28 | Lightship Medical Limited | Calibrator for a sensor |
US20130344619A1 (en) | 2012-06-21 | 2013-12-26 | Lightship Medical Limited | Glucose sensor |
CN103712927B (en) * | 2012-09-29 | 2016-12-21 | 埃科莱布美国股份有限公司 | Detecting system and method and water treatment system and method |
US8803090B2 (en) | 2012-11-09 | 2014-08-12 | Fenwal, Inc. | Citrate detector for blood processing system |
US11320418B2 (en) | 2012-12-12 | 2022-05-03 | Iassay, Inc. | Modular hand-held point of care testing system |
GB201317746D0 (en) | 2013-10-08 | 2013-11-20 | Smith & Nephew | PH indicator |
WO2014137993A1 (en) * | 2013-03-04 | 2014-09-12 | David Reed Markle | METHODS FOR USE IN A CALIBRATION-FREE ABSORBANCE SENSOR FOR MEASURING pH AND pCO2 |
CA2904031A1 (en) | 2013-03-14 | 2014-10-02 | Profusa, Inc. | Method and device for correcting optical signals |
CN105307559B (en) | 2013-06-06 | 2020-06-05 | 普罗菲尤萨股份有限公司 | Apparatus and method for detecting optical signals from implanted sensors |
US9662050B2 (en) | 2013-06-21 | 2017-05-30 | Verify Life Sciences LLC | Physiological measurement using wearable device |
US9963556B2 (en) | 2013-09-18 | 2018-05-08 | Senseonics, Incorporated | Critical point drying of hydrogels in analyte sensors |
US10379125B2 (en) * | 2013-12-27 | 2019-08-13 | Becton, Dickinson And Company | System and method for dynamically calibrating and measuring analyte concentration in diabetes management monitors |
US10039491B2 (en) * | 2014-06-30 | 2018-08-07 | Verily Life Sciences Llc | Methods for reducing noise in optical biological sensors |
JP2017523280A (en) | 2014-07-10 | 2017-08-17 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | Improvements in and relating to polymer materials |
PT3171765T (en) | 2014-07-24 | 2021-10-27 | Univ Health Network | Collection and analysis of data for diagnostic purposes |
WO2016036887A1 (en) * | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Fluorescence assay for intestinal permeability |
EP3206567A1 (en) | 2014-10-13 | 2017-08-23 | Glusense, Ltd. | Analyte-sensing device |
GB201600746D0 (en) | 2016-01-14 | 2016-03-02 | Smith & Nephew | Improvements in and relating to polymer materials |
GB201600747D0 (en) | 2016-01-14 | 2016-03-02 | Smith & Nephew | Improvements in and relating to devices |
US10871487B2 (en) | 2016-04-20 | 2020-12-22 | Glusense Ltd. | FRET-based glucose-detection molecules |
EP3487406A4 (en) * | 2016-07-20 | 2020-01-08 | University of Maryland, Baltimore | Silicone hydrogel based fluorescent assay and contact lens |
US11331018B2 (en) | 2016-12-22 | 2022-05-17 | Profusa, Inc. | System and single-channel biosensor for and method of determining analyte value |
AU2018354120A1 (en) | 2017-10-24 | 2020-04-23 | Dexcom, Inc. | Pre-connected analyte sensors |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
DE102017128290B4 (en) * | 2017-11-29 | 2020-07-09 | Bundesrepublik Deutschland, vertreten durch die Bundesministerin für Wirtschaft und Energie, diese vertreten durch den Präsidenten der Bundesanstalt für Materialforschung und-prüfung (BAM) | Measuring device and measuring system for determining the pH value and method for determining the pH value |
CN113711017A (en) * | 2019-07-03 | 2021-11-26 | 松下知识产权经营株式会社 | Detection device and detection method |
US20220248986A1 (en) * | 2021-02-09 | 2022-08-11 | Medtronic, Inc. | Optical based glucose sensor |
Family Cites Families (460)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338157B1 (en) | 1992-09-09 | 1999-11-02 | Sims Deltec Inc | Systems and methods for communicating with ambulat |
US1120700A (en) | 1914-02-02 | 1914-12-15 | Hoechst Ag | Arseno-azo compounds and process of making same. |
US1334901A (en) | 1918-12-10 | 1920-03-23 | Higdon Emma | Turning-sheet and pad |
US2112244A (en) | 1933-08-26 | 1938-03-29 | Squibb & Sons Inc | Amino azobenzene arsonic acids |
US2018792A (en) | 1933-10-17 | 1935-10-29 | Soc Of Chemical Ind | Process for the manufacture of hydroxypyrene |
US2094224A (en) | 1934-05-25 | 1937-09-28 | Gen Aniline Works Inc | Pyrene 3, 5, 8, 10-tetra-sulphonic acid and derivatives thereof |
US2274551A (en) | 1939-06-30 | 1942-02-24 | Eastman Kodak Co | Derivatives of resins and their preparation |
US2496151A (en) | 1946-08-14 | 1950-01-31 | Harvel Corp | Azo dyestuffs |
US3011293A (en) | 1953-03-24 | 1961-12-05 | Pickering Dorothy Frances | Collapsible container |
US2812524A (en) | 1955-03-25 | 1957-11-12 | Lawrence C Pruitt | Patient turner |
AT267017B (en) | 1965-04-02 | 1968-12-10 | Ceskoslovenska Akademie Ved | Process for the preparation of new, substituted 2,7-bisphenylazo derivatives of chromotropic acid |
US3302219A (en) | 1966-01-14 | 1967-02-07 | Joe F Harris | Hospital bed and lifting and turning device |
US3488098A (en) | 1968-03-26 | 1970-01-06 | Teletype Corp | Motion translating device |
US3659586A (en) | 1969-05-20 | 1972-05-02 | Univ Johns Hopkins | Percutaneous carbon dioxide sensor and process for measuring pulmonary efficiency |
US3846353A (en) | 1970-06-08 | 1974-11-05 | Department Of Health Education | Nonthrombogenic plastic material and method for making the same |
US3685059A (en) * | 1970-07-28 | 1972-08-22 | Gulf General Atomic Inc | Prosthetic blood circulation device having a pyrolytic carbon coated blood contacting surface |
CH530006A (en) | 1970-10-01 | 1972-10-31 | Hoffmann La Roche | Electrode arrangement |
US3827089A (en) | 1971-09-16 | 1974-08-06 | W Grow | Turnover bed assembly |
US3808615A (en) | 1972-05-22 | 1974-05-07 | W Geary | Bed and pillow assembly |
US3865548A (en) | 1972-06-13 | 1975-02-11 | Einstein Coll Med | Analytical apparatus and process |
CH564771A5 (en) | 1973-05-10 | 1975-07-31 | Hoffmann La Roche | |
US3884225A (en) | 1973-06-01 | 1975-05-20 | Evelyn Ruth Witter | Bed patient turn and hold device |
SE428596B (en) | 1975-04-09 | 1983-07-11 | Raychem Corp | DEVICE FOR CONNECTING SUBSTRATE EXV RODS INCLUDING A MEMORIAL METAL BODY |
US3930580A (en) | 1973-10-19 | 1976-01-06 | Medical Products Corporation | Sterilizable, peelable pouch or tray assembly |
US3909504A (en) | 1973-11-05 | 1975-09-30 | Carrier Tel Corp America Inc | Ruggedized package for electronic components and the like |
GB1447163A (en) | 1974-03-13 | 1976-08-25 | Gibbs J R | Beds |
US3895403A (en) | 1974-04-05 | 1975-07-22 | Sanford Davis | Patient orienting device |
US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4041932A (en) | 1975-02-06 | 1977-08-16 | Fostick Moshe A | Method for monitoring blood gas tension and pH from outside the body |
DE2508637C3 (en) | 1975-02-28 | 1979-11-22 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Arrangement for the optical measurement of blood gases |
SE400173B (en) * | 1975-03-20 | 1978-03-20 | Aminkemi Ab | PROCEDURE FOR STABILIZING A HEPARINIZED SURFACE CONTAINING FOR BLOOD CONTACT RELEASE HEPARIN |
IT1057223B (en) | 1976-02-19 | 1982-03-10 | Cselt Centro Studi Lab Telecom | OPTICAL EQUALIZER FOR TRANSMISSION OF SIGNALS OF MULTIMODE OPTICAL GUIDES |
FR2350831A1 (en) | 1976-05-13 | 1977-12-09 | Caneva Moutinho Mario | Bedridden patient movement aid mechanism - has cloth harness with ends coupled to motor driven rope reeved round supports |
SU621624A2 (en) | 1977-04-28 | 1978-08-30 | Ленинградский Ордена Ленина Ордена Октябрьской Революции И Ордена Трудового Красного Знамени Горный Институт Им.Г.В.Плеханова | Stand for studying conditions of fouling and cleaning conveyer belts |
GB2005418B (en) | 1977-07-26 | 1982-04-21 | Searle & Co | Electrochemical sensor system |
FR2403098A1 (en) | 1977-09-19 | 1979-04-13 | Merieux Inst | NEW MATERIAL CAPABLE OF REVERSIBLE BINDING OF BIOLOGICAL MACROMOLECULES, ITS PREPARATION AND APPLICATION |
CA1065969A (en) | 1977-09-28 | 1979-11-06 | Gratien Bouillon | Self-blocking cerebral catheter |
US4200110A (en) | 1977-11-28 | 1980-04-29 | United States Of America | Fiber optic pH probe |
US4345606A (en) | 1977-12-13 | 1982-08-24 | Littleford Philip O | Split sleeve introducers for pacemaker electrodes and the like |
NO141592C (en) | 1978-06-22 | 1980-04-23 | Kjell Roeisaeth | DEVICE FOR HANDLING A PERSON ON A SUBSTRATE |
US4269605A (en) | 1978-06-28 | 1981-05-26 | Amicon Corporation | Method and kit for separation of glycoproteins |
US4344438A (en) | 1978-08-02 | 1982-08-17 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Optical sensor of plasma constituents |
US4180879A (en) | 1978-08-04 | 1980-01-01 | Mann Rose A | Body positioner |
US4240438A (en) | 1978-10-02 | 1980-12-23 | Wisconsin Alumni Research Foundation | Method for monitoring blood glucose levels and elements |
US4306562A (en) | 1978-12-01 | 1981-12-22 | Cook, Inc. | Tear apart cannula |
GB2038017B (en) | 1978-12-20 | 1982-11-24 | Standard Telephones Cables Ltd | Optical fibre directional coupler |
JPS5618342Y2 (en) | 1979-04-26 | 1981-04-30 | ||
US4307933A (en) | 1980-02-20 | 1981-12-29 | General Dynamics, Pomona Division | Optical fiber launch coupler |
US4358851A (en) | 1980-02-28 | 1982-11-09 | Xerox Corporation | Fiber optic laser device and light emitter utilizing the device |
DE3036868A1 (en) | 1980-09-30 | 1982-05-13 | Siemens AG, 1000 Berlin und 8000 München | Coupling, junction-forming and combining light conductor fibres - using supporting body with grooves for fixing fibres and grinding or polishing region of grooves |
US4371374A (en) | 1980-11-17 | 1983-02-01 | The Rockefeller University | Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine |
EP0061884A1 (en) | 1981-03-30 | 1982-10-06 | Imperial Chemical Industries Plc | Optical fibre sensor |
US4659817A (en) | 1981-05-01 | 1987-04-21 | The Children's Medical Center Corporation | Reporter compounds containing boron |
US4459712A (en) | 1981-06-11 | 1984-07-17 | Pathan Rajendra K | Hospital bed |
NO160563C (en) | 1981-07-27 | 1989-05-03 | Vasterviks Pulverlackering Ab | SIDE TURNOVER OF SLEEPING PERSONS. |
GB2103786A (en) | 1981-08-14 | 1983-02-23 | Ici Plc | Fibre optic sensor |
EP0073558A3 (en) | 1981-08-25 | 1984-09-26 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Fiber optic ph probe for tissue measurements |
US4476870A (en) | 1982-03-30 | 1984-10-16 | The United States Of America As Represented By The Department Of Health And Human Services | Fiber optic PO.sbsb.2 probe |
US4654327A (en) | 1982-04-21 | 1987-03-31 | Research Corp. | Quaternary ammonium complexes of heparin |
DE3216516A1 (en) | 1982-05-03 | 1983-11-03 | Siemens AG, 1000 Berlin und 8000 München | OPTICAL WAVELENGTH MULTIPLEXER IN ACCORDANCE WITH THE GRILLED PRINCIPLE |
USRE32514E (en) | 1982-06-14 | 1987-10-06 | Eastman Kodak Company | Polymer compositions having a low coefficient of friction |
US4515584A (en) | 1982-07-06 | 1985-05-07 | Fujisawa Pharmaceutical Co., Ltd. | Artificial pancreas |
US4557900A (en) | 1982-09-28 | 1985-12-10 | Cardiovascular Devices, Inc. | Optical sensor with beads |
US4465335A (en) | 1982-10-12 | 1984-08-14 | The United States Of America As Represented By The Secretary Of The Army | Concentric core optical fiber coupler |
US4490867A (en) | 1982-12-21 | 1985-01-01 | Lycksele Nya Platprodukter Ab | Bed rocking mechanism |
US5030420A (en) | 1982-12-23 | 1991-07-09 | University Of Virginia Alumni Patents Foundation | Apparatus for oxygen determination |
US4495293A (en) | 1983-02-24 | 1985-01-22 | Abbott Laboratories | Fluorometric assay |
US4528616A (en) | 1983-03-28 | 1985-07-09 | Gte Automatic Electric Inc. | Printed wiring board enclosure |
US4548907A (en) | 1983-09-14 | 1985-10-22 | Allied Corporation | Fluorescent fluid determination method and apparatus |
US5007704A (en) | 1983-10-28 | 1991-04-16 | Baxter International Inc. | Oximeter |
US4754538A (en) | 1983-11-15 | 1988-07-05 | Raychem Corporation | Annular tube-like driver |
AU559681B2 (en) | 1983-12-19 | 1987-03-19 | Litton Systems, Incorporated | Three port coupler |
SE441128B (en) | 1984-01-25 | 1985-09-09 | Asea Ab | FIBER OPTICAL SENSOR FOR SURGERY OF DYNAMIC ACCELERATION |
US4654127A (en) | 1984-04-11 | 1987-03-31 | Sentech Medical Corporation | Self-calibrating single-use sensing device for clinical chemistry and method of use |
JPS60231156A (en) | 1984-04-30 | 1985-11-16 | Kuraray Co Ltd | Liquid junction type reference electrode |
US4846543A (en) | 1984-05-02 | 1989-07-11 | Kaptron, Inc. | Star coupler for optical fibers |
JPS6114562A (en) * | 1984-06-30 | 1986-01-22 | Terumo Corp | Ph measuring instrument |
US5217691A (en) | 1984-11-19 | 1993-06-08 | Miles Inc. | Nonenzymatic glucose test |
US4621049A (en) | 1984-11-19 | 1986-11-04 | Miles Laboratories, Inc. | Enzymatic high range glucose test |
US4803049A (en) | 1984-12-12 | 1989-02-07 | The Regents Of The University Of California | pH-sensitive optrode |
DE3446726A1 (en) | 1984-12-21 | 1986-06-26 | Fa. Carl Zeiss, 7920 Heidenheim | OPTICAL ARRANGEMENT WITH A CONCAVE MIRROR OR CONCAVE GRID |
GB8504521D0 (en) | 1985-02-21 | 1985-03-27 | Genetics Int Inc | Electrochemical assay |
DE3509262A1 (en) | 1985-03-12 | 1985-10-10 | Heinrich Dipl.-Ing. 1000 Berlin Ranke | Bed for the disabled having a lifting device and a bath tub |
US4654031A (en) | 1985-04-15 | 1987-03-31 | Warner-Lambert Company | Flash chamber |
US4776047A (en) | 1985-05-07 | 1988-10-11 | Med Bed Technologies, Inc. | Multiple function invalid bed arrangement |
US4750795A (en) | 1985-06-13 | 1988-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Optical fiber coupler |
US4943364A (en) | 1985-06-21 | 1990-07-24 | Spectramed, Inc. | Fiber optic CO2 sensor |
US4796633A (en) | 1985-06-25 | 1989-01-10 | American Hospital Supply Corporation | Method and apparatus for in vitro calibration of oxygen saturation monitor |
US4810655A (en) | 1985-07-03 | 1989-03-07 | Abbott Laboratories | Method for measuring oxygen concentration |
US4650472A (en) | 1985-08-30 | 1987-03-17 | Cook, Incorporated | Apparatus and method for effecting percutaneous catheterization of a blood vessel using a small gauge introducer needle |
US4629451A (en) | 1985-09-23 | 1986-12-16 | Victory Engineering Corp. | Stereotaxic array plug |
FR2588471B1 (en) | 1985-10-15 | 1990-06-08 | Bernard Jean Marc | ANTI-PRESSURE BED |
US4792689A (en) | 1985-11-12 | 1988-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Method for obtaining a ratio measurement for correcting common path variations in intensity in fiber optic sensors |
CN1003110B (en) | 1985-11-15 | 1989-01-25 | 李鸿柱 | Program-controlled rejuvenating bed |
JPH025799Y2 (en) | 1986-02-07 | 1990-02-13 | ||
US4684538A (en) | 1986-02-21 | 1987-08-04 | Loctite Corporation | Polysiloxane urethane compounds and adhesive compositions, and method of making and using the same |
US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
US4710623A (en) | 1986-02-27 | 1987-12-01 | Eli Lilly And Company | Optical fiber catheter with fiber-contained reactive element |
US4675925A (en) | 1986-04-03 | 1987-06-30 | Henrietta Littleton | Device for manipulating bedridden patients |
US4798738A (en) * | 1986-10-10 | 1989-01-17 | Cardiovascular Devices, Inc. | Micro sensor |
US4801187A (en) | 1986-04-30 | 1989-01-31 | Baxter Travenol Laboratories, Inc. | Liquid light tube end cap assembly |
US4689308A (en) | 1986-05-01 | 1987-08-25 | International Biomedics, Inc. | Article for preparing a chemical sensor for use |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
AT385755B (en) | 1986-06-13 | 1988-05-10 | Koller Ernst | METHOD FOR THE PRODUCTION OF NEW PYRENSULPHONIC ACID DERIVATIVES |
US4927222A (en) | 1986-06-16 | 1990-05-22 | Shiley Incorporated | Dual optical fiber device |
US4822127A (en) | 1986-06-16 | 1989-04-18 | Shiley Incorporated | Multi-channel optical transmission system |
US4854321A (en) | 1986-06-18 | 1989-08-08 | Medex, Inc. | Integrated optic system for monitoring blood gases |
US4727730A (en) | 1986-07-10 | 1988-03-01 | Medex, Inc. | Integrated optic system for monitoring blood pressure |
US4886338A (en) * | 1986-10-10 | 1989-12-12 | Minnesota Mining And Manufacturing Company | Optical fiber event sensor |
US5012809A (en) | 1986-10-10 | 1991-05-07 | Shulze John E | Fiber optic catheter system with fluorometric sensor and integral flexure compensation |
KR960003550B1 (en) | 1986-11-28 | 1996-03-15 | 다께다 야꾸힝 고오교 가부시끼가이샤 | A process for producing carboxylic acid ester |
US4794619A (en) | 1986-12-05 | 1988-12-27 | Conax Buffalo Corporation | Optical fiber temperature sensor |
US5162130A (en) | 1986-12-17 | 1992-11-10 | Mclaughlin Gerald G | Light activated coloration of dental restorations |
US4833091A (en) | 1987-02-06 | 1989-05-23 | Shiley Incorporated | Sensor system |
US5093266A (en) | 1987-02-06 | 1992-03-03 | Shiley Inc. | Sensor system |
US4746751A (en) | 1987-05-07 | 1988-05-24 | Baxter Travenol Laboratories, Inc. | Silicone reactive/fluorescent silane dye compositions |
DE3720736A1 (en) | 1987-06-23 | 1989-01-05 | Erwin Dr Schleicher | Method, reagents and equipment for the simple determination of non-enzymatically glycosylated proteins in body fluids |
US4816130A (en) | 1987-07-02 | 1989-03-28 | Becton, Dickinson And Company | Blood electrolyte sensors including crosslinked polyetherurethane membranes |
EP0298333B1 (en) | 1987-07-07 | 1992-03-18 | Siemens Aktiengesellschaft | Sensor for gases or ions |
US4861728A (en) | 1987-07-24 | 1989-08-29 | Becton, Dickinson And Company | Immunoassay of glycosylated hemoglobin using a labeled boron reagent |
US4785814A (en) * | 1987-08-11 | 1988-11-22 | Cordis Corporation | Optical probe for measuring pH and oxygen in blood and employing a composite membrane |
US4851195A (en) | 1987-08-17 | 1989-07-25 | Pfizer Hospital Products Group, Inc. | Carbon dioxide sensor |
US5047020A (en) | 1987-09-14 | 1991-09-10 | Baxter International Inc. | Ionic heparin coating |
US4923273A (en) | 1987-10-13 | 1990-05-08 | Texas A&M University System | Method for producing reflective taps in optical fibers and applications thereof |
US5185263A (en) * | 1987-10-23 | 1993-02-09 | Avl Medical Instruments Ag | Method for calibration of a measurement apparatus |
US4821738A (en) | 1987-11-19 | 1989-04-18 | Marquest Medical Products, Inc. | Arterial blood gas syringe |
FR2624007A1 (en) | 1987-12-02 | 1989-06-09 | Perdu Jean Francois | Sanitary bed with special rollers for treatment of bedridden patients |
US4906232A (en) | 1988-03-01 | 1990-03-06 | Abbott Laboratories | Intravascular delivery device |
US4838269A (en) | 1988-03-24 | 1989-06-13 | Scimed Life Systems, Inc. | Manifold for angioplasty balloon catheter |
EP0336985B1 (en) | 1988-04-09 | 1993-01-27 | Hewlett-Packard GmbH | Method for manufacturing an optical probe |
US4960412A (en) | 1988-04-15 | 1990-10-02 | Universal Medical Instrument Corp. | Catheter introducing system |
US4903707A (en) | 1988-04-22 | 1990-02-27 | Camino Laboratories | Ventricular catheter assembly |
US4872226A (en) | 1988-06-06 | 1989-10-10 | Robert Lonardo | Means for positioning bedfast patients |
US5361758A (en) | 1988-06-09 | 1994-11-08 | Cme Telemetrix Inc. | Method and device for measuring concentration levels of blood constituents non-invasively |
US5000901A (en) | 1988-07-25 | 1991-03-19 | Abbott Laboratories | Fiber-optic physiological probes |
US4941308A (en) | 1988-07-25 | 1990-07-17 | Abbott Laboratories | Method of packaging for a sterilizable calibratable medical device |
AT390517B (en) * | 1988-08-04 | 1990-05-25 | Avl Verbrennungskraft Messtech | OPTICAL SENSOR AND METHOD FOR THE PRODUCTION THEREOF |
US4966597A (en) | 1988-11-04 | 1990-10-30 | Cosman Eric R | Thermometric cardiac tissue ablation electrode with ultra-sensitive temperature detection |
US4937901A (en) | 1988-11-04 | 1990-07-03 | Brennan Louis G | Apparatus for turning a patient from a supine to a prone position and vice-versa |
US4985022A (en) | 1988-11-23 | 1991-01-15 | Med Institute, Inc. | Catheter having durable and flexible segments |
US5188803A (en) | 1988-12-01 | 1993-02-23 | Abbott Laboratories | Device for preparing a medical sensor for use |
US4889407A (en) | 1988-12-02 | 1989-12-26 | Biomedical Sensors Limited | Optical waveguide sensor and method of making same |
US4939801A (en) | 1988-12-22 | 1990-07-10 | Schaal Gary A | Patient transporting and turning gurney |
IT1225494B (en) | 1988-12-23 | 1990-11-20 | Italpres Snc Di Fregni & C | APPARATUS TO PREVENT TRAINING AND TAKE CARE OF PADS IN LONG PATIENTS |
US5153827A (en) | 1989-01-30 | 1992-10-06 | Omni-Flow, Inc. | An infusion management and pumping system having an alarm handling system |
US5047208A (en) | 1989-02-23 | 1991-09-10 | Medtronic, Inc. | Blood gas monitoring sensors |
US4955862A (en) | 1989-05-22 | 1990-09-11 | Target Therapeutics, Inc. | Catheter and catheter/guide wire device |
US5141497A (en) | 1989-06-06 | 1992-08-25 | Becton, Dickinson And Company | Apparatus and method for an introducer |
US5330718A (en) * | 1989-08-16 | 1994-07-19 | Puritan-Bennett Corporation | Sensor element and method for making the same |
US5182353A (en) | 1989-08-16 | 1993-01-26 | Puritan-Bennett Corporation | Method for bonding an analyte-sensitive dye compound to an addition-cure silicone |
US5129906A (en) | 1989-09-08 | 1992-07-14 | Linvatec Corporation | Bioabsorbable tack for joining bodily tissue and in vivo method and apparatus for deploying same |
US5512246A (en) * | 1989-09-21 | 1996-04-30 | Anthony P. Russell | Method and means for detecting polyhydroxyl compounds |
US5137833A (en) * | 1989-09-21 | 1992-08-11 | Russell Anthony P | Method for detecting polyhydroxyl compounds |
US5132432A (en) | 1989-09-22 | 1992-07-21 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
DK0428990T3 (en) | 1989-11-16 | 1995-04-24 | N E Chemcat Corp | Method and apparatus for applying a liquid coating to a honeycomb structure |
US5342789A (en) * | 1989-12-14 | 1994-08-30 | Sensor Technologies, Inc. | Method and device for detecting and quantifying glucose in body fluids |
US4946038A (en) | 1989-12-20 | 1990-08-07 | Rolland Eaton | Medicine container and cover therefor |
US5054497A (en) | 1990-02-21 | 1991-10-08 | Biomedical Monitors And Implants, Inc. | Cranial sensor attaching device and method for its use |
US5098618A (en) | 1990-03-14 | 1992-03-24 | Joseph Zelez | Surface modification of plastic substrates |
EP0447196A1 (en) | 1990-03-16 | 1991-09-18 | Hewlett-Packard Company | Boronic acid dyes |
US5175016A (en) | 1990-03-20 | 1992-12-29 | Minnesota Mining And Manufacturing Company | Method for making gas sensing element |
US5180376A (en) | 1990-05-01 | 1993-01-19 | Cathco, Inc. | Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters |
US5104388A (en) | 1990-05-08 | 1992-04-14 | Fbk International Corporation | Membrane splittable tubing |
US5047627A (en) | 1990-05-18 | 1991-09-10 | Abbott Laboratories | Configuration fiber-optic blood gas sensor bundle and method of making |
US5109452A (en) | 1990-07-16 | 1992-04-28 | Puritan-Bennett Corporation | Electrical-optical hybrid connector |
US5279596A (en) | 1990-07-27 | 1994-01-18 | Cordis Corporation | Intravascular catheter with kink resistant tip |
US5166990A (en) | 1990-08-10 | 1992-11-24 | Puritan-Bennett Corporation | Multiple optical fiber event sensor and method of manufacture |
US5176882A (en) * | 1990-12-06 | 1993-01-05 | Hewlett-Packard Company | Dual fiberoptic cell for multiple serum measurements |
US5178267A (en) | 1990-12-20 | 1993-01-12 | Abbott Laboratories | Packaging system for a sterilizable calbratable medical device |
US5082112A (en) | 1991-02-05 | 1992-01-21 | United States Surgical Corporation | Package for endoscopic ligating instrument |
AR245376A1 (en) | 1991-02-25 | 1994-01-31 | Liliana Rosa Grinfeld Y Robert | Arterial profusion nozzle, for extra-corporal circulation and other uses. |
US5167715A (en) | 1991-03-04 | 1992-12-01 | General Electric Company | Apparatus and method for impregnating superconductor windings |
US5119463A (en) | 1991-04-09 | 1992-06-02 | Abbott Laboratories | Compound optical probe employing single optical waveguide |
JP2948678B2 (en) | 1991-04-24 | 1999-09-13 | 玄々化学工業株式会社 | Vacuum coating equipment |
US5068931A (en) | 1991-06-21 | 1991-12-03 | Smith Gene A | Apparatus for lifting and turning a patient confined to a bed |
US5137033A (en) | 1991-07-15 | 1992-08-11 | Norton John L | Patient monitoring device |
US5380304A (en) | 1991-08-07 | 1995-01-10 | Cook Incorporated | Flexible, kink-resistant, introducer sheath and method of manufacture |
US5305740A (en) | 1991-09-12 | 1994-04-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Sealing means for endotracheal tubes |
US5335305A (en) | 1991-12-19 | 1994-08-02 | Optex Biomedical, Inc. | Optical sensor for fluid parameters |
US5261887A (en) | 1992-01-22 | 1993-11-16 | Baxter International Inc. | Easy-to-handle, self-guiding catheter stripper |
US5168587A (en) | 1992-05-18 | 1992-12-08 | Shutes Robert S | Patient positioning device |
US5354448A (en) | 1992-05-22 | 1994-10-11 | Biomedical Sensors Ltd. | Electrochemical sensor |
US5262037A (en) | 1992-05-22 | 1993-11-16 | Biomedical Sensors, Ltd. | Electrochemical sensor |
US5257338A (en) | 1992-05-22 | 1993-10-26 | Biomedical Sensors, Ltd. | Device for transmitting and returning light and apparatus and method of manufacture |
US5230031A (en) | 1992-05-22 | 1993-07-20 | Biomedical Sensors, Ltd. | Barrier for a connector |
US5246109A (en) | 1992-05-22 | 1993-09-21 | Biomedical Sensors, Ltd. | Package for an active medical device |
US5280130A (en) | 1992-05-22 | 1994-01-18 | Biomedical Sensors, Ltd. | Assembly of a tube and a part and apparatus and method of manufacture |
US5302731A (en) | 1992-07-13 | 1994-04-12 | Becton, Dickinson And Company | Fluorescent pH indicators |
JP2599994Y2 (en) * | 1992-07-30 | 1999-09-27 | 株式会社堀場製作所 | Automatic calibration system for laboratory ion concentration meter |
US5290266A (en) | 1992-08-14 | 1994-03-01 | General Electric Company | Flexible coating for magnetic resonance imaging compatible invasive devices |
JPH08501392A (en) | 1992-09-14 | 1996-02-13 | パーデュー リサーチ ファウンデーション | Chemical analysis by electrophoresis |
WO1994010553A1 (en) | 1992-10-23 | 1994-05-11 | Optex Biomedical, Inc. | Fibre-optic probe for the measurement of fluid parameters |
EP0596700A1 (en) | 1992-11-03 | 1994-05-11 | Hewlett-Packard Company | Cis-diol detection method and solid supports |
US5832448A (en) | 1996-10-16 | 1998-11-03 | Health Hero Network | Multiple patient monitoring system for proactive health management |
US5956501A (en) | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US5307263A (en) | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
DK25793A (en) | 1993-03-09 | 1994-09-10 | Pharma Plast Int As | Infusion set for intermittent or continuous administration of a therapeutic agent |
US5280548A (en) | 1993-03-11 | 1994-01-18 | Boc Health Care, Inc. | Emission based fiber optic sensors for pH and carbon dioxide analysis |
US5607644A (en) | 1993-06-10 | 1997-03-04 | Optical Sensors Incorporated | Optical sensor for the measurement of pH in a fluid, and related sensing compositions and methods |
JPH08507470A (en) * | 1993-06-30 | 1996-08-13 | バイオメディカル・センサーズ・リミテッド | Biphasic material |
US5527325A (en) | 1993-07-09 | 1996-06-18 | Device For Vascular Intervention, Inc. | Atherectomy catheter and method |
US5954651A (en) | 1993-08-18 | 1999-09-21 | Scimed Life Systems, Inc. | Catheter having a high tensile strength braid wire constraint |
US5334157A (en) | 1993-09-09 | 1994-08-02 | Gesco International, Inc. | Catheter introducer |
US5409469A (en) | 1993-11-04 | 1995-04-25 | Medtronic, Inc. | Introducer system having kink resistant splittable sheath |
GB2284809B (en) * | 1993-11-07 | 1998-04-29 | Japan Res Dev Corp | A fluorescent phenylboronic acid suitable for use in the detection of saccharides |
US5514710A (en) | 1994-01-11 | 1996-05-07 | Molecular Probes, Inc. | Photocleavable derivatives of hydroxyprenesulfonic acids |
US5511547A (en) | 1994-02-16 | 1996-04-30 | Biomedical Sensors, Ltd. | Solid state sensors |
US5536249A (en) | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
US5391250A (en) | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
US5389217A (en) | 1994-04-28 | 1995-02-14 | Biomedical Sensors Ltd. | Measurement of bladder oxygen |
ATE176048T1 (en) * | 1994-05-02 | 1999-02-15 | Novartis Ag | OPTICAL SENSOR SYSTEM FOR DETERMINING PH VALUES AND IONIC STRENGTH |
US5605152A (en) * | 1994-07-18 | 1997-02-25 | Minimed Inc. | Optical glucose sensor |
IE72524B1 (en) | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
US5658264A (en) | 1994-11-10 | 1997-08-19 | Target Therapeutics, Inc. | High performance spiral-wound catheter |
DE19502183C1 (en) | 1995-01-25 | 1996-08-14 | Wolfgang Dr Fleckenstein | Bracket for brain probes |
JP2799837B2 (en) * | 1995-03-03 | 1998-09-21 | 科学技術振興事業団 | Boronic acid compounds having a binaphthyl group |
US5676784A (en) | 1995-03-15 | 1997-10-14 | Abbott Laboratories | Method of fabricating a heater coil for a catheter used to monitor cardiac output |
US5702373A (en) | 1995-08-31 | 1997-12-30 | Target Therapeutics, Inc. | Composite super-elastic alloy braid reinforced catheter |
US5634911A (en) | 1995-05-19 | 1997-06-03 | General Surgical Innovations, Inc. | Screw-type skin seal with inflatable membrane |
US5665065A (en) | 1995-05-26 | 1997-09-09 | Minimed Inc. | Medication infusion device with blood glucose data input |
US5622259A (en) | 1995-06-07 | 1997-04-22 | Church; Jonathan M. | Reduction of discoloration in plastic materials |
US5545179A (en) | 1995-07-21 | 1996-08-13 | Ethicon Endo-Surgery, Inc. | Endoscopic access assembly |
JP3183390B2 (en) * | 1995-09-05 | 2001-07-09 | キヤノン株式会社 | Photoelectric conversion device and imaging device using the same |
US6019736A (en) | 1995-11-06 | 2000-02-01 | Francisco J. Avellanet | Guidewire for catheter |
US6174424B1 (en) | 1995-11-20 | 2001-01-16 | Cirrex Corp. | Couplers for optical fibers |
US6002954A (en) * | 1995-11-22 | 1999-12-14 | The Regents Of The University Of California | Detection of biological molecules using boronate-based chemical amplification and optical sensors |
AU1058297A (en) * | 1995-11-22 | 1997-06-11 | Minimed, Inc. | Detection of biological molecules using chemical amplification and optical sensors |
US6766183B2 (en) * | 1995-11-22 | 2004-07-20 | Medtronic Minimed, Inc. | Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers |
US5797876A (en) | 1995-11-27 | 1998-08-25 | Therox, Inc. | High pressure perfusion device |
US5951929A (en) | 1995-12-12 | 1999-09-14 | Medi-Dyne Inc. | Method for forming a catheter having overlapping welds |
USD388418S (en) | 1996-03-18 | 1997-12-30 | Iomega Corporation | Computer screen with an icon |
US5827242A (en) | 1996-06-21 | 1998-10-27 | Medtronic, Inc. | Reinforced catheter body and method for its fabrication |
DE19624753A1 (en) | 1996-06-21 | 1998-01-02 | Teves Gmbh Alfred | Hydraulic motor vehicle brake system with wheel slip control |
US5755704A (en) | 1996-10-29 | 1998-05-26 | Medtronic, Inc. | Thinwall guide catheter |
US6607509B2 (en) | 1997-12-31 | 2003-08-19 | Medtronic Minimed, Inc. | Insertion device for an insertion set and method of using the same |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
US5747666A (en) * | 1997-03-26 | 1998-05-05 | Willis; John P. | Point-of-care analyzer module |
DE19717107B4 (en) | 1997-04-23 | 2005-06-23 | Disetronic Licensing Ag | System of container and drive device for a piston, which is held in the container containing a drug fluid |
US6186982B1 (en) | 1998-05-05 | 2001-02-13 | Elan Corporation, Plc | Subcutaneous drug delivery device with improved filling system |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
EP0989872A4 (en) | 1997-06-17 | 2000-08-30 | Injectimed Inc | Method and apparatus for introducing an intravenous catheter |
US5947940A (en) | 1997-06-23 | 1999-09-07 | Beisel; Robert F. | Catheter reinforced to prevent luminal collapse and tensile failure thereof |
ES2227880T3 (en) | 1997-08-09 | 2005-04-01 | Roche Diagnostics Gmbh | ANALYSIS DEVICE FOR PERFORMING LIVE ANALYSIS IN A PATIENT'S BODY. |
DE19738942A1 (en) | 1997-09-05 | 1999-03-25 | Pulsion Verwaltungs Gmbh & Co | Method and device for determining the injection time and duration of injection in thermodilution measurements |
US6117290A (en) | 1997-09-26 | 2000-09-12 | Pepex Biomedical, Llc | System and method for measuring a bioanalyte such as lactate |
US5891114A (en) | 1997-09-30 | 1999-04-06 | Target Therapeutics, Inc. | Soft-tip high performance braided catheter |
AT409306B (en) * | 1997-10-03 | 2002-07-25 | Hoffmann La Roche | OPTICAL CHEMICAL SENSOR |
US6119028A (en) * | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
AU6325798A (en) | 1997-11-12 | 1999-05-31 | Stereotaxis, Inc. | Intracranial bolt and method of placing and using an intracranial bolt to position a medical device |
US20010008766A1 (en) * | 1998-03-17 | 2001-07-19 | Sylvia Daunert | Quantitative binding assays using green fluorescent protein as a label |
US7647237B2 (en) | 1998-04-29 | 2010-01-12 | Minimed, Inc. | Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
DE19820808C2 (en) | 1998-05-09 | 2000-11-02 | Wolfgang Fleckenstein | Insertion device for brain probes |
JP2002514452A (en) | 1998-05-13 | 2002-05-21 | シグナス, インコーポレイテッド | Signal processing for measurement of physiological analytes |
US6702972B1 (en) | 1998-06-09 | 2004-03-09 | Diametrics Medical Limited | Method of making a kink-resistant catheter |
US6736797B1 (en) | 1998-06-19 | 2004-05-18 | Unomedical A/S | Subcutaneous infusion set |
US6355021B1 (en) | 1998-07-14 | 2002-03-12 | Maersk Medical A/S | Medical puncturing device |
DE69941085D1 (en) | 1998-07-17 | 2009-08-20 | Univ Maryland | MANIPULATED PROTEINS FOR ANALYSIS PROOF |
JP2002522103A (en) | 1998-08-07 | 2002-07-23 | インフィニット バイオメディカル テクノロジーズ インコーポレイテッド | Method for detecting, indicating and operating implantable myocardial ischemia |
US6248067B1 (en) | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
US6558320B1 (en) | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
AU770909B2 (en) * | 1998-08-26 | 2004-03-04 | Sensors For Medicine And Science, Inc. | Optical-based sensing devices |
US6304766B1 (en) * | 1998-08-26 | 2001-10-16 | Sensors For Medicine And Science | Optical-based sensing devices, especially for in-situ sensing in humans |
GB2342863B (en) | 1998-10-02 | 2003-02-19 | Diametrics Medical Ltd | Probe |
GB9821575D0 (en) | 1998-10-02 | 1998-11-25 | Diametrics Medical Limited | Cranial bolt |
DK1413245T3 (en) | 1998-10-08 | 2011-10-10 | Medtronic Minimed Inc | Installations for monitoring a characteristic of remote sensing |
DE29817986U1 (en) | 1998-10-08 | 1998-12-24 | Homedica Ag | Probe holder |
DK1124608T3 (en) | 1998-10-29 | 2006-04-03 | Medtronic Minimed Inc | reservoir connector |
US6248093B1 (en) | 1998-10-29 | 2001-06-19 | Minimed Inc. | Compact pump drive system |
US7193521B2 (en) | 1998-10-29 | 2007-03-20 | Medtronic Minimed, Inc. | Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump |
US7666204B2 (en) | 1999-04-09 | 2010-02-23 | Evalve, Inc. | Multi-catheter steerable guiding system and methods of use |
US6187130B1 (en) * | 1999-05-26 | 2001-02-13 | Scimed Life Systems, Inc. | Method of creating a tip on a catheter |
US7806886B2 (en) | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
WO2001006253A2 (en) | 1999-07-16 | 2001-01-25 | Board Of Regents, The University Of Texas System | Detection system based on an analyte reactive particle |
US6273874B1 (en) | 1999-08-18 | 2001-08-14 | Becton, Dickinson And Company | Protected peelable U-wing introducer |
US6682938B1 (en) | 1999-09-15 | 2004-01-27 | The Regents Of The University Of California | Glucose sensing molecules having selected fluorescent properties |
US6464849B1 (en) * | 1999-10-07 | 2002-10-15 | Pepex Biomedical, L.L.C. | Sensor for measuring a bioanalyte such as lactate |
US6453956B2 (en) | 1999-11-05 | 2002-09-24 | Medtronic Minimed, Inc. | Needle safe transfer guard |
US6363273B1 (en) | 1999-12-22 | 2002-03-26 | Codman & Shurtleff, Inc. | Introducer element and method of using same |
US6454744B1 (en) | 1999-12-23 | 2002-09-24 | Tfx Medical, Inc. | Peelable PTFE sheaths and methods for manufacture of same |
US7003336B2 (en) | 2000-02-10 | 2006-02-21 | Medtronic Minimed, Inc. | Analyte sensor method of making the same |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US7890295B2 (en) | 2000-02-23 | 2011-02-15 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US6375627B1 (en) * | 2000-03-02 | 2002-04-23 | Agilent Technologies, Inc. | Physiological fluid extraction with rapid analysis |
US20010041869A1 (en) | 2000-03-23 | 2001-11-15 | Causey James D. | Control tabs for infusion devices and methods of using the same |
AU2001254621A1 (en) | 2000-05-05 | 2001-11-20 | K.U. Leuven R And D | Critical illness neuropathy |
US6442413B1 (en) | 2000-05-15 | 2002-08-27 | James H. Silver | Implantable sensor |
US7769420B2 (en) | 2000-05-15 | 2010-08-03 | Silver James H | Sensors for detecting substances indicative of stroke, ischemia, or myocardial infarction |
US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
WO2001088534A2 (en) * | 2000-05-16 | 2001-11-22 | Cygnus, Inc. | Methods for improving performance and reliability of biosensors |
CN101845116B (en) * | 2000-08-04 | 2013-04-24 | 传感技术股份有限公司 | Detection of analytes in aqueous environments |
AU8857501A (en) | 2000-09-08 | 2002-03-22 | Insulet Corp | Devices, systems and methods for patient infusion |
US7807210B1 (en) * | 2000-10-31 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
US6387672B1 (en) | 2000-12-04 | 2002-05-14 | Beckman Coulter, Inc. | Photo-induced electron transfer fluorescent sensor molecules |
US6627177B2 (en) * | 2000-12-05 | 2003-09-30 | The Regents Of The University Of California | Polyhydroxyl-substituted organic molecule sensing optical in vivo method utilizing a boronic acid adduct and the device thereof |
US6653141B2 (en) * | 2000-12-05 | 2003-11-25 | The Regents Of The University Of California | Polyhydroxyl-substituted organic molecule sensing method and device |
US7470420B2 (en) * | 2000-12-05 | 2008-12-30 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6800451B2 (en) * | 2001-01-05 | 2004-10-05 | Sensors For Medicine And Science, Inc. | Detection of glucose in solutions also containing an alpha-hydroxy acid or a beta-diketone |
US6432695B1 (en) | 2001-02-16 | 2002-08-13 | Institute Of Microelectronics | Miniaturized thermal cycler |
EP1381408A4 (en) | 2001-02-22 | 2007-06-13 | Insulet Corp | Modular infusion device and method |
WO2002081012A2 (en) | 2001-04-06 | 2002-10-17 | Disetronic Licensing Ag | Infusion set |
US20020071225A1 (en) | 2001-04-19 | 2002-06-13 | Minimed Inc. | Direct current motor safety circuits for fluid delivery systems |
US7682669B1 (en) * | 2001-07-30 | 2010-03-23 | Advanced Cardiovascular Systems, Inc. | Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
ATE509120T1 (en) | 2001-09-18 | 2011-05-15 | Carnegie Inst Of Washington | FUSION PROTEINS FOR DETECTING ANALYTES |
US20050267326A1 (en) * | 2001-10-02 | 2005-12-01 | Alfred E. Mann Institute For Biomedical Eng. At The University Of Southern California | Percutaneous chemical sensor based on fluorescence resonant energy transfer (FRET) |
AU2002367906A1 (en) | 2001-10-02 | 2003-12-12 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Internal biochemical sensing device |
US20030232383A1 (en) * | 2001-11-02 | 2003-12-18 | Sylvia Daunert | Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein |
WO2003048190A2 (en) | 2001-12-04 | 2003-06-12 | The Curators Of The University Of Missouri | Acyclovir-peptide analogs |
US7399277B2 (en) | 2001-12-27 | 2008-07-15 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US7064103B2 (en) | 2002-01-04 | 2006-06-20 | Becton, Dickinson And Company | Binding protein as biosensors |
US6855556B2 (en) | 2002-01-04 | 2005-02-15 | Becton, Dickinson And Company | Binding protein as biosensors |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
JP4489437B2 (en) | 2002-02-21 | 2010-06-23 | エンセル,インコーポレイテッド | Immobilized bioactive hydrogel matrix as a surface coating |
US7041082B2 (en) | 2002-02-28 | 2006-05-09 | Smiths Medical Md, Inc. | Syringe pump control systems and methods |
JP4014897B2 (en) | 2002-03-08 | 2007-11-28 | 株式会社堀場製作所 | Automatic ion concentration measuring device |
JP4381820B2 (en) | 2002-03-11 | 2009-12-09 | ポーリスツィン、ジャヌス・ビー | Micro extractor for biological tissue examination |
US6960192B1 (en) | 2002-04-23 | 2005-11-01 | Insulet Corporation | Transcutaneous fluid delivery system |
US20040087842A1 (en) * | 2002-05-30 | 2004-05-06 | Lakowicz Joseph R. | Fluorescent probes for saccharrides |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
US20040068230A1 (en) | 2002-07-24 | 2004-04-08 | Medtronic Minimed, Inc. | System for providing blood glucose measurements to an infusion device |
US20050118726A1 (en) * | 2002-08-26 | 2005-06-02 | Schultz Jerome S. | System and method for detecting bioanalytes and method for producing a bioanalyte sensor |
US7317111B2 (en) | 2002-09-23 | 2008-01-08 | Aries Associates, Inc. | Green and orange fluorescent labels and their uses |
US6819951B2 (en) | 2002-09-24 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Peripherally inserted central catheter with continuous central venous oximetry and proximal high flow port |
US7226414B2 (en) | 2002-10-09 | 2007-06-05 | Biotex, Inc. | Method and apparatus for analyte sensing |
EP1556162A1 (en) | 2002-11-01 | 2005-07-27 | McMaster University | Multicomponent protein microarrays |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
AU2003287735A1 (en) * | 2002-11-12 | 2004-06-03 | Argose, Inc. | Non-invasive measurement of analytes |
CA2451054A1 (en) * | 2002-11-27 | 2004-05-27 | Z-Tech (Canada) Inc. | Improved apparatus and method for performing impedance measurements |
US7390462B2 (en) * | 2002-12-17 | 2008-06-24 | The University Of Maryland Baltimore County | Ratiometric fluorescent pH sensor for non-invasive monitoring |
US6669929B1 (en) * | 2002-12-30 | 2003-12-30 | Colgate Palmolive Company | Dentifrice containing functional film flakes |
US7229450B1 (en) | 2003-02-11 | 2007-06-12 | Pacesetter, Inc. | Kink resistant introducer with mapping capabilities |
DE10311452B4 (en) | 2003-03-15 | 2006-04-13 | Roche Diagnostics Gmbh | Analysis system for the reagent-free determination of the concentration of an analyte in living tissue |
US7358094B2 (en) | 2003-05-01 | 2008-04-15 | Bell Michael L | Sensor system for saccharides |
US7718353B2 (en) | 2003-05-09 | 2010-05-18 | University Of Maryland Baltimore County | Proteins, sensors, and methods of characterizing analytes using the same |
US20080009687A1 (en) | 2003-06-06 | 2008-01-10 | Smith Joseph T | Coiled circuit bio-sensor |
NO317911B1 (en) * | 2003-06-10 | 2004-12-27 | Lifecare As | Sensor for in vivo paints of osmotic changes |
US7353055B2 (en) * | 2003-06-18 | 2008-04-01 | Hogan Josh N | Non-invasive analysis system |
US7488601B2 (en) | 2003-06-20 | 2009-02-10 | Roche Diagnostic Operations, Inc. | System and method for determining an abused sensor during analyte measurement |
US20040267203A1 (en) | 2003-06-26 | 2004-12-30 | Potter Daniel J. | Splittable cannula having radiopaque marker |
US7879024B2 (en) * | 2003-06-26 | 2011-02-01 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Splittable cannula having radiopaque marker |
US6931327B2 (en) | 2003-08-01 | 2005-08-16 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20080119703A1 (en) | 2006-10-04 | 2008-05-22 | Mark Brister | Analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20050124896A1 (en) | 2003-08-25 | 2005-06-09 | Jacob Richter | Method for protecting implantable sensors and protected implantable sensors |
US7559894B2 (en) * | 2003-09-18 | 2009-07-14 | New Paradigm Concepts, LLC | Multiparameter whole blood monitor and method |
US7699807B2 (en) | 2003-11-10 | 2010-04-20 | Smiths Medical Asd, Inc. | Device and method for insertion of a cannula of an infusion device |
US7181260B2 (en) | 2003-11-14 | 2007-02-20 | Guillermo Gutierrez | Apparatus and method for measuring myocardial oxygen consumption |
US7787923B2 (en) * | 2003-11-26 | 2010-08-31 | Becton, Dickinson And Company | Fiber optic device for sensing analytes and method of making same |
US7496392B2 (en) | 2003-11-26 | 2009-02-24 | Becton, Dickinson And Company | Fiber optic device for sensing analytes |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
WO2005064336A1 (en) | 2003-12-09 | 2005-07-14 | Molecular Probes, Inc. | Pyrenyloxysulfonic acid fluorescent agents |
WO2005057175A2 (en) | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
GB0329161D0 (en) | 2003-12-16 | 2004-01-21 | Precisense As | Reagant for detecting an analyte |
GB0329849D0 (en) | 2003-12-23 | 2004-01-28 | Precisense As | Fluorometers |
EP1718753A4 (en) * | 2004-01-28 | 2009-01-21 | Univ Johns Hopkins | Methods for making and using molecular switches involving circular permutation |
US7499746B2 (en) * | 2004-01-30 | 2009-03-03 | Encore Medical Asset Corporation | Automated adaptive muscle stimulation method and apparatus |
GB2410793B (en) | 2004-02-05 | 2006-05-17 | Elan Vital | Fluid analyser systems |
US7345160B2 (en) | 2004-03-29 | 2008-03-18 | University Of Kentucky Research Foundation | Aequorin and obelin mutants with differing wavelengths and bioluminescence |
WO2005119223A1 (en) * | 2004-04-14 | 2005-12-15 | Bioprocessors Corp. | Compositions of matter useful as ph indicators and related methods |
US20050241959A1 (en) * | 2004-04-30 | 2005-11-03 | Kenneth Ward | Chemical-sensing devices |
US20080319286A1 (en) | 2004-05-24 | 2008-12-25 | Trent Ridder | Optical Probes for Non-Invasive Analyte Measurements |
FI118951B (en) * | 2004-06-04 | 2008-05-30 | Newtest Oy | Sensor unit, device arrangement and method utilizing the device arrangement to form and display an assessment of bone mass development |
US8696564B2 (en) | 2004-07-09 | 2014-04-15 | Cardiac Pacemakers, Inc. | Implantable sensor with biocompatible coating for controlling or inhibiting tissue growth |
USD525632S1 (en) | 2004-07-12 | 2006-07-25 | Sevic System Ag | Set of icons for a portion of an automotive windshield display |
US7344500B2 (en) | 2004-07-27 | 2008-03-18 | Medtronic Minimed, Inc. | Sensing system with auxiliary display |
US8313433B2 (en) | 2004-08-06 | 2012-11-20 | Medtronic Minimed, Inc. | Medical data management system and process |
EP1787107A2 (en) | 2004-08-19 | 2007-05-23 | Blood Cell Storage, Inc. | FLUORESCENT pH DETECTOR SYSTEM AND RELATED METHODS |
US7468033B2 (en) | 2004-09-08 | 2008-12-23 | Medtronic Minimed, Inc. | Blood contacting sensor |
US20090171381A1 (en) * | 2007-12-28 | 2009-07-02 | Schmitz Gregory P | Devices, methods and systems for neural localization |
JP2006115948A (en) * | 2004-10-19 | 2006-05-11 | Hitachi Ltd | Blood-sugar level measuring apparatus |
US20060088722A1 (en) | 2004-10-25 | 2006-04-27 | Aller Robert C | Optical pH sensor |
US20060105174A1 (en) * | 2004-10-25 | 2006-05-18 | The Research Foundation Of State University Of New York | Optical pH sensor |
US7306621B1 (en) | 2004-11-19 | 2007-12-11 | National Semiconductor Corporation | Heat transfer control for a prosthetic retinal device |
US8377461B2 (en) | 2004-12-06 | 2013-02-19 | Surmodics, Inc. | Multifunctional medical articles |
WO2006078432A2 (en) * | 2005-01-18 | 2006-07-27 | Cyberkinetics Neurotechnology Systems, Inc. | Biological interface system with automated configuration |
US20060189926A1 (en) | 2005-02-14 | 2006-08-24 | Hall W D | Apparatus and methods for analyzing body fluid samples |
US7625372B2 (en) | 2005-02-23 | 2009-12-01 | Vnus Medical Technologies, Inc. | Methods and apparatus for coagulating and/or constricting hollow anatomical structures |
US20070207498A1 (en) | 2005-02-24 | 2007-09-06 | Lifescan, Inc. | Design and construction of dimeric concanavalin a mutants |
CN101180093B (en) | 2005-03-21 | 2012-07-18 | 雅培糖尿病护理公司 | Method and system for providing integrated medication infusion and analyte monitoring system |
EP1877116A1 (en) | 2005-04-13 | 2008-01-16 | Novo Nordisk A/S | Medical skin mountable device and system |
US7686787B2 (en) | 2005-05-06 | 2010-03-30 | Medtronic Minimed, Inc. | Infusion device and method with disposable portion |
US8137314B2 (en) | 2006-08-23 | 2012-03-20 | Medtronic Minimed, Inc. | Infusion medium delivery device and method with compressible or curved reservoir or conduit |
US8277415B2 (en) | 2006-08-23 | 2012-10-02 | Medtronic Minimed, Inc. | Infusion medium delivery device and method with drive device for driving plunger in reservoir |
US20080097291A1 (en) | 2006-08-23 | 2008-04-24 | Hanson Ian B | Infusion pumps and methods and delivery devices and methods with same |
US7713240B2 (en) | 2005-09-13 | 2010-05-11 | Medtronic Minimed, Inc. | Modular external infusion device |
JP2009508584A (en) * | 2005-09-16 | 2009-03-05 | ビージー インプラント インコーポレイテッド | Glaucoma treatment apparatus and method |
WO2007047962A2 (en) * | 2005-10-20 | 2007-04-26 | Biological Targets, Inc. | Insecticides that target protein kinase a (pka) |
US20090048430A1 (en) | 2005-11-02 | 2009-02-19 | Duke University | Site specific protein modification |
US8475408B2 (en) | 2005-11-08 | 2013-07-02 | Asante Solutions, Inc. | Infusion pump system |
USD559264S1 (en) | 2005-11-10 | 2008-01-08 | Sony Corporation | Computer generated image for a display panel or screen |
USD550242S1 (en) | 2005-11-10 | 2007-09-04 | Sony Corporation | Computer generated image for a display panel or screen |
USD550245S1 (en) | 2005-11-10 | 2007-09-04 | Sony Corporation | Computer generated image for a display panel or screen |
DE102005056310B4 (en) | 2005-11-25 | 2017-02-02 | Drägerwerk AG & Co. KGaA | Method and device for monitoring infusions |
USD544871S1 (en) | 2005-12-02 | 2007-06-19 | Samsung Electronics Co., Ltd. | Generated image for a portable telephone |
US7985330B2 (en) | 2005-12-30 | 2011-07-26 | Medtronic Minimed, Inc. | Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy |
US8114268B2 (en) | 2005-12-30 | 2012-02-14 | Medtronic Minimed, Inc. | Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy |
US8114269B2 (en) | 2005-12-30 | 2012-02-14 | Medtronic Minimed, Inc. | System and method for determining the point of hydration and proper time to apply potential to a glucose sensor |
DE502006009203D1 (en) | 2006-01-30 | 2011-05-12 | Pulsion Medical Sys Ag | System for establishing a dilution site |
US7367942B2 (en) * | 2006-02-02 | 2008-05-06 | Palco Labs, Inc. | Method and apparatus for testing blood glucose in a reversible infusion line |
US20080154107A1 (en) | 2006-12-20 | 2008-06-26 | Jina Arvind N | Device, systems, methods and tools for continuous glucose monitoring |
JP2009533101A (en) * | 2006-04-10 | 2009-09-17 | エルンスト,アルネボルグ | Portable balancing prosthesis |
USD560224S1 (en) | 2006-04-17 | 2008-01-22 | Samsung Electronics Co., Ltd. | Telephone with video display |
US7942844B2 (en) | 2006-04-28 | 2011-05-17 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
ATE514755T1 (en) * | 2006-07-25 | 2011-07-15 | Glumetrics Inc | FLUORESCENT DYES FOR USE IN GLUCOSE DETECTION |
US7789857B2 (en) | 2006-08-23 | 2010-09-07 | Medtronic Minimed, Inc. | Infusion medium delivery system, device and method with needle inserter and needle inserter device and method |
US7828764B2 (en) | 2006-08-23 | 2010-11-09 | Medtronic Minimed, Inc. | Systems and methods allowing for reservoir filling and infusion medium delivery |
USD582427S1 (en) | 2006-10-12 | 2008-12-09 | Bystronic Laser Ag | Printed material and icon for computer display, electronic screen |
USD592223S1 (en) | 2006-10-12 | 2009-05-12 | Bystronic Laser Ag | Printed material and icon for computer display, electronic screen |
EP2087021B1 (en) | 2006-10-27 | 2011-12-28 | Basf Se | Radiation-curable mixture containing low-molecular, ethylenically unsaturated compounds having non-aromatic ring systems |
US20080125700A1 (en) | 2006-11-29 | 2008-05-29 | Moberg Sheldon B | Methods and apparatuses for detecting medical device acceleration, temperature, and humidity conditions |
US7946985B2 (en) | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US8075499B2 (en) * | 2007-05-18 | 2011-12-13 | Vaidhi Nathan | Abnormal motion detector and monitor |
US20090018426A1 (en) | 2007-05-10 | 2009-01-15 | Glumetrics, Inc. | Device and methods for calibrating analyte sensors |
US7751863B2 (en) * | 2007-02-06 | 2010-07-06 | Glumetrics, Inc. | Optical determination of ph and glucose |
US7824918B2 (en) | 2007-08-06 | 2010-11-02 | Glumetrics, Inc. | HPTS-Mono and BIS Cys-Ma polymerizable fluorescent dyes for use in analyte sensors |
US8088097B2 (en) * | 2007-11-21 | 2012-01-03 | Glumetrics, Inc. | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
EP2989975B1 (en) | 2007-02-06 | 2018-06-13 | Medtronic MiniMed, Inc. | Optical systems and methods for rationmetric measurement of blood glucose concentration |
EP2122334B1 (en) | 2007-02-06 | 2018-01-24 | Medtronic Minimed, Inc. | Method for polymerizing a monomer solution within a cavity to generate a smooth polymer surface |
USD626143S1 (en) | 2007-02-06 | 2010-10-26 | Glumetrics, Inc. | Computer-generated icon for a blood glucose display |
US20080269714A1 (en) | 2007-04-25 | 2008-10-30 | Medtronic Minimed, Inc. | Closed loop/semi-closed loop therapy modification system |
US8323250B2 (en) | 2007-04-30 | 2012-12-04 | Medtronic Minimed, Inc. | Adhesive patch systems and methods |
US7963954B2 (en) | 2007-04-30 | 2011-06-21 | Medtronic Minimed, Inc. | Automated filling systems and methods |
WO2008137604A1 (en) | 2007-05-01 | 2008-11-13 | Glumetrics, Inc. | Pyridinium boronic acid quenchers for use in analyte sensors |
WO2008141241A1 (en) | 2007-05-10 | 2008-11-20 | Glumetrics, Inc. | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement |
US8600681B2 (en) * | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
JP5453248B2 (en) * | 2007-05-22 | 2014-03-26 | ベクトン・ディキンソン・アンド・カンパニー | Dyes with a ratiometric fluorescence response to detect metabolites |
USD580950S1 (en) | 2007-06-15 | 2008-11-18 | Microsoft Corporation | Icon for a portion of a display screen |
WO2009009756A2 (en) * | 2007-07-11 | 2009-01-15 | Glumetrics, Inc. | Polyviologen boronic acid quenchers for use in analyte sensors |
PL2183006T3 (en) | 2007-07-20 | 2019-07-31 | F.Hoffmann-La Roche Ag | Manually operable portable infusion device |
US8202731B2 (en) | 2007-08-06 | 2012-06-19 | Glumetrics, Inc. | HPTS-mono and bis Cys-MA polymerizable fluorescent dyes for use in analyte sensors |
EP2194858B1 (en) * | 2007-09-14 | 2017-11-22 | Corventis, Inc. | Medical device automatic start-up upon contact to patient tissue |
US9023661B2 (en) | 2007-10-18 | 2015-05-05 | Becton, Dickinson And Company | Visual glucose sensor and methods of use thereof |
EP2055369A1 (en) * | 2007-10-30 | 2009-05-06 | Sensile Pat AG | Sensitively permeable coated membrane |
US7888754B2 (en) * | 2007-12-28 | 2011-02-15 | Yamaha Corporation | MEMS transducer |
WO2009129186A2 (en) * | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
US8207860B2 (en) | 2008-04-28 | 2012-06-26 | Medtronic Minimed, Inc. | Automobile physiological monitoring system and method for using the same |
USD610065S1 (en) | 2008-12-19 | 2010-02-16 | Dr. Ing. H.C. F. Porsche Aktiengesellschaft | Automobile wheel |
US8181849B2 (en) | 2008-12-30 | 2012-05-22 | Medtronic Minimed, Inc. | Color detection system for detecting reservoir presence and content in device |
US8376968B2 (en) * | 2009-05-15 | 2013-02-19 | The Hong Kong Polytechnic University | Method and system for quantifying an intention of movement of a user |
EP2438152A4 (en) | 2009-06-05 | 2012-12-12 | Glumetrics Inc | Algorithms for calibrating an analyte sensor |
US8308679B2 (en) | 2009-12-30 | 2012-11-13 | Medtronic Minimed, Inc. | Alignment systems and methods |
EP2483679A4 (en) | 2009-09-30 | 2013-04-24 | Glumetrics Inc | Sensors with thromboresistant coating |
JP5368249B2 (en) | 2009-10-20 | 2013-12-18 | 日東電工株式会社 | Double-sided adhesive sheet |
US8467843B2 (en) * | 2009-11-04 | 2013-06-18 | Glumetrics, Inc. | Optical sensor configuration for ratiometric correction of blood glucose measurement |
WO2011075710A1 (en) | 2009-12-17 | 2011-06-23 | Glumetrics, Inc. | Identification of aberrant measurements of in vivo glucose concentration using temperature |
DK2534470T3 (en) * | 2010-02-08 | 2016-12-05 | Medtronic Minimed Inc | Antioxidant protection of a chemical sensor |
EP2545373B1 (en) | 2010-03-11 | 2022-08-24 | Medtronic Minimed, Inc. | Measuring analyte concentration incorporating temperature and ph correction |
US20110263953A1 (en) | 2010-04-27 | 2011-10-27 | Glumetrics, Inc. | Deployment system and method for optical analyte sensor |
US20120053427A1 (en) | 2010-08-31 | 2012-03-01 | Glumetrics, Inc. | Optical sensor configuration and methods for monitoring glucose activity in interstitial fluid |
JP5413347B2 (en) | 2010-09-29 | 2014-02-12 | ブラザー工業株式会社 | Terminal device, display control method, and display control program |
-
2008
- 2008-05-09 WO PCT/US2008/063330 patent/WO2008141241A1/en active Application Filing
- 2008-05-09 US US12/118,401 patent/US8738107B2/en active Active
- 2008-05-09 CA CA002686065A patent/CA2686065A1/en not_active Abandoned
- 2008-05-09 JP JP2010507711A patent/JP5517919B2/en not_active Expired - Fee Related
- 2008-05-09 EP EP08769426A patent/EP2162057A1/en not_active Withdrawn
-
2014
- 2014-04-17 US US14/255,482 patent/US9693720B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200163595A1 (en) * | 2017-02-12 | 2020-05-28 | Hoon Kim | Portable apparatus for noninvasively measuring blood glucose level and operating method thereof |
US11766197B2 (en) * | 2017-02-12 | 2023-09-26 | Hoon Kim | Portable apparatus for noninvasively measuring blood glucose level and operating method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP5517919B2 (en) | 2014-06-11 |
US20090018418A1 (en) | 2009-01-15 |
US8738107B2 (en) | 2014-05-27 |
US20150080685A1 (en) | 2015-03-19 |
EP2162057A1 (en) | 2010-03-17 |
JP2010526599A (en) | 2010-08-05 |
US9693720B2 (en) | 2017-07-04 |
WO2008141241A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9693720B2 (en) | Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement | |
EP2122361B1 (en) | Optical determination of ph and glucose | |
US8535262B2 (en) | Use of an equilibrium intravascular sensor to achieve tight glycemic control | |
US9839378B2 (en) | Optical systems and methods for ratiometric measurement of blood glucose concentration | |
US9757057B2 (en) | Dry insertion and one-point in vivo calibration of an optical analyte sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |